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Akute generalisierte exanthematöse Pustulose (AGEP) ist eine schwere 
Arzneimittelreaktion der Haut. Sie zeichnet sich durch die rasche Entwicklung von 
sterilen, nicht-follikulären Pusteln auf der Grundlage eines ödematösen Erythems 
aus und wird durch die Einnahme bestimmter Medikamente ausgelöst. Obwohl über 
eine Beteiligung von medikamenten-spezifischen T-Zellen in AGEP berichtet wurde, 
sind die Pathophysiologie der AGEP und der zugrundeliegende Mechanismus der 
neutrophilen Hautentzündung noch nicht eindeutig geklärt. 
Der Schwerpunkt dieser Dissertation lag darin, die Rolle des pro-inflammatorischen 
Zytokins Interleukin (IL) -36 in der Pathogenese von AGEP zu untersuchen. Darüber 
hinaus wurde die Beteiligung früher Immunantworten nach Medikamenten-
exposition in zirkulierenden Immunzellen und Keratinozyten von AGEP-Patienten 
untersucht. 
Eine unvoreingenommene Genexpressionsanalyse ergab eine signifikante 
Hochregulation der Zytokine IL-36α und -γ in läsionaler Haut von AGEP-Patienten 
im Vergleich zum makulo-papulösen Exanthem (MPE). IL-36γ stellt hierbei die am 
häufigsten vorkommende Isoform dar und wird vorwiegend von Keratinozyten und 
Makrophagen in AGEP produziert. In vitro induzierte eine Stimulation mit dem 
auslösenden Medikament eine spezifische IL-36γ-Freisetzung entweder direkt aus 
mononukleären Zellen des Blutes oder indirekt aus Keratinozyten, die in Gegenwart 
von autologen mononukleären Blutzellen von AGEP-Patienten kultiviert wurden. 
Medikamenten-induzierte IL-36γ-Freisetzung in vitro war spezifisch für AGEP und 
konnte in MPE nicht beobachtet werden.  
Des Weiteren konnten wir zeigen, dass auch IL-1β eine mögliche wichtige Rolle in 
der Pathogenese von AGEP einnimmt. Wir konnten demonstrieren, dass IL-1β ein 
positiver Regulator der IL-36γ-Produktion in humanen Monozyten und 
Keratinozyten ist. Zudem konnte gezeigt werden, dass der IL-1β-Gehalt im Blut und 
in der Haut von AGEP-Patienten erhöht ist. Ähnlich der IL-36γ-Expression konnte 
auch die IL-1β-Expression direkt durch Stimulation mit dem auslösenden 
Medikament in mononukleären Blutzellen induziert werden. Dies konnte partiell 
durch den IL-36-Rezeptorantagonisten antagonisiert werden, was auf eine 
regulatorische Rolle von IL-36γ hindeutet. 
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Interessanterweise wurde nach Stimulation mit Lipopolysaccharid (LPS) eine 
gesteigerte Produktion von IL-36γ und IL-1β durch mononukleäre Zellen des Blutes 
von AGEP-Patienten im Vergleich zu Monozyten von MPR-Patienten und gesunden 
Individuen festgestellt. Diese gesteigterte Entzündungsantwort von AGEP-
Monozyten auf LPS und die Tatsache, dass Monozyten direkt dazu angeregt 
werden konnten, IL-36γ und IL-1β zu exprimieren, liess eine gesteigerte Aktivität im 
Toll-like-Rezeptor (TLR) - NF-κB-Signalweg vermuten. Dies wurde unterstützt durch 
die Tatsache, dass zwei Nukleotidpolymorphismen (D299G und T399I) in dem für 
TLR4 (Rezeptor für LPS) kodierenden Gen bei AGEP-Patienten signifikant häufiger 
als bei gesunden Kontrollen gefunden wurden. 
Zusammenfassend konnte in dieser Arbeit eine entscheidende Rolle der beiden 
Zytokine IL-36γ und IL-1β in der Pathogenese der AGEP demonstriert werden. Zum 
ersten Mal konnte eine direkte Aktivierung von Monozyten durch Medikamente 
gezeigt werden, was auf einen wichtigen Einfluss des angeborenen Immunsystems 
in der AGEP-Pathogenese hindeutet. Die Assoziation von 
Nukleotidpolymorphismen in dem für TLR4 kodierenden Gen mit AGEP unterstützt 
ferner die Annahme eines dysregulierten TLR-NF-κB-Signalweges. Diese 
Erkenntnisse zeigen einen interessanten neuen Aspekt bei der Entstehung von 
Medikamentenreaktionen der Haut auf und eröffnen neue Perspektiven in der 









Acute generalized exanthematous pustulosis (AGEP) is a severe adverse 
cutaneous drug reaction. It is characterized by the rapid development of sterile, non-
follicular pustules on the background of edematous erythema triggered by culprit 
drug intake. Although previous findings reported an involvement of drug-specific T 
cells in AGEP, the physiopathology of AGEP and the underlying mechanism of 
neutrophilic skin inflammation remains incompletely understood.  
The main focus of this PhD thesis was to investigate the role of the pro-inflammatory 
cytokine Interleukin (IL) -36 in the pathogenesis of AGEP. Moreover, it probes the 
involvement of early immune responses in both circulating immune cells and 
keratinocytes, from AGEP patients, upon culprit drug exposure. 
An unbiased approach revealed significant IL-36α and γ upregulation in lesional skin 
of AGEP patients, when compared to macular papular rash (MPR), with IL-36γ 
representing the most abundant isoform. Keratinocytes and macrophages were 
found to be the source of IL-36γ production in AGEP patients. In vitro, culprit drug 
exposure specifically induced IL-36γ release, either directly by peripheral blood 
monocytes, or indirectly by keratinocytes cultured in the presence of autologous 
peripheral blood mononuclear cells (PBMCs) from AGEP patients. Culprit drug-
induced IL-36γ secretion in vitro was specific for AGEP and was not observed for 
MPR. 
Furthermore, we identified IL-1β as another key player in the pathogenesis of 
AGEP. IL-1β has been demonstrated to be a positive regulator of IL-36γ production 
in human monocytes and keratinocytes and IL-1β levels are elevated in AGEP blood 
and skin. Like IL-36γ, IL-1β expression is directly induced by culprit drug exposure 
in peripheral blood monocytes and this could be partially antagonized by IL-36Ra, 
suggesting a regulatory role of IL-36γ in amplifying this inflammatory loop. 
Interestingly, PBMCs from AGEP patients showed an enhanced reponse to 
lipopolysacchardie (LPS) stimulation compared to PBMCs from MPR patients and 
healthy controls. This exaggerated response of AGEP PBMCs in response to LPS 
and the fact that monocytes could be directly stimulated to express IL-36γ and IL-
1β, was suggestive of exacerbated Toll-like receptor (TLR) - NF-κB activity. Indeed, 
using whole exome sequencing, the presence of two single nucleotide 
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polymorphisms (D299G and T399I) in the gene encoding TLR4 (the receptor for 
LPS) were found significantly more frequently in AGEP patients than in healthy 
controls. 
Collectively, the findings described in this thesis demonstrate crucial roles of IL-36γ 
and IL-1β in the pathogenesis of AGEP. Strikingly, a direct activation of monocytes 
by culprit drugs could be shown for the first time, suggesting an important impact of 
the innate immune system in AGEP pathogenesis. The association of single 
nucleotide polymorphisms in the gene encoding TLR4 with AGEP is further 
supportive of a dysregulated TLR-NF-κB signaling axis. Together, these findings 
open up new relevant research avenues to explore in the field of cutaneous adverse 
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1 Introduction  
 The immune system  
 Overview and basic principles  
The human body is constantly exposed to a variety of environmental insults 
including millions of pathogens but also potentially harmful chemicals or radiations 
such as UV light. However, not every contact with environmental stimuli leads to 
infection or disease as homeostasis and integrity of the body is ensured by several 
defense mechanisms. These include physical barriers such as the skin and mucosa, 
complement factors and antimicrobial peptides and the immune system. The 
immune system is a host defense system that can be classified in 2 subsystems, 
namely the innate and the adaptive immune system (Fig. 1) [1]. 
 
 
Fig. 1: Protection against environmental insults relies on several levels of defense. The first 
defense level is represented by anatomic barriers provided by the epithelia of the body’s surfaces. 
Second, various chemical and enzymatic systems, including complement, act as an immediate 
antimicrobial barrier near these epithelia. As a next step of host defense, various innate immune cells 
can coordinate rapid immune responses. If the innate immune mechanisms are not sufficient, the 
slower-acting defenses of the adaptive immune system are brought to bear. Adapted from 
Janeways’s Immunobiology [1]. 
 
Innate immune system 
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The innate immune system represents the first line of defense of the human body. 
It is already present from birth and provides very rapid and efficient mechanisms to 
prevent invasion by microbes. Innate immune responses are mediated through 
several mechanisms. One is the signaling through soluble proteins or small 
molecules such as defensins, ficolins or complement factors that are constitutively 
present in bio-organic fluids [2, 3]. Another is innate immune cells which can release 
soluble mediators upon activation, thereby directly affecting microorganisms and 
also amplifying the immune response by recruiting or activating other immune cell 
types. These include cytokines, chemokines, reactive oxygen species, lipid 
mediators, bioactive amines and enzymes [4]. Nonthelesss, the most efficient host 
defense is mediated through germ-line-encoded pattern-recognition receptors 
(PRRs). PRRs are able to sense conserved structures of microorganisms, the so-
called pathogen-associated molecular patterns (PAMPs), as well as tissue damage 
by endogenous molecules released from damaged cells, the so-called danger-
associated molecular patterns (DAMPs). The sensing of PAMPs and DAMPs by 
PRRs leads to the upregulation of genes coding for inflammatory cytokines or to the 
activation and release of the latter [5]. The nature of PRRs and their respective 





Fig. 2. Innate and adaptive immune cells. The innate immune response functions as the first line 
of defence against pathogens and danger signals. It consists of soluble factors, such as complement 
components, and diverse cellular components including granulocytes (basophils, eosinophils and 
neutrophils, mast cells), macrophages, dendritic cells and natural killer cells. The adaptive immune 
response is a slower acting defense system, with stronger antigen-specificity and memory. It consists 
of antibodies, B cells, and CD4+ and CD8+ T lymphocytes. Natural killer T cells and γδ T cells are 
cytotoxic lymphocytes that straddle the interface of innate and adaptive immunity. Note: Innate 
lymphoid cells are missing in this figure. Adapted from Dranoff et. al [6]. 
 
When the innate defense mechanisms are not sufficient to fight infection or 
inflammation, an adaptive immune response is initiated. In contrast to the innate 
immune system, adaptive immunity requires prior sensitization to an antigen [7]. 
Unlike the germ-line-encoded receptors of the innate immune system, the antigen-
specific receptors of the adaptive response are encoded by genes that are 
assembled by somatic rearrangement of germ-line gene elements to form receptor 
genes [4]. The adaptive immune system is composed of antigen-specific T-cell 
activity (cell-mediated immunity) and specific antibody production by B cells 
(humoral immunity). Thus, the adaptive immune system relies on two main cell 
types, the T lymphocytes (T cells) and the B lymphocytes (B cells).  
Both cell types show little functional activity until an antigen binds to their specific 
receptor. In this non-actived state, the cells are known as naive lymphocytes. Once 
an antigen binds specifically to its receptor, the lymphocyte will be activated and 
differentiates into a fully functional cell, the so-called effector lymphocytes [8]. 
There are three different types of effector T cells: Cytotoxic T cells are capable of 
destroying cells that are infected with an intracellular pathogen carrying the antigen 
or cells that are recognized as non-self (grafted cells, tumor cells). Helper T cells 
(Th cells) can help activate other immune cells by releasing soluble factors, e.g. 
cytokines, in order to optimally regulate an immune response. Th cells can further 
be distinguished in Th1, Th2, Th17 and Th9 cells, depending on the factors initiating 
their differentiation, the presence of specific transcription factors, and the secretion 
of characteristic cytokines. Interferon (IFN) γ and Interleukin- (IL-) 12 can initiate the 
differentiation of Th1 cells, IL-2 and IL-4 are critical for Th2 differentiation, IL-23 
induces differentiation into Th17 cells and IFNβ diverts the differentiation of Th2 
towards the development of Th9 cells [9]. Regulatory T cells downregulate or 
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suppress the activity of other lymphocytes, in particular effector T cells, in order to 
prevent autoimmunity or other fulminant immune reactions and to maintain 
tolerance to self-antigens [10]. 
B cells are the only cell type in our human body that are able to produce antibodies. 
When a naïve or memory B cell is activated by antigen (with the help of a Th cell), 
it proliferates and differentiates into an antibody-secreting effector cell. Each B cell 
produces only one type of antibody with a unique antigen-binding site. Antibodies 
(Immunoglobulins, Ig) consist of four polypeptide chains, two identical light 
chains and two identical heavy chains. In humans, there are five different types of 
heavy chains, namely α, δ, ε, γ, and μ. According to their heavy chain, Ig are 
classified as IgA, IgD, IgE, IgG or IgM. Each of these Ig classes has distinct 
properties [11].  
Both B and T cells express distinct types of antigen receptors on their surface, 
resulting in different roles in the adaptive immune system. The assembly of these 
antigen-receptors from only a couple hundred germ-line-encoded gene elements 
gives rise to millions of different antigen receptors that are each specific for a 
particular antigen [4]. 
T cell receptors (TCR) recognize antigens as small peptide fragments presented on 
major histocompatibility complex (MHC) molecules on the cell surface of 
professional antigen-presenting cells (APC). Such APCs have the unique capacity 
to take up antigens and to process them in order to form MHC-peptide complexes 
which will be transported to the cell surface for antigen-presentation. [12] Dendritic 
cells represent the most potent APCs but monocytes, macrophages, B cells and 
neutrophils can also present antigens (cell types will be described in more detail in 
the chapter 1.1.2.1). There are two classes of MHC molecules, class I and class II. 
MHC class I molecules are found on the cell surface of all nucleated cells and 
mediate the activation of CD8+ T cells. MHC class II molecules are only present on 
professional APCs and are responsible for the activation of CD4+ T cells.  
B cells make use of antibodies in a membrane protein form as their antigen-binding 
receptors. The latter are capable of recognizing three-dimensional structures which 
allows them to bind and neutralize extracellular pathogens. They have the same 
unique antigen-binding site as the soluble antibodies [13]. 
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Even though the innate and the adaptive immune system represent two distinct and 
separate arms of host defense, synergy between them is crucial for efficient immune 
responses. Indeed, besides its function as first-line defense, the innate immune 
system contributes to the activation of the adaptive immune system via the release 
of soluble mediators such as cytokines and chemokines, subsequently leading to 
the clonal expansion of antigen-specific B and T cells. The latter, in turn, can amplify 
immune responses by further recruiting innate effector cells [4].  
 
 Innate Immunity 
1.1.2.1 Innate immune cells and their functions 
Innate immune cells comprize white blood cells that arise both from common 
myeloid progenitor cells (CMP) and the common lymphoid progenitor (CLP). CMP 
are progenitors of granulocytes (neutrophils, eosinophils, basophils, mast cells), 
dendritic cells, monocytes and macrophages. The CLP gives rise to NK cells and to 
the recently defined group of innate lymphoid cells (ILCs) [14]. 
 
Granulocytes  
Granulocytes include four different cell types: neutrophils, eosinophils, basophils 
and mast cells. Their life-span is very short (only a few days) and they are 
continuously produced from their precursors in the bone marrow. During immune 
responses, they migrate towards the site of infection and their production increases. 
Neutrophils are the most abundant type of granulocytes and play an important role 
in innate immune responses to pathogens. They function as phagocytes and are 
able to kill microorganisms by using lytic enzymes from their granules and other 
antimicrobial molecules like reactive oxygen species (ROS). Moreover, they can be 
stimulated to release complement components, chemokines and cytokines and 
express Fc receptors [15]. Eosinophils are a less abundant type of granulocytes 
that play an important role in the defense against infections, in particular parasite 
infections. Moreover, they are actively involved in the regulation of Th2-type immune 
responses and diseases such as asthma and skin allergy. Here, eosinophils are 
recruited to the inflamed tissue where they produce chemokines, cytokines and 
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other mediators and release highly toxic granule proteins. This leads to tissue 
damage but also facilitates tissue repair and regulates immune responses [16, 17]. 
Moreover, eosinophils have the capability to initiate antigen-specific immune 
responses by presenting antigens to T cells [18]. Basophils are the least common 
type of granulocytes. They have high-affinity IgE receptors that are cross-linked 
upon binding to specific IgE and its corresponding antigen, thereby leading to the 
release of a number of cytokines. Like eosinophils, they are also implicated in the 
control of parasite infections, and can also be involved in allergic reactions [19]. 
Mast cells are granulocytes containing a high number of granules rich in histamine 
and various proteases. Upon mast cell degranulation, immunomodulatory and 
vasoactive molecules are released and exert protective functions against parasitic 
and bacterial infections. Moreover, mast cells have an important role in allergy as 
they are also possessing high-affinity IgE receptors [20]. 
 
Dendritic cells 
Dendritic cells (DCs) are professional APCs that have the unique capacity to 
stimulate naive T cells and thereby initiate primary adaptive immune responses. 
DCs are the most effective APCs, in part due to their constitutive expression of MHC 
class II (MHC-II) molecules, and their ability to express a number of costimulatory 
molecules, such as CD80/86 and CD40. DCs are grouped in several subtypes but 
there is no consensus regarding the way they are classified [21]. A very common 
classification consists in the differentiation between monocyte-derived DCs, which 
are dependent on M-CSF,  and monocyte-independent DCs, which require Flt-3L 
for their development and are mostly found in lymphoid tissues [22]. DCs reside 
both in lymphoid and in non-lymphoid tissues. Lymphoid tissue DCs reside in the 
lymph nodes, spleen, thymus and mucosal-associated tissues. Non-lymphoid tissue 
DCs, also called interstitial DCs, populate stratified squamous tissues like the 
epidermis or connective tissues, and can be found in the skin, lung, liver, kidney, 
pancreatic islets and the intestine [23]. Besides their origin, DCs are classified into 
two main subsets, namely the classical and the plasmacytoid DCs. The classical 
DC (cDC) subset includes CD8+ and CD8- cells [24]. In the steady state, CD8+ DCs 
are mainly found in the T cell areas of the spleen and lymph nodes. Besides 
presenting endogenous antigens via MHC-II, they are also capable of 
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crosspresenting exogenous antigens via the MHC class I (MHC-I) pathway to CD8+ 
T cells [25]. CD8- DCs are predominantly localized in the marginal zone of the lymph 
nodes [26] and are specialized in the presentation of exogenous antigens via MHC-
II [27]. Plasmacytoid DCs (pCDs) reside mainly in lymphoid organs and express 
high amounts of certain TLRs which allows them to recognize viruses and to induce 
a Type-I-Interferon-dominated immune response. Another important DC subset are 
the migratory DCs. These cells act as sentinels for pathogens and self-antigens in 
the periphery and subsequently migrate towards a draining lymph node [24]. These 
migratory DCs include Langerhans cells and dermal DCs that can migrate to skin-
draining lymph nodes [28]. Langerhans cells are found within the epidermis, 
whereas dermal DCs belong to the interstitial DC subset [29].  
 
Monocytes and macrophages 
Monocytes are one of the largest groups of leukocytes in the blood. They originate 
from bone marrow progenitors and are able to differentiate into macrophages and 
monocyte-derived DCs. After circulating in the bloodstream for about one to three 
days, monocytes migrate into tissues where they differentiate into tissue-resident 
macrophages or DCs. This recruitment of monocytes to the tissues can be 
enhanced by infection and inflammation [30]. Based on the expression of the 
surface molecules Cluster of differentiation (CD) 14 and 16, different monocyte 
subsets are defined. CD14++CD16- represent the classical monocytes, CD14++CD16+ 
are defined as intermediate population and CD14+CD16++ are the nonclassical 
population [31].  Classical monocytes are potent phagocytic cells and secrete IL-10 
and ROS upon lipopolysaccharide (LPS) stimulation, whereas intermediate and 
non-classical monocytes secrete pro-inflammatory cytokines upon stimulation. 
During inflammation, classical and intermediate monocytes are invading tissues 
where they differentiate into macrophages [32]. Macrophages are the mature form 
of monocytes and are typically tissue- and niche-specific. They are a heterogenous 
group of cells and different macrophage subsets have been described. The most 
common classification consists in the distinction between M1 and M2 macrophages 
but recent research is suggestive of additional subtypes/phenotypes [33]. M1 are 
classically activated macrophages that mediate host defence against a variety of 
pathogens and tumors. They release pro-inflammatory cytokines such as tumor 
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necrosis factor (TNF) and IL-1β and show strongly expressed MHC-II molecules. 
They have a key role in the initiation of T cells responses and proteolysis. In 
contrast, M2 macrophages are alternatively activated macrophages that possess 
anti-inflammatory properties. In reponse to Fcγ ligation, they secrete large amounts 
of IL-10. They have been shown to be involved in processes like wound healing, 
tissue fibrosis, angiogenesis and tumorigenesis [32]. 
 
Innate lymphoid cells  
ILCs represent a recently-defined group of innate immune cells that morphologically 
appear as lymphoid cells but do not express rearranged antigen-specific receptors 
and lineage (Lin-) specific markers of other leukocyte populations [34, 35]. The first 
two members of the ILC family were already discovered in the 1970s and 1980s, 
namely NK and lymphoid tissue inducer (LTi)  and NK cells [36]. NK cells are cells 
that express a variety of innate receptors and can induce immediate immune 
responses to specific viral infections and cellular stress. NK cells are able to kill 
certain cells without prior antigen-specific priming. LTi cells are cells that have a 
critical role in the development of lymphoid tissues during embryogenesis and in the 
formation of the gut-associated lymphoid tissue in the adult [37, 38]. More recently, 
new non-cytotoxic ILCs have been discovered [39-41]. They are characterized by 
their similarities with Th cell subsets regarding their cytokine and transcription factor 
(TF) profiles [42]. Based on these profiles, different ILC subsets can be defined: 
Group 1 ILCs express the TF T-bet and are able to produce IFNγ and TNFα; group 
2 ILCs express the TF GATA3 and produce the typical Th2 cytokines IL-4, IL-5 and 
IL-13; group 3 ILCs express the three TFs T-bet, aryl hydrocarbon receptor and the 
RAR-related orphan receptor gamma t (RORγt). The latter produce IFNγ, TNF, IL-
17 and IL-22 [43, 44]. Functions of ILCs include the maintenance of epithelial 
integrity as they can quickly respond to epithelial cell-derived mediators like thymic 
stromal lymphopoietin (TSLP) and IL-1β [45]. They are also involved in early 




1.1.2.2 Pattern-recognition by Toll-like receptors 
The innate immune system has been long considered to consist only of unspecific 
defense mechanisms to pathogens, antigen-specificity being thought to be an 
exclusive characteristic of the adaptive immune system. However, since the 
discovery of Toll-like receptors (TLR) in the mid-1990s and the more recent 
description of other PRRs, the innate immune system is not considered to be 
unspecific anymore. Indeed, it is now known that PRRs exhibit some specificity in 
terms of stimuli sensing and subsequent intracellular signaling. PRRs include 
Nucleotide-binding oligomerization domain-like receptors (NOD)-like receptors 
(NLRs), RIG-I-like receptors (RLRs), C-type lectin receptors (CLRs) and TLRs [48]. 
TLRs belong to the group of germline-encoded PRRs which can detect PAMPs and 
DAMPs. They are type I transmembrane proteins containing leucin-rich repeat 
regions and play a crucial role in the early immune response to pathogens.  
The TLR family is one of the best characterized PRR families. In humans, ten 
different TLRs have been identified of which each recognizes different molecular 
patterns (Table 1). TLR2 is localized in the plasma membrane and is able to sense 
various components from bacteria, fungi, and viruses on the cell surface. These 
components include lipoproteins of bacteria and mycoplasma. TLR2 is expressed 
on monocytes, neutrophils, DCs as well as ectodermic cells like keratinocytes, and 
recognizes its ligands by forming heterodimers with either TLR1 or TLR6 [49]. All 
other TLRs exist as homodimers. TLR3, 7, 8 and 9 are mainly present on the 
endoplasmic reticulum (ER) membrane and can sense both exogenous and 
endogenous nucleic acids [50]: TLR3  senses double-strand ribonucleotide acid 
(dsRNA), TLR7 and 8  sense single-strand ribonucleotide acid (ssRNA) and TLR9  
senses CpG-DNA. Nucleic acid-sensing TLRs are recruited from the ER to 
endolysosomes following stimulation by their respective ligands. As they are not 
localized on the cell membrane, the access is restricted, which can prevent the 
constitutive activation of the TLRs by self-antigens and the resulting excessive 
immune response [51, 52]. TLR3 expression has been observed in keratinocytes, 
macrophages, mast cells [53], T lymphocytes [54] and NK cells, further in myeloid-
derived DCs but not in pDCs [55]. TLR7 and 9 are primarily expressed in pDCs and 
to some extent in monocytes/macrophages and B cells. In contrast, TLR8 is 
predominantly expressed in monocytes/macrophages and myeloid DCs [56-58]. 
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TLR5 is not highly expressed in skin cells but has been shown to play an important 
role in the gut immune system as it is expressed at high levels on DCs of the lamina 
propria in the small intestine, where it recognizes flagellin from flagellated bacteria 
of the intestinal flora [59].  
 
Table 1. Toll-like receptors and their ligands. Adapted from Takeuchi et. al [48]   
 Localization Ligand Origin of the Ligand 
TLR1 Plasma membrane Triacyl lipoprotein Bacteria 
TLR2 Plasma membrane Lipoprotein 
Bacteria, viruses, parasites, self-
antigen 
TLR3 Intracellular membranes dsRNA Virus 
TLR4 Plasma membrane LPS Bacteria, viruses, self-antigen 
TLR5 Plasma membrane Flagellin Bacteria 
TLR6 Plasma membrane Diacyl lipoprotein Bacteria, viruses 
TLR7 Intracellular membranes ssRNA Virus, bacteria, self-antigen 
TLR8 Intracellular membranes ssRNA Virus, bacteria, protozoa, self-antigen 
TLR9 Intracellular membranes CpG-DNA Bacteria, Self-antigen 
TLR10 Intracellular membranes  Unknown Unknown 
 
  
TLR4 is the first TLR to be discovered, and was done so by Jules Hoffmann [60] 
who was awarded the 2011 Nobel Prize together with Bruce Beutler [61] in 
Physiology or Medicine. TLR4 is highly expressed in myeloid cells like monocytes, 
macrophages and granulocytes  [62]. Less expression has been shown in T cells 
[63]. It is also expressed in immature DCs but its expression gets lost during 
maturation. No TLR4 expression has been reported in pDCs [62]. In the skin, 
functional TLR4 was found to be expressed by keratinocytes and fibroblasts [64-
66]. However, compared to myeloid cells, the level of expression is rather low. TLR4 
is able to sense LPS alone, a component of the outer membrane of gram-negative 
bacteria. TLR4 can not recognize LPS alone but needs to form a complex on the 
cell surface with several other proteins. In the serum, LPS is released by LPS-
binding protein (LBP) which transfers LPS to CD14. The latter presents LPS in form 
of monomeric molecules to the TLR4-MD-2 complex. The aggregation of this 
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complex results in the activation of the signaling pathways leading to nuclear factor 
'kappa-light-chain-enhancer' of activated B-cells (NF-κB) and Interferon Regulatory 
Factor 3 (IRF3) activation [62, 67].    
Upon recognition of their ligands, TLRs change their conformation and recruit 
adaptor proteins to iniate a signaling cascade. The cell surface TLR homo- and 
heterodimers recruit Myeloid differentiation primary response gene 88 (MyD88) and 
TIR Domain Containing Adaptor Protein (TIRAP) and subsequently activate the NF-
κB signaling pathway. In addition, TLR4 recruits the the adaptor proteins TRIF and 
TRAM that initiate the IRF3 pathway, leading to IFNβ production. MyD88 and TIRAP 
also get recruited by the endolysosomal TLRs TLR7, 8 and 9. TLR3 is able to induce 
both NF-κB and IRF3 through its adaptor protein TIR-domain-containing adapter-





Fig 3. Overview of TLR signaling.  The TLR family can be categorized into two subgroups. TLR1, 
TLR2, TLR4, TLR5 and TLR6 are located primarily on the plasma membrane. Conversely, TLR3, 
TLR7, TLR8 and TLR9 are located within intracellular vesicles, the endolysosomes. Most TLRs are 
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found as homodimers but TLR2 is able to form heterodimers with TLR1 and TLR6 (TLR1/2 and 
TLR2/6). Upon PAMP recognition, the TLR changes its conformation and recruits adapter proteins 
such as TRIF, TRAM, MyD88 and TIRAP. IFN, interferon; IRF, IFN regulatory factor; PAMP, 
pathogen-associated molecular pattern; NF, nuclear factor; TLR, Toll-like receptor. Adapted from 
Cervantes et. al [52].  
 
 Interleukin-36 
  Biology and function of Interleukin-36 
Interleukin-36 (IL-36) is a member of the IL-1 family of cytokines. The latter consists 
of eleven members of which seven are agonists and four are antagonists. The 
agonists, namely IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β and IL-36γ, show pro-
inflammatory properties whereas the receptor antagonists (Ra), namely IL-1Ra, IL-
36Ra, IL-37, and IL-38, have anti-inflammatory effects [68]. IL-1 cytokines bind to 
their specific receptor. The three IL-36 agonists IL-36α, IL-36β and IL-36γ signal 
specifically through their common receptor IL-36R and its co-receptor IL-1R/AcP 
which leads to the activation of NF-κB and mitogen-activated protein kinases 
(MAPK) [69]. The IL-36R is expressed on many different cell types. Interestingly, 
keratinocytes and mDCs show the highest expression of IL-36R, but monocytes, 
macrophages and granulocytes also express IL-36R. In contrast, human B cells, T 
cells and NK cells do not express this receptor [70, 71].  
Like other members of the IL-1 family, IL-36 cytokines are expressed as inactive 
proforms and require proteolytic processing for full activation. Indeed, the biological 
activity of the three agonists IL-36α, IL-36β and IL-36γ is increased 500-1000-fold 
upon cleavage at their N-terminal sites [72]. Recently, it has been demonstrated that 
neutrophil-derived proteases differentially process and activate all three agonists of 
the IL-36 family. IL-36α is activated by cathepsin G and elastase, IL-36β by 
cathepsin G and IL-36γ by elastase and proteinase-3 [73] (Fig. 4). Unpublished data 






Fig. 4. IL-36 cytokines require proteolytic processing for full activation. IL-36α, IL-36β, and IL-
36γ are activated differentially by the neutrophil granule-derived proteases cathepsin G, elastase, 
and proteinase-3, increasing their biological activity ∼500-fold. [73] 
 
IL-36 cytokines lack a signal sequence and therefore they are not directed to the 
ER for secretion [75, 76]. Their mechanism of secretion still remains unclear but a 
nonclassical mechanism has been suggested since IL-36γ secretion by skin 
epithelial cells requires adenosine 5'-triphosphate. As IL-36γ is realeased during 
pyroptosis, it was further sugessted that IL-36γ also acts as an alarmin [77].  
 
 Interleukin-36 in skin inflammation 
In the last decade, IL-36 cytokines have emerged as important cytokines mediating 
inflammatory responses in the skin. Several reports have shown that all IL-36 
isoforms are overexpressed in psoriatic skin [75, 78-80]. In keratinocytes, 
production of IL-36 family members can be induced by TNF, IL-17 and IL-22, 
cytokines known to be involved in psoriasis which further supports an important role 
for IL-36 in this disease [81]. The role of IL-36 in psoriasis has also been 
demonstrated in animal models. Transgenic expression of IL-36α leads to the 
development of psoriasiform skin lesions in mice [82]. Moreover, the psoriasis-like 
phenotype induced by the TLR7 agonist Imiquimod is dramatically increased in IL-
36RN-/- mice [83]. In another mouse model where human psoriatic lesional skin is 
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transplanted onto mice lacking a functional adaptive immune system (SCID-mice), 




Fig. 5. IL-36 signaling. IL-36α, IL-36β and IL-36γ are released by activated immune cells or 
keratinocytes and bind to IL-36R (1). IL-1RAcP is recruited (2) and an intracellular signalling cascade 
is initiated, thereby leading to gene transcription of proinflammatory mediators (3). IL-36Ra is acting 
as competitive inhibor of IL-36 cytokines by its binding to IL-36R (4). IL-36 can stimulate various 
cellular immune responses and is involved in diseases like psoriasis and generalized pustular 
psoriasis (5). DC: dendritic cell; ERKs: extracellular signal regulated kinases; IL-1RAcP: IL-1 receptor 
accessory protein; IL-36R: IL-36 receptor; NF-κB: nuclear factor κB, MAPKs: mitogen-activated 
protein kinases. Adapted from Dietrich et. al [85]. 
 
A fulminant IL-36-mediated immune response seems to further play a crucial role in 
generalized pustular psoriasis (GPP). Marrakchi et al. identified homozygous 
missense mutations in IL36RN, the gene encoding for the IL-36RA in GPP. They 
demonstrated that the L27P variant of IL36RN has less potency to antagonize the 
effects of IL-36, thereby leading to an excessive immune response, in particular via 
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IL-8, a downstream target of IL-36. [86] This connection between mutations in 
IL36RN and GPP has been confirmed in several other reports [87-92]. Interestingly, 
4 out of 96 patients with the adverse cutaneous drug eruption acute generalized 
exanthematous pustulosis (AGEP), which clinically resembles GPP, also carried a 
mutation in IL36RN [87]. Upregulation of IL-36 expression has been further 
observed in cells carrying a deficient adaptor protein complex subunit σ1C gene 
AP1S3 gene [93], a mutation that has been found in 10% of pustular psoriasis 
patients [94]. 
Further support for a role of IL-36 in skin inflammation was provided by the study of 
Foster et al., showing that exposure of human keratinocytes to all three isoforms of 
IL-36 significantly increased the expression of the potent chemotactic agents 
CXCL1, CXCL8, CCL3, CCL5, and CCL20 in human keratinocytes [71]. In the same 
study, it has been shown that IL-36 was able to induce high expression of of IL-1α, 
IL-1β and IL-6 in human blood monocytes. Also, mDCs and Langerhans cells 
showed a strong response to IL-36, as shown by the upregulation of CD83, CD86, 
HLA-DR, and the secretion of IL-1β and IL-6, thereby driving T cell proliferation. In 
contrast, no direct effect of IL-36 on human neutrophils and T cells could be 
demonstrated [70, 71]. 
 
 The skin 
 Skin structure 
The skin is one of the largest organs of the human body and functions as a protective 
interface between internal organs and the environment. It consists of three layers: 
the epidermis, the dermis and the subcutis.  
The epidermis is a stratified epithelium which consists mainly of keratinocytes and 
is divided into the four sublayers Stratum basale (basal layer), Stratum spinosum 
(spinous layer), Stratum granulosum (granular layer) and Stratum corneum (corneal 
layer). Depending on their differentiation status, keratinocytes reside in different 
sublayers of the epidermis. The basal layer is composed of undifferentiated stem 
and progenitor cells of which the latter have a very strong proliferative capacity. 
Upon migration into the suprabasal layers, they undergo a controlled differentiation 
program [95-97]. The corneal layer consists of terminally differentiated 
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keratinocytes, so-called corneocytes, which have lost their transcriptional activity, 
nuclei and intracellular organelles. These cells consist mainly of keratin filaments 
that are surrounded by a complex series of proteins (filaggrins, involucrin, loricrin 
and others) forming the cornified envelope. They are held together by 
corneodesmosomes, and the intercellular space is filled with hydrophobic lipids in 
order to build a lipid bilayer [97].  Both the cornified envelope proteins and the lipid 
bilayer are indispensable for the integrity of epidermal barrier function and defects 
in these structures result in water loss, entry of pathogens, chemicals and other 
harmful stimuli that can contribute to a disease like atopic dermatitis [98]. Upon 
degradation of the corneodesmosomes by proteases in a last step, the corneocytes 
scale off in a process called desquamation [99, 100].  
In addition to keratinocytes that represent the majority of the cells, the epidermis 
also contains other cell types. The pigment-building cells or melanocytes, are 
located in the basal layer of the epidermis where they produce melanin which is 
delivered to their surrounding keratinocytes in melanosomes and are responsible 
for skin pigmentation [101]. Furthermore, immune cells like Langerhans cells, skin-
specific DCs, and tissue-resident CD8+ T cells reside within the epidermis [102, 
103].    
The dermis is mainly composed of the extracellular matrix and a variety of immune 
and non-immune cells. Fibroblasts are producers of the extracellular matrix and 
collagen, and they interact closely with epidermal cells during hair development. 
Moreover, they play an important role in skin tissue-repair and wound healing [104]. 
The dermis is full of small blood and lymphatic vessels, through which migrating 
cells can traffic. They consist of endothelial cells and a basal lamina. Contractile 
cells, so-called pericytes, wrap around these endothelial cells. They are important 
in regulating stability and morphogenesis of small vessels [105], but are also thought 
to play a role in tissue regeneration because of their pluripotent differentiation 
capacity [106]. The immune cells of the skin reside mainly within the dermis and 
include macrophages, pDCs, dermal DCs, CD4+ Th1 cells, CD4+ Th2 cells, CD4+ 
Th17 cells, γδT cells, NK cells and granulocytes including neutrophils, eosinophils, 
basophils and mast cells. The functions of these immune cells will be discussed in 
the next chapter. 
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The subcutis is a loose connective tissue layer localized between dermis and the 
muscle compartment. It is attached to the neighboring dermis by collagen and 
elastin fibers, moreover connecting the skin to the deep fascia by fibrous bands. It 
contains blood and lymphatic vessels, as well as cutaneous nerves. There is only a 
low number of cells residing within the subcutis, including mast cells and adipose-
derived mesenchymal stem cells. However, the subcutaneous layer is mainly 
composed of fat cells (adipocytes) which can act as energy reservoir and minor 
thermoregulator [107]. 
 
 The skin and the immune system 
In addition to their physical barrier function, keratinocytes are also immunologically 
active cells that can initiate immediate immune reactions to pathogens and danger 
signals. One important mechanism is the release of antimicrobial peptides, such as 
LL-37, cathelicidin or β-defensins, [108-110]. These peptides are able to enter lipid-
rich membranes of microbes and kill target cells by causing membrane instability 
[111-113] or by inhibiting important pathways inside the cell such as DNA replication 
and protein synthesis [114]. Another important immune tool of keratinocytes is the 
expression of PRRs that are able to initiate early and rapid immune responses in 
the skin. Various studies have reported that keratinocytes express TLRs 1–10 [64, 
115-122]. Additionally, keratinocytes express the TLR4-associated CD14 and MD-
2 proteins that enables TLR4 to respond to LPS [123]. Other important PRRs are 
the NLRs that can sense various intracellular PAMPs and DAMPs, thereby initiating 
the assembly of intracellular immune complexes, the so-called inflammasomes. 
Inflammasome assembly leads to the activation of caspase-1 which in turn cleaves 
pro-IL-1β and pro-IL-18 to generate the active forms of these pro-inflammatory 
cytokines [124]. Besides NLRs, the inflammasome in keratinocytes can also be 
activated by the DNA sensor protein AIM2 [125]. Moreover, keratinocytes express 
RIG-I-like receptors (RLRs) that allow the recognition of RNA virus infection to 
initiate and modulate antiviral immunity [126]. PRRs are not only expressed by 
keratinocytes but also by other cells in the skin including Langerhans cells, dermal 
DCs, macrophages, B and T cells, γδ T-cells, NK cells, granulocytes and fibroblasts 





Figure 6. Skin anatomy and cellular effectors. The skin has multiple functions in host defense 
including acting as protective barrier and in having an active immunological role. The epidermis is 
composed the stratum basale, the stratum spinosum, the stratum granulosum and the stratum 
corneum. Specialized cells in the epidermis include melanocytes (pigment-producing cells) and 
Langerhans cells, a subtype of skin DCs. Few CD8+ cytotoxic T cells can be found in the stratum 
basale and stratum spinosum. The dermis is composed of collagen, reticular fibres, elastic tissue, 
and many specialized immune cells, such as dermal DCs and pDCs, and CD4+ Th1, Th2 and Th17 
cells, γδ T cells and NKT cells. Other important dermal cells are macrophages, fibroblasts and mast 
cells. Blood and lymphatic vessels and nerves (not shown) are also present throughout the dermis. 
DC = dendritic cell; pDCs = plasmacytoid DCs; Th1 = T helper 1; NKT = natural killer T. Adapted 
from Nestle et. al [102].  
 
However, pattern-recognition is not the only function of skin immune cells. DCs are 
professional antigen-presenting cells that have the ability to initiate adaptive 
immune responses by presenting antigens in a processed form via MHC-molecules. 
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In addition, the interaction of DCs with naive CD4+ and CD8+ T cells is further 
increased by the co-stimulatory molecules CD40, CD80 and CD86 present on DCs. 
The expression of these molecules can be augmented by type I interferons. 
Therefore they represent key molecules in the augmentation and maintanance of T 
cell responses [128, 129].  
Another important group of innate immune cells in the skin are macrophages. Even 
though they also belong to the group of professional APCs, their main mechanisms 
of host defense are phagocytosis and the release of cytokines and chemokines. 
Due to the high levels of PRRs on their cell surface and intracellularly, macrophages 
represent excellent sensors of pathogen-derived or danger signals in the skin. 
Resident skin macrophages are responsible for tissue homeostasis, whilst the 
recruitment of monocytes from the bone marrow and the peripheral blood and 
differentiation into mature macrophages occurs upon skin infection, inflammation, 
and skin repair [130]. 
A key event in the early inflammatory response against pathogens and tissue 
damage is the migration of neutrophils to the skin. Whilst there are only a very limited 
number of neutrophils in the epidermis at steady state, millions of neutrophils can 
be recruited to the skin upon skin infection and inflammation. The most potent 
neutrophil attractants in the skin are chemokine (C-X-C motif) ligand (CXCL)-1, 
CXCL-2, IL-8 (also known as CXCL8), IL-1β and granulocyte colony-stimulating 
factor (G-CSF) that all can be produced by macrophages, keratinocytes and T cells 
[131-135].  
T cells are the key cells of the adaptive immune system in the skin. Already in a 
healthy state, T cells are found in high numbers in the skin: healthy skin contains 
twice as many T cells as the blood and it has even been shown that 98% of CLA+ 
effector memory T cells in the body reside within the skin [136]. Skin-resident T cells 
are characterized by the expression of CD103 and Very Late Activation Protein 1 
(VLA-1) and play a key role in skin inflammation and inflammatory skin diseases 
such as psoriasis [137, 138]. CD4+ and CD8+ T cells are present in equal numbers 
in the skin [139]. In the context of inflammation, T cells from the periphery expand 
clonally and migrate towards the skin. In distinct pathological situations, different 
types of CD4+ responses can be observed. During infection with intracellular 
microorganisms, Th1 cells predominate [140]. Th1 have also been found in high 
numbers in psoriasis skin [141]. In contrast, Th2 cells are associated with allergic 
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skin diseases and atopic dermatitis (AD) [142]. Another very important T cell 
subgroup in the skin are the IL-17 and IL-22 producing Th17 cells that have been 
shown to play a role in both AD [143] and psoriasis [144], moreover it has been 
shown that Propionibacterium acnes promotes Th17 responses in acne patients 
[145]. These Th17 cells are furthermore important in defense against acute and 
chronic bacterial and fungal infections [146-148]. Recently, another IL-22 producing 
circulatory T cell subset with skin-homing properties has been described. These so-
called Th22 cells are not able to produce IL-17 or IFNγ but they seem to be involved 
in AD [149-151]. 
The TCR of the above described Th cell populations consists of an α and a β chain, 
and are therefore called αβ T cells and represent 95% of all T cells in humans. The 
other 5% of T cells are γδ T cells that also reside within the skin. γδ T cells express 
heterodimers consisting of the γ- and δ-chains of the TCR and represent only 2-9% 
of dermal T cells and 1-10% in the epidermis [102]. They enter the skin without 
priming in lymphoid tissues and are able to respond rapidly to antigen challenge. 
They have been shown to play an important role in tissue homeostasis and wound 
healing due to the release of particular growth factors, including connective tissue 
growth factor, keratinocyte growth factor, fibroblast growth factor 9, and insulin-like 
growth factor 1 [152]. Moreover it has been shown that the number of γδ T cells is 
increased in several skin diseases including psoriasis, chronic cutaneous lupus 
erythamtosus, Langerhans cell histiocytosis and melanoma [153-156].  
 
 Adverse cutaneous drug reactions 
 Definition 
According to the World Health Organisation (WHO), an adverse drug reaction (ADR) 
is defined as a noxious and unintended response to a drug that occurs at a usual 
dose [157]. ADR represent a major health problem worldwide and approximately 5-
8% of all hospitalisations are due to ADRs. Among all diseases, ADRs are rated as 
fifth leading cause of death. Within this group, ADRs with cutaneous manifestations 
represent 30-45% of all cases, and are therefore the most common ADRs. 





Drug reactions can have both by immunologic and non-immunologic causes. 
Interestingly, the immune-mediated hypersensitivity reactions represent the minority 
of all ADRs, most of the ADRs are non-immune-mediated, and usually due to dose-
dependent toxic effects of a drug. 
 
 
Figure 7. Revised Gell and Coombs classification of drug reactions. Drug-induced immune 
reactions can be classified into different subtypes. Depending on the involved cell types and effector 
functions, drug reactions can result in distinct clinical reaction patterns. AGEP = Acute Generalized 
Exanthematous Pustulosis; PMN = polymorphonuclear leukocyte; CTL = cytotoxic T lymphocytes; 
GM-CSF = granulocyte-macrophage colony-stimulating factor. Adapted from Hausmann et. al [159]. 
 
The most commonly used classification of ADRs has been proposed by Rawlins 
and Thompson [160]. They propose two major subtyes of ADRs, type A and type B 
reactions. A type A reaction represents a non-immune-mediated ADR that is caused 
by the pharmacological property of a drug. They are also considered as side effects. 
A type B reaction can be both immune-mediated and non-immune-mediated and 
occur only in predisposed individuals. Non-immunological type B reactions include 
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nonspecific mast cell degranulation, nonspecific cytokine dysbalances and 
enzymopathies [159]. Immune-mediated ADRs include IgE-mediated reactions 
(type I, according to Gell and Coombs, see Fig. 7), IgG-mediated cytotoxicity (type 
II), immune complex deposition (type III) and delayed drug hypersensitivity reactions 
(type IV). The latter can be further divided into the subtypes a-d. Type IVa reactions 
are characterized by the predominance of Th1 cells that activate and recruit 
monocytes/macrophages by the secretion of cytokines like IFNγ and TNF. Such 
reactions can be seen in contact dermatitis. In type IVb reactions, Th2 cells secrete 
IL-4, IL-5 and IL-13, leading to a strong eosinophilic inflammation. Clinical examples 
for a type IVb reaction is maculopapular exanthema with eosinophilia. In type IVc 
hypersensitivity reactions, cytotoxic T cells are the predominant cell type, leading to 
cell death of keratinocytes via the release of perforin and granzyme B and/or in a 
FasL-dependent manner. A typical example for a type IVc reaction are bullous skin 
reactions, toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS). 
Type IVd reactions are characterized by the predominance of CXCL-8 and 
Granulocyte-macrophage colony-stimulating factor (GM-CSF) that recruit 
neutrophils and thereby cause neutrophil-rich inflammation of the skin, such as in 
AGEP [159]. 
 
 Uncomplicated cutaneous drug eruptions 
The clinical manifestations of CADR range from mild to very severe. The majority of 
CADRs are mild and resolve with the termination of the medication. The most 
frequent (>90%) CADRs are the uncomplicated drug-induced disseminated 
exanthemas [161]. They manifest as different forms of drug-induced exanthemas 
that do not share a unique pathophysiology. Macular papular exanthemas (MPE) 
are the most common drug-induced exanthemas and are type IV hypersensitivitiy 
reactions. MPE manifest as polymorphic exanthemas with macules, papules and 
single pustules without systemic symptoms. The skin eruption appears after a 
sensitization phase of 5 to 7 days following first drug intake. Other uncomplicated 
CADRs include SDRIFE (Symmetrical Drug-Related Intertriginous and Flexural 
Exanthema, Baboon Syndrome), drug-induced urticaria, drug-induced 
leukocytoclastic vasculitis and fixed drug eruptions [162]. 
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 Severe cutaneous drug eruptions 
Severe cutaneous drug eruptions represent about 2% of all CADRs. However, while 
being rare, they are potentially life-threatening and therefore a rapid diagnosis, 
identification and interruption of the culprit drug and intensive supportive care are 
crucial. Severe ADRs include Stevens-Johnson Syndrome (SJS), Toxic epidermal 
necrolysis (TEN, also known as Lyell syndrome), Drug Reaction with Eosinophilia 
and Systemic Symptoms (DRESS) and AGEP.  
The most severe of all CADRs is TEN. It is considered to belong to the same 
spectrum of diseases as SJS, differing only by the extent of epidermal detachment 
(<10% in SJS, 10-30% in TEN-SJS-Overlap, >30% in TEN). Both diseases are rare 
with an incidence of 1-2/million per year. The mortality of TEN is 25-35% on 
average, whereas it is only of 1-5% in SJS. Clinical signs are involvement of mucosa 
and conjunctiva, grey skin lesions, and epidermal detachment. To date, the 
pathogenesis of SJS/TEN is incompletely understood. However, CD8+ cytotoxic T 
cells seem to play an important role in the effector phase of the disease as a 
multitude of CD8+ T cells has been found in the blister fluid of acute stage patients 
and it has been shown that these cells exert a drug-specific cytotoxicity against 
keratinocytes in a granzyme B-mediated manner [163, 164]. Another important 
mechanism leading to keratinocyte apoptosis involves the cytotoxic molecule 
FasLigand (FasL, CD95L). It has been demonstrated that keratinocytes from TEN 
patients express lytically active FasL and it has been proposed that Fas (CD95)-
FasL interactions are directly involved in massive keratinocyte death TEN [165, 
166]. Additionally the cytotoxic molecules granulysin and Annexin A1 have been 
shown to play a role in the pathogenesis of SJS/TEN [165, 167]. Moreover, a strong 
association of HLA-B*15:02 with carbamazepine-induced SJS/TEN in Han Chinese 
has been demonstrated [168], suggesting that genetic factors can influence the 
susceptibility to SJS/TEN [165].  
DRESS is a severe ADR which is characterized by a polymorphic macular popular 
rash (MPR) with high eosinophilia, facial edema and systemic symptoms including 
fever and visceral involvement. The latency period is relatively long and varies 
between two and eight weeks after culprit drug intake. The skin symptoms are 
versatile, usually appearing as a MPR, but vesicles, purpura, pustules and 
erythroderma have also been reported in many cases. Systemic symptoms are 
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fever, lymphadenopathy, cytotoxic hepatitis, pneumonitis, myocarditis, nephritis and 
colitis. Most cases are associated with elevated blood eosinophilia (>90%). The 
underlying pathomechanism is not well understood but it has been suggested that 
the reactivation of several herpes viruses and the expansion of activated memory 
CD8+ T cells that can specifically recognize viral peptides in the context of Human 
Leukocyte Antigen (HLA) class I play an important role [169]. This theory is 
supported by the strong association between DRESS caused by allopurinol and 




AGEP is a severe cutaneous adverse drug reaction characterized by the very rapid 
onset of a pustular eruption on an erythematous background, accompanied by fever 
and neutrophilia. 
 Epidemiology 
AGEP is a rare form of CADR, with a reported incidence of one to five cases per 
million people per year [171]. In 1968, Baker and Ryan were the first to describe 
such pustular eruption but it was then considered as the exanthematic subtype of 
pustular psoriasis [172]. The term AGEP was only introduced in 1980 by Beylot 
[173]. Women are preferably affected by this CADR [174]. The mortality rate of 
AGEP, reported between 1 and 5%, is the lowest among all severe CADRs. In >90% 
of cases, AGEP is caused by drugs [175]. The most frequent culprit drugs are 
aminopenicillins, sulphonamides, hydroxychloroquine, quinolone, terbinafin and 
diltiazem [176]. In rare cases, bacterial, viral or parasitic infections can also cause 
AGEP [177-182]. Spider bites have also been reported to induce AGEP [183, 184].   
 
 Clinical and histological features 
AGEP is characterized by the rapid disseminated development of a multitude of 
non-follicular, sterile pustules on an erythematous background. Usually it is 
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accompanied by fever >38°C and blood neutrophilia, with 30% of patients also 
presenting eosinophilia. Internal organs are usually not involved [185]. 
Upon interruption of culprit drug intake, the disease is usually self-limiting but topical 
and sometimes systemic steroids are recommended. In some severe cases, 
intensive supportive care is needed. Patients in the healing phase show pronounced 




Fig. 8. Clinical appearance of AGEP. Patient with numerous non-follicular pustules on a 
background of edematous erythema on the chest and on the abdomen after the intake of Terbinafin. 
Adapted from Hoetzenecker et. al. [162] 
 
Histological features are intraepidermal/subcorneal pustules, an abundant 





Figure 9. AGEP histology. Hematoxylin and Eosin staining of lesional skin of an AGEP patient 
revealing subcorneal neutrophil infilatration, necrosis of single keratinocytes and a dermal 
inflammatory infiltrate. Adapted from Sulewski et. al. [187]. 
 
 Etiology and pathogenesis 
To date, the pathophysiology of AGEP remains unclear. However, as for most other 
ADR, AGEP is currently considered as a T cell-mediated disease [188]. Indeed, 
drug-specific T cells are suspected to play a central role in AGEP as evidenced by 
the high levels of T cell stimulation induced selectively by causative (culprit) drugs 
as measured by the lymphocyte transformation test (LTT) [189]. Furthermore, drug-
specific CD4+ and CD8+ T cells have been derived in vitro from AGEP patients’ 
peripheral blood. Most of these drug-specific T cells [190] produce IL-8 [185, 191], 
a powerful chemoattractant for neutrophils. IL-8-producing T cells are therefore, to 
date, considered to be the cause of neutrophil survival and recruitment to the skin 
[192]. More recently, it has also been suggested that Th17 effector cytokines, 
namely IL-17 and IL-22, stimulate keratinocytes to produce IL-8, and that 
keratinocyte-derived IL-8 may also contribute to neutrophil accumulation in the skin 
of AGEP patients [193].  Hence, T cell- and keratinocyte-derived IL-8 has been 




AGEP shares certain clinical and histological features with pustular psoriasis and 
these overlapping features can render the diagnosis challenging. However, signs 
including the rapid onset and short duration of disease as well as an association 
with a recently administered drug and a spontaneous healing after its 
discontinuation, favor the diagnosis of AGEP. Recently, genetic studies identified 
mutations in IL-36RN, the gene encoding for IL-36Ra, in patients with general 
pustular psoriasis [86, 194-196]. Interestingly, mutations in IL-36RN have also been 
reported in rare cases of AGEP [197], suggesting that a dysregulation in IL-36 
signaling is involved in the physiopathology of both diseases. A mutation in IL-36RN 
may result in exacerbated IL-36 signaling leading to the downstream production of 
IL-1, IL-6 and IL-8 and subsequent neutrophilic skin infiltration with pustule 
formation.  
 
 Aim of the project 
AGEP is a rare and severe cutaneous drug eruption whose pathophysiology is 
largely unknown. Like all medication-induced side effects, AGEP is an important 
limitation to the use of certain important drugs in some patients. Thus, it is of high 
importance to understand the early mechanisms leading to this adverse reaction in 
order to be able to envisage means of prevention in patients known to present such 
risks.  
In this PhD thesis, I aim to investigate the pathomechanisms leading to AGEP. I will 
provide novel evidence that drugs causing AGEP can specifically trigger IL-36 
cytokine production by peripheral blood monocytes and keratinocytes from AGEP 
patients and subsequently induce IL-8 by peripheral blood mononuclear cells in an 
IL-36-dependent manner. These observations are supportive of a drug-specific 
dysregulation of IL-36 signaling as an important potential driver of the 
immunopathogenesis of AGEP, and identify myeloid cells and keratinocytes as new 
important players in AGEP. Furthermore, I will provide mechanistic insights into the 
disease development by showing an abnormal regulation of the NF-κB pathway in 




2 Materials and Methods 
 Materials 
 Skin biopsy and blood sampling 
Skin biopsies were taken from lesional skin of patients in the acute phase of the 
ADR (2x 6mm punch biopsies). Healthy skin samples were obtained from the 
Department of Plastic Surgery, University Hospital of Zurich. For paraffinization, skin 
samples were fixed in formalin 5% overnight. For RNA isolation, samples were 
snap-frozen in liquid nitrogen and stored at -80°C before use.   
Peripheral blood from patients were taken both in the acute phase of the disease 
and under healthy conditions (at least 6 months after the ADR). Serum from AGEP 
and MPR patients were obtained from Switzerland (N=17, Dermatology 
Department, University Hospital of Zürich), and from Asia (N=32, Dermatology 
Department of Chang Gung Memorial Hospital in Chinese Taiwan and Department 
of Dermatology of the Hokkaido University Graduate School of Medicine in Sapporo, 
Japan). Healthy controls were obtained from the Blood Donation Center, Schlieren, 
Switzerland.  
The characteristics of all studied AGEP patients from the Dermatology Department 
of the University Hospital of Zürich are presented in Supplementary Tables 1 and 2. 
All human samples were collected after informed written patient consent with 




AID ELISpot Reader (AID GmbH, Strassberg, Germany) 
Aperio ScanScope slide scanner (Leica Biosystems, Wetzlar, Germany) 
Axio Imager 2 Fluorescence Microscope (Zeiss, Oberkochen, Germany) 
BD FACS Canto (Franklin Lakes, NJ, USA) 
BD FACS Canto II (Franklin Lakes, NJ, USA) 
Bioanalyzer 2100 (Agilent, Waldbronn, Germany) 
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Cytation 3 (BioTek, Winooski, VT, USA) 
Facscanto A (Becton-Dickinson, Franklin Lakes, NJ, USA)  
Facscanto II (Becton-Dickinson, Franklin Lakes, NJ, USA)  
Illumina HiSeq device (Illumina, San Diego, CA, USA) 
Light Cycler 96 (Roche, Basel, Schweiz) 
Light Cycler 480 II (Roche, Basel, Schweiz) 
QuadroMACS™ Separator (Miltenyi Biotec, Bergisch Gladbach, Germany) 
Mastercycler gradient PCR machine (Eppendorf, Hamburg, Germany)  
Tissue Rupter (Polytron, Kinematica AG, Luzern, Switzerland) 
Qubit® (1.0) Fluorometer (Life Technologies, Carlsbad, CA, USA)  
Zeiss Axio Imager M2 Fluorescence Mikroskop (Zeiss, Oberkochen, Germany) 
Widefield BX61 fluorescence microscope (Olympus, Tokyo, Japan) 
 
 Primary antibodies 
Target Company Catalog 
number 
Dilution Assay 
CD3 Dako M7254 1:50 IF 
CD3-APC Biolegend 300312 1:20 FACS 
CD14-FITC BD 555397 1:5 FACS 
CD45-PE-Cy7 BD 560915 1:20 FACS 
CD68 Dako M0876 1:100 IF 
HLA-ABC Biolegend 311412 1:200 Neutralization 
HLA-DR Biolegend 307612 1:200 Neutralization 
IgG1 Biolegend 403102 Assay-
dependent 
Neutralization 
IL-36α R&D MAB2297 1:400 ICH/IF 
IL-36γ R&D AF2320 1:400 ICH/IF 
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IL-36γ Peprotech 500-P316 1:100 ELISpot 
IL-36γ 
biotinylated 
Peprotech 500-P316Bt 1:100 ELISpot 
IL-8 LSBio LS-C165213 1:100 IHC 
IL-1β Abcam ab53175 1:100 IHC 
TLR2 Invivogen maba2-htlr2 Assay-
dependent 
Neutralization 





 Secondary antibodies 
Target Company Catalog number Dilution 
anti-rabbit IgG 
biotinylated 
Abcam ab6720 1:200 
anti-mouse IgG 
biotinylated 
Abcam ab6788 1:200 
anti-goat IgG 
biotinylated 
Santa Cruz sc-2042 1:200 
Alexa Fluor® 488 
Goat Anti-Mouse IgG 
Life technologies A11001 1:200 
Alexa Fluor® 647 
Donkey Anti-Goat IgG 
Abcam ab150131 1:100 
 
 
 Kits and reagents 
 
Agilent SureSelectXT All exons V5 kit Agilent Technologies, Santa Clara, CA, 
USA 




CD14 MicroBeads, human Miltenyi Biotech, Bergisch Gladbach, 
Germany 
ELISA development kit for human IFNγ R&D Systems, Minneapolis, MN, USA 
ELISA development kit for human IL-1β R&D Systems, Minneapolis, MN, USA 
ELISA development kit for human IL-6 R&D Systems, Minneapolis, MN, USA 
ELISA development kit for human IL-8 Biolegend, San Diego, CA, USA 
ELISA development kit for human IL-17A Biolegend, San Diego, CA, USA 
Human Exon 1.0 ST Affymetrix chips Affymetrix, Santa Clara, CA, USA 
LEGENDplex Kit Biolegend, San Diego, CA, USA 
MACS Separator Miltenyi Biotech, Bergisch Gladbach, 
Germany 
NBT/BCIP substrate kit Promega, Madison, WC, USA 
Pan T Cell Isolation Kit, human Miltenyi Biotech, Bergisch Gladbach, 
Germany 
QIAamp DNA mini kit Qiagen, Hilden Deutschland 
RevertAid First Strand cDNA Synthesis 
Kit 
Thermo Fisher Scientific, Carlsbad, CA, 
USA  
RNeasy® Fibrous Mini Kit Qiagen, Hilden Deutschland 
RNeasy® Micro Kit Qiagen, Hilden Deutschland 
TruSeq PE Cluster Kit v3-cBot-HS Illumina, Inc., San Diego, CA, USA 
TruSeq SBS Kit v3- Illumina, Inc., San Diego, CA, USA 
Vectastain ABC kit Vector Laboratories, Burlingame, CA, USA 
 
 Chemicals and other consumables 
 
Albumin from human serum Sigma, Munich, Germany 
Amoxicillin  Sigma, Munich, Germany 
Antibody Diluent  Dako, Glostrup, Denmark  
Bovine serum albumin (BSA) Sigma, Munich, Germany 
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Carbamazepine Sigma, Munich, Germany 
DAPI (4',6-Diamidino-2-phenylindole) Thermo Fisher Scientific, Carlsbad, CA, 
USA 
Deoxynucleotide triphosphates (dNTPs) Roche, Basel, Switzerland 
Dulbecco’s Phosphate buffered saline (PBS)  
(w/o Ca2+, Mg2+) 
Biochrom, Berlin, Deutschland 
Ethanol (EtOH) Fluka Chemie, Buchs, Switzerland 
Ethanol 70 % V/V Kantonsapotheke, Zurich, Switzerland 
Ethanol 80 % V/V KA PhEur Kantonsapotheke, Zurich, Switzerland 
Ethanol 96 % V/V KA PhEur Kantonsapotheke, Zurich, Switzerland 
Ethanol absolut KA PhEur Kantonsapotheke, Zurich, Switzerland 
Faramount Mounting Medium, Aqueous Dako, Glostrup, Denmark 
FastStart Universal SYBR Green Master  Roche, Basel, Switzerland 
Ficoll-Paque PLUS  GE Healthcare, Little Chalfont, UK 
Flasks and (multiwell) dishes for cell culture Nunc, Roskilde, Denmark 
Fluconazol Sigma, Munich, Germany 
Fluorescence Mounting Medium  Dako, Glostrup, Denmark 
Haematoxylin solution J.T.Baker, Phillipsburg, US-NJ 
Peroxidase-Blocking solution Dako, Glostrup, Denmark 
Letrozole Sigma, Munich, Germany 
Metamizole sodium hydrate Sigma, Munich, Germany 
Pan-caspase inhibitor (z-VAD-fmk) Alexis, Lausen, Switzerland 
Pepinh-MYD (MyD88 Inhibitory Peptide) Invivogen, San Diego, CA, USA 
PepinhTRIF (TRIF Inhibitory Peptide) Invivogen, San Diego, CA, USA 
Recombinant (r) IFNα  
rIFNγ Peprotech, Rocky Hill, NJ 
rIL-1β Peprotech, Rocky Hill, NJ 
rIL-8 R&D Systems, Minneapolis, MN, USA 
rIL-36Ra R&D Systems, Minneapolis, MN, USA 
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rTNFα Peprotech, Rocky Hill, NJ 
RNA later Qiagen, Hilden, Germany 
Slides Super FrostTM Plus Thermo Scientific, Watham, MA, USA 
SYBR Green (FS Eessential DNA Green 
Master) 
Roche, Basel, Switzerland 
Target Retrieval Solution  Dako, Glostrup, Denmark  
Terbinafin hydrochloride Sigma, Munich, Germany 
Tetradecanoyl-Phorbolacetate (TPA) Sigma, Munich, Germany 
Tetramethylethylenediamide (TEMED) Sigma, Munich, Germany 
TIRAP Inhibitor Peptide Millipore, Billerica, MA, USA 
Transwell polycarbonate membrane cell 
culture inserts, 12 mm Transwell with 0.4 μm 
pore polycarbonate membrane insert 
Corning, Corning, NY, USA 
Triton-X 100 Sigma, Munich, Germany 
Trypsin Gibco BRL, Paisley, Scotland 
Ultrapure LPS (upLPS) Invivogen, Toulouse, France 
Vancomycin Sigma, Munich, Germany  
Xylene Synopharm, Ofingen, Switzerland 





 Buffers and solutions 
 
AP (Alkaline phosphatase) buffer  100 mM NaCl 
5 mM MgCl2  
100 mM TRIS/HCl (pH 9.5)  
PBS (Phosphate buffered saline) 
 
137 mM NaCl  
2,7 mM KCl 




Tween20 0.1 % (v/v) 
Reagent Diluent  PBS 
1% BSA 
2N H2SO4 5.5ml H2SO4 
ad 100ml ddH20 
 
 Cell culture media and additives  
Anti-anti antibiotic-antimycotic (A/A) Gibco BRL, Paisley, Scotland 
DMEM Gibco BRL, Paisley, Scotland 
Fetal bovine serum (FBS), heat inactivated Gibco BRL, Paisley, Scotland 
Keratinocyte-SFM, EGF, BPE  Gibco BRL, Paisley, Scotland 
RPMI 1640  Gibco BRL, Paisley, Scotland 
Complete Keratinocyte medium for keratinocyte 
isolation from hair follicles 
¾ DMEM + 1% Pyruvate + ¼ HAM's 
F12  
10% FCS 
102 U/ml penicillin 
 0.1 mg/ml streptomycin  
2 mM glutamin  
0.4 µg/ml hydrocortison  
10-10 M choleratoxin  
5 µg/ml insulin 
20 µg/ml adenin  
5 µg/ml transferrin  
2 x 10-9 M trijodthyronin  






 Gene expression array  
2.2.1.1 General remark 
Experiments have been performed by the staff of the Functional Genomics Center 
of Zurich.  
2.2.1.2 Sample processing and data analysis 
Gene expression profiling was performed using arrays of Human Exon 1.0 ST 
Affymetrix chips. The Raw fluorescence intensity values were analyzed using the R 
packages Affy [198] and Limma of Bioconductor [199]. 
The gene expression data analysis consists of the following steps: 1. between-array 
normalization, 2. probe summary with the rma algorithm, 3. fitting the data to a linear 
model and 4. detection of differential gene expression. Quantile-normalization was 
applied to the log2-transformed intensity values as a method for between-array 
normalization, to ensure that the intensities had similar distributions across arrays 
[200]. To find genes with significant expression changes between groups, empirical 
Bayes statistics were applied to the data by moderating the standard errors of the 
estimated values. P-values were obtained from the moderated t-statistic and 
corrected for multiple testing with the Benjamini–Hochberg method [201]. The P-
value adjustment guarantees a smaller number of false positive findings by 
controlling the false discovery rate (FDR). 
Quality control and gene expression microarray data analysis was done using 
R/Bioconductor software (Fred Hutchinson Cancer Research Center, Seattle, WA) 
[199]; signal intensity files were summarized using the robust multi array average 
(RMA) [200] for processing and quantile normalization. A modified t-test using limma 
software (part of the Bioconductor project) [202] was performed for comparison of 
the experimental conditions. Both the p-values and the Benjamini-Hochberg False 





2.2.2.1 General remark 
Experiments have been performed by the staff of the Functional Genomics Center 
of Zurich.  
2.2.2.2 Library preparation 
The quantity and quality of the isolated RNA was determined with a Qubit® (1.0) 
Fluorometer (Life Technologies, California, USA) and a Bioanalyzer 2100 (Agilent, 
Waldbronn, Germany). The TruSeq Stranded mRNA Sample Prep Kit (Illumina, Inc, 
California, USA) was used in the subsequent steps. Total RNA samples (500ng to 
1 μg) were ribosome depleted and then reverse-transcribed into double-stranded 
cDNA with Actinomycin added during first-strand synthesis. The cDNA samples 
were fragmented, end-repaired and polyadenylated before ligation of TruSeq 
adapters. The adapters contain the index for multiplexing. Fragments containing 
TruSeq adapters on both ends were selectively enriched by PCR. The quality and 
quantity of the enriched libraries were validated using a Qubit® (1.0) Fluorometer 
and the Bioanalyzer 2100 (Agilent). The product is a smear with an average 
fragment size of approximately 360 bp. The libraries were normalized to 10nM in 
Tris-Cl 10mM, pH8.5 with 0.1% Tween 20. 
 
2.2.2.3 Cluster Generation and RNA Sequencing 
The TruSeq PE Cluster Kit v3-cBot-HS (Illumina, Inc., CA) was used for cluster 
generation using 8pM of pooled normalized libraries on the cBOT. RNA sequencing 
was performed on an Illumina HiSeq with a 2500 paired end approach at 2 X126 bp 
using the TruSeq SBS Kit v3-HS (Illumina, Inc.). 
 
2.2.2.4 Data analysis 
Bioinformatic analysis was performed using SUSHI [203]. In detail, the raw reads 
were quality checked using Fastqc 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and FastQ Screen 
(http://www.bioinformatics.babraham.ac.uk/projects/fastq_screen/). Quality 
controlled reads (first five bases trimmed, minimum average quality Q20, minimum 
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tail quality Q10) were aligned to the reference transcriptome (Ensembl GRCh38, not 
patched) for transcript abundance estimation using RSEM [204]. Differential 
expression analysis was performed using edgeR [205]. Gene ontology (GO) 
enrichment analysis was performed using the Bioconductor packages goseq [206] 
and GOStats [207], and visualized using ReViGo [208]. Enrichment analysis of other 
gene sets was performed using Enrichr [209].    
 
 Serum preparation 
Blood was taken from AGEP, MPR and healthy donors in serum tubes (BD 
Vacutainer, BD, Franklin Lakes, NJ) and left untouched for 30-60 minutes to allow 
the cells and clotting factors to clot to form. Serum was prepared by centrifugation 
of whole blood at 1’300 rpm for 10 minutes in a 50 ml Falcon. The supernatant 
(representing the serum) was taken, aliquoted and stored at -20°C until use in 
experiment. 
 
 PBMC isolation 
PBMCs were isolated using a density gradient. For this purpose EDTA blood from 
AGEP, MPR and healthy donors was diluted 1:1 with PBS. 50 ml Falcon tubes were 
filled with 15 ml Ficoll-Paque Plus® (GE Healthcare, Little Chalfont, UK) and 35ml of 
the diluted blood was slowly applied on the Ficoll layer, followed by centrifugation at 
2000rpm with slow acceleration and breaking rate for 20 minutes at room 
temperature (RT). PBMC were then collected from the interphase and transfered to 
a fresh 50ml Falcon tube. The tube was filled up with PBS and centrifuged at 
1200rpm for 10 minutes to wash the cells. The supernatant was discarded and the 
washing  step was repeated. Cells were then resuspended in medium for use in 
experiment or frozen down in FBS containing 10% DMSO using a cryo-box. 
 
 CD14+ monocytes isolation 
CD14+ monocytes were isolated using magnetic-activated cell sorting (MACS). 
Freshly isolated PBMC from human AGEP, MPR and healthy blood were counted 
and resuspended in cold MACS buffer. Cells were centrifuges at 1200 rpm for ten 
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minutes, then the supernatant was discarded. Cells were resuspended in 80µl of 
MACS buffer per 107 total cells and 20µl of CD14 beads were added. The 
suspension was mixed and incubated for 15 minutes at 4-8°C in the dark. Cells were 
washed by adding 30 ml of cold MACS buffer, followed by centrifugation at 1200 
rpm for 10 minutes. The supernatant was discarded and the cells were resuspended 
in 500µl of MACS buffer. Magnetic separation was then performed using MACS 
columns LS. For this purpose the LS columns were placed in the magnetic field of 
the QuadroMACS™ Separator (Miltenyi Biotec, Bergisch Gladbach, Germany) and 
50ml Falcon tubes were placed under each column to collect the flow-through. The 
columns were prepared by rinsing with 3ml of MACS buffer. The cell suspension 
was added onto the column, followed by 3x 3ml of MACS buffer. The unlabeled cells 
were collected in the Falcon tube. To elute the CD14+ cell fraction, the column was 
placed on a new 10ml falcon tube and 5ml of MACS buffer were added to the 
column. The plunger was then pushed into the column, thereby eluting the 
magnetically labeled CD14+ cells.  
 
 CD3+ T cell isolation 
The flow-through from step 1.8.5 was centrifuged at 1300 rpm for 10 minutes and 
the supernatant was discarded. The cells were resuspended in 40µl of MACS buffer 
per 107 total cells and 10µl of Pan T cell Biotin-Antibody was added. The cell 
suspension was mixed well and incubated for 5 minutes at 4-8°C. As a next step, 
30µl of MACS buffer were added, followed by 20µl of Pan T Cel MicroBead Cocktail. 
The suspension was mixed well and incubated for 10 minutes at 4-8°C in the dark. 
Magnetic separation was then performed using MACS columns LS. For this purpose 
the LS columns were placed in the magnetic field of the QuadroMACS™ Separator 
(Miltenyi Biotec) and 50ml Falcon tubes were placed under each column to collect 
the flow-through. The columns were prepared by rinsing with 3ml of MACS buffer. 
The cell suspension was applied onto the column and the flow-through was 
collected, and the columns were washed with 3x 3ml of MACS buffer. The flow-




 Flow cytometry 
Cells in a pellet were washed 3 times with PBS and transferred to 96-well U-bottom 
plates. After washing the cells 3 times with FACS buffer (2 % FCS in PBS), 5µl of 
PE-Cy7-labeled anti-CD45, 20µl of FITC-labeled anti-CD14 or 5µl of APC-labeled 
anti-CD3 (single stainings and triple-stainings) were added to the cell suspensions 
in a total volume of 100µl and incubated for 30 minutes at 4°C in the dark. The cells 
were washed 3 times with FACS buffer, taken up in 200 µl FACS buffer and 
analyzed directly using a FACSCanto (BD, Franklin Lakes, US-NJ) with FACS DIVA 
software (BD, Franklin Lakes, US-NJ). Data were compiled using FlowJo analysis 
software (TreeStar Inc.).  
 
 Keratinocyte isolation from hair follicles 
Hair including follicles were collected from patients and the extremities containing 
outer root sheath were cut. After washing the hair in complete keratinocyte medium 
[210] containing 100µg/ml kanamycin, it was incubated for 3 minutes in 1mg/ml 
Dispase II, followed by three washing steps in keratinocyte medium. The hair was 
then plated on Mitomycin-treated J2 feeder cells in complete keratinocyte medium 
and cultured until small colonies of keratinocytes become visible. Cells were splitted 
at 80% confluence and passaged three times before being used for experiments. 
 
 Preparation of drug solutions for cell stimulation 
Drug solutions were prepared by dissolving the drugs in powder form in RPMI + 
10%FBS, in Opti-MEM or PBS. Concentrations were administered by testing cell 
viability upon 24 hours of drug stimulation and the highest possible concentration 
was used for experiment.   
 
   Co-culture experiments 
70.000 AGEP hair follicle keratinocytes were plated in Gibco keratinocyte medium 
(Thermo Scientific) on a 12mm transwell plate with 0.4µm pore polycarbonate 
membrane inserts (Corning, Corning, NY, USA) overnight to allow them to adhere. 
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The following day, keratinocyte medium was replaced by Gibco Opti-MEM medium 
(Thermo Scientific) and 1x106 PBMC from patients having experienced AGEP, but 
in remission at the time of blood and hair collection (blood and hair collection at least 
6 months after remission), added inside the polycarbonate membrane inserts, 
followed by addition of stimuli in both compartments at the same concentration. After 
6 hours of incubation, cells were harvested and RNA was isolated for Real-Time 
quantitative PCR analysis. 
 
   RNA isolation  
2.2.11.1 RNA isolation from fresh-frozen skin  
Total RNA was isolated from AGEP, MPR and healthy skin biopsies using the 
Fibrous Tissue Kit (Qiagen, Hilden, Germany). All mentioned chemicals were 
provided with the kit.  
Fresh-frozen skin was thawed in 300µl of RLT buffer containing β-Mercaptoethanol 
(β-ME) in a 14ml Falcon round-bottom tube. The tissue was then disrupted and the 
lysate was homogenized using a Tissue Rupter (Polytron, Kinematica AG, Luzern, 
Switzerland). The homogenized tissue was transferred into a 2ml Eppendorf tube 
and 590µl of RNase-free water was added, followed by 10µl of proteinase K. The 
solution was mixed well and incubated at 55°C for 10 minutes. The samples were 
centrifuged at 10.000 rpm for 3 minutes at RT and the supernatant was then 
transferred into a new 2ml Eppendorf tube. 450µl of 100% ethanol were added and 
mixed well by pipetting. 700µl of the sample were transferred to an RNeasy Mini 
Spin Column and centrifuged at 10.000 rpm for 15 seconds. The flow-through was 
discarded and the last step was repeated until no sample was left. To wash the 
membrane, 350µl of buffer RW1 was added to the RNeasy Spin Column, 
centrifuged for 15 seconds and the flow-through was discarded. DNase I treatment 
was performed by preparing a mix of DNase I and buffer RDD (10µl DNase I + 70µl 
buffer RDD per sample). This mix was added onto the membrane of the RNeasy 
Mini Spin Column and incubated for 15 minutes at RT. The column was washed 
with 350µl buffer RW1 and centrifuged at 10.000 rpm for 15 seconds. The flow-
through was discarded and 500µl of buffer RPE was added to the spin column, 
followed by centrifugation at 10.000 rpm for 15 seconds. The flow-through was 
 
 41 
discarded and another 500µl of buffer RPE was added to the spin column, followed 
by centrifugation at 10.000 rpm for 2 minutes. The spin column was then placed into 
a new 2ml collection tube and centrifuged at full speed for 5 minutes to remove 
residual liquid and dry out the membrane. The spin column was then placed into a 
new 1.5ml collection tube and 15-20µl of RNase-free water were added directly onto 
the membrane. The columns were centrifuged at full speed for 1 minute at RT to 
elute the RNA. The isolated RNA was kept on ice for further processing or stored at 
-80°C. 
 
2.2.11.2 RNA isolation from cells 
Total RNA was isolated from PBMC and keratinocytes using the RNeasy Micro Kit 
(Qiagen, Hilden, Germany). All mentioned chemicals were provided with the kit.  
Cells were harvested and collected as a pellet in a 2ml Eppendorf tube and 350µl 
of RLT buffer containing β-ME was added. The same volume of 70% ethanol was 
added. The solution was mixed well and 700µl was transferred to an RNeasy 
MinElute spin column in a 2ml collection tube, centrifuged at 10.000 rpm for 15 
seconds and the flow-through was discarded. This step was repeated until no 
sample was left. 350µl of buffer RW1 was added to the spin column and centrifuged 
for 15 seconds at 10.000 rpm. The flow-through was discarded. DNase I treatment 
was performed by preparing a mix of DNase I and buffer RDD (10µl DNase I + 70µl 
buffer RDD per sample). This mix was added onto the membrane of the spin column 
and incubated for 15 minutes at RT. The column was washed with 350µl of RW1 
and the flow-through was discarded. 500µl of buffer RPE was added, centrifuged 
for 15 seconds at 10.000 rpm and the flow-through was discarded. Then 500µl of 
80% ethanol was added and centrifuged for 2 minutes at 10.000 rpm. The spin 
column was placed in a new 2ml collection tube. The lid of the spin column was 
opened and the samples were centrifuged at full speed for 5 minutes to dry out the 
membrane. The spin column was then placed in a new 1.5ml collection tube and 
14µl of RNase-free water was added and centrifuged for 1 minute at full speed to 





   cDNA synthesis  
cDNA synthesis was performed by reverse transcription using the Revert Aid First 
Strand cDNA Kit (Thermo Scientific, Watham, MA). Mix 1 was prepared in a 0.2ml 
Eppendorf tube on ice according to the RNA concentration and incubated for 5 
minutes at 65°C. The tubes were then stored on ice and mix 2 was prepared of 
which 8µl was added to each reaction. The PCR program included 5 minutes 
incubation at 25 °C, 60 minutes at 42°C and 5 minutes at 70°C. The PCR reaction 




RNA          1g (max volume 11l) 
Random Primer  1l 




5x Reaction buffer       4 l 
RiboLock RNase inhibitor 1 l 
10mM dNTP Mix       2 l 





   Real-Time quantitative PCR 
Primer sequences were obtained from http://pga.mgh.harvard.edu/primerbank/:  
 
hRPL27 F 5`-ATC GCC AAG AGA TCA AAG ATA A-3' 
hRPL27 R 5`-TCT GAA GAC ATC CTT ATT GAC G-3' 
hIL36a F 5`-CCA GAC GCT CAT AGC AGT CC-3' 
hIL36a R 5`-AGA TGG GGT TCC CTC TGT CTT-3' 
hIL36b F 5`-ATG AAC CCA CAA CGG GAG G-3` 
hIL36b R 5`-TAA TGC TGC GGC TAA GAG GAG-3` 
hIL-36g F 5`-AGG AAG GGC CGT CTA TCA ATC-3' 
hIL-36g R 5`-CAC TGT CAC TTC GTG GAA CTG-3' 
hIL-36R F 5`-CCG AGG TGT TGG AGA GAC AAT G-3' 
hIL-36R R 5`-GGA CCA CAA TGA CAA TCA GCC TC-3' 
hIL36RN F 5`-ACT CGG CAT TGA AGG TGC TTT-3' 
hIL36RN R 5`-GGG ACC ACG CTG ATC TCT T-3' 
hIL-8 F 5`-TTT TGC CAA GGA GTG CTA AAG A-3' 
hIL-8 R 5`-AAC CCT CTG CAC CCA GTT TTC-3' 
hIL-1β F 5`-CAC GAT GCA CCT GTA CGA TCA-3' 
hIL-1β R 5`-GTT GCT CCA TAT CCT GTC CCT-3' 
ITGA6 F 5'-TCA TGG ATC TGC AAA TGG AA-3' 
ITGA6 R 5'-AGG GAA CCA ACA GCA ACA TC-3' 
CD45 F 5'-ACA GCC AGC ACC TTT CCT AC-3' 
CD45 R 5'-GTG CAG GTA AGG CAG CAG A-3' 
 
 
The real-time PCR was performed with cDNA from total cellular RNA or from tissue 
RNA and a primer pair designed to a fragment of ~150 bp in length flanking an 
intron-exon border of the desired gene. To quantify the relative expression level of 
a certain gene, two reaction mixes were prepared. One contained the primer pair 
targeting the gene of interest, the other contained a primer pair targeting an internal 




The following mixture was prepared on ice in LightCycler 96 or 480 Multiwell 
detection plates: 
 
qPCR reaction mix  
cDNA 1µl 
Primer mix 0.5µl 
SYBR Green  5µl 
RNase-free H2O 3.5µl 
 
The primer mix was prepared by adding 7.5µl of 3’-
7.5µl of 5’-Primer solution (100µM) to 185µl RNase-free water. 
 
Real-time quantitative PCR was performed using a Light Cycler 96 and a Light 
Cycler 480 II (Roche, Basel, Switzerland) and included an initial denaturation at 
95°C for 10 min, followed by 40 cycles at 95°C for 30 s, 55°C for 1 min, 72°C for 1 
min, and one cycle at 95°C for 1 min, 55°C for 30 s, 95°C for 30 s.  
Specificity of the reaction was ensured by surveying the dissociation curve of a given 
primer pair. Data processing was performed using the LightCycler 480 software 
provided by the manufacturers according to the guidelines. Data evaluation and 
statistical analysis followed the rules of the ᴧCT method described by the system 
manufacturer. 
 
   Immunohistochemical stainings  
To analyze IL-36, IL-8 and IL-1β expression on tissue, 5µm paraffin-embedded 
AGEP, MPR and healthy control skin sections were deparaffinized and rehydrated. 
Antigen demasking was performed using pressure cooker heating of the slides for 
25 minutes in Target Retrieval solution (DAKO, Glostrup, Denmark). After 
permeabilization using 0.03% Triton X in PBS for 10 minutes, sections were blocked 
using 5% BSA in PBS for one hour at room temperature. After washing with PBS, 
sections were stained overnight at 4°C with 0.5µg/ml goat anti-human IL-36α or 
0.5µg/ml goat anti-human IL-36γ (both from R&D, Minneapolis, MN), or 2µg/ml 
rabbit anti-human IL-8 (LSBio, Seattle, WA) or 10µg/ml rabbit anti-human IL-1β 
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(Abcam, Cambridge, UK). A goat IgG isotype antibody (R&D, Minneapolis, MN) and 
a rabbit IgG isotype antibody (Abcam) at corresponding concentrations were used 
as controls. Slides were washed with PBS and a goat-anti-rabbit secondary 
antibody (Southern Biotech, Birmingham, USA) was added and incubated for 1 hour 
at room temperature. Slides were washed with PBS and mounted with an Avidin-
Biotin-complex (Vector Laboratories, Peterborough, UK). After 45 minutes of 
incubation, slides were washed with PBS, and AEC (3-amino-9-ethylcarbazole) 
HRP substrate (Vector Laboratories) was added to produce a red reaction product. 
After washing, a counterstain with hematoxylin was performed. The sections were 
mounted in Faramount mounting medium (DAKO) and imaged by using an Aperio 
ScanScope (Leica Biosystems, Wetzlar, Germany).   
 
   Immunofluorescence stainings 
To analyze the cellular source of IL-36 expression cells in tissue, 5µm paraffin-
embedded AGEP sections were deparaffinized and rehydrated. Antigen demasking 
was performed using pressure cooker heating of the slides for 25 minutes in Target 
Retrieval solution (Dako). After permeabilization using 0.03% Triton X in PBS for 10 
minutes, sections were blocked using 5% BSA in PBS for one hour at room 
temperature. Sections were then stained overnight at 4 °C with a) 0.5µg/ml goat 
anti-human IL-36α (R&D), together with either 20µg/ml mouse anti-human CD3 
(Dako) or 20µg/ml mouse anti-human CD68 (Dako), or b) with 0.5µg/ml goat anti-
human IL-36γ (R&D), together with either 20µg/ml mouse anti-human CD3 (Dako) 
or 20µg/ml mouse anti-human CD68 (Dako) or 20 µg/ml mouse anti-human 
Myeloperoxidase (Dako). Goat IgG isotype (R&D, Minneapolis, MN) and mouse IgG 
isotype (Abcam) antibodies at corresponding concentrations was used as isotype-
specific controls. After washing with PBS, samples were incubated for 60 min at 
room temperature with conjugated secondary antibodies as follows: Alexa Fluor® 
488 Goat Anti-Mouse IgG (Life Technologies, Carlsbad, CA) and Alexa Fluor® 647 
Donkey Anti-Goat IgG (Abcam). Nuclear staining was performed at the same time 
using 4',6-diamidino-2-phenylindole (DAPI, Thermo Fisher Scientific, Carlsbad, 
CA). Slides were mounted with Fluorescence Mounting Medium (Dako) and 
analyzed with a Widefield BX61 fluorescence microscope (Olympus, Tokyo, Japan) 
using the Analysis Pro software (Soft Imaging Systems, Münster, Germany) and the 
 
 46 
Axio Imager 2 Fluorescence Microscope (Zeiss, Oberkochen, Germany) using the 
ZEN software (Zeiss).   
 
   Enzyme Linked Immunosorbent Assay (ELISA) 
AGEP, MPR and healthy control serum samples were analyzed for the presence of 
cytokines by ELISA. Human IL-6, IL-17A and IFN-γ were determined using ELISA 
kits from R&D Systems, and human TNF and IL-8 using ELISA kits from Biolegend 
(San Diego, CA, USA).  
ELISA plates were coated with 70µl of capture antibodies diluted in PBS and 
incubated overnight at RT. The next day, the plate was washed 2x with 
PBS+Tween-20 and 100 µl of reagent diluent (PBS + 5% BSA) were added to each 
well. After one hour of incubation the wells were washed 2x with PBS-T and 70µl of 
samples, standard, blank and negative control were added to the according wells 
and incubated for two hours at RT. The samples were discarded and the wells were 
washed 3x with PBS-T. As a next step, 70µl of the detection antibodies, diluted in 
reagent diluent, were added to the wells and incubated for two hours at RT. After 
washing the wells 3x with PBS-T, 70µl of Strepatavidin-HRP, diluted in reagent 
diluent, were added to each well and incubated for 30 minutes at RT. The wells were 
then washed 5x with PBS-T and 70µl of substrate was added to each well and 
incubated at RT in the dark until blue colour emerged. The reaction was then 
stopped  by adding 35µl of 2N H2SO4 to each well. Optical densities were measured 
by the the Cytation 3 ELISA reader at a wavelength of 450 nm.  
 
Human IL-36α and IL-36γ were detected using ELISA kits from Cusabio (Hubei, 
China). The ELISA assays were performed according to the manufacturer’s 
instructions. Optical densities were measured by the the Cytation 3 ELISA reader at 
a wavelength of 450 nm.  
 
   Enzyme Linked Immuno Spot Assay (ELISpot) 
To perform ELIspot analysis, PVDF-plates (Merck Millipore, Billerica, MA) were pre-
wetted by 50µl 70% ethanol per well for 2 minutes. After washing with PBS, plates 
were coated with 2μg/ml anti-human IL-36γ (Peprotech, Rocky Hill, NJ) or 15μg/ml 
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anti-human IL-1β (Mabtech, Nacka Strand, Sweden) per well overnight. After 
removing excess antibody and washing with PBS, a blocking step was performed 
using RPMI medium containing 10% FBS. After one hour of incubation, the medium 
was removed and the cell suspensions ± stimuli were added and incubated at 37°C 
for the indicated time (Fig. 5). After washing with PBS, 2μg/ml biotinylated anti-IL-
36γ (Peprotech) or 1μg/ml biotinylated anti-IL-1β antibody was added to the wells 
and incubated for 2 hours at room temperature, followed by one-hour incubation 
with Streptavidin-ALP (Mabtech). For detection of the protein, BCIP/NBT substrate 
mix (Promega, Dübendorf, Switzerland) in AP buffer was added and developed until 
distinct spots emerged. Data was analyzed using the AID ELISpot Reader (AID 
GmbH, Strassberg, Germany).  
 
   Cytometric bead assay  
The experiment has been performed by Alaz Özcan Özge from the research group 
of Prof. Dr. Onur Boyman.  
Cytometric bead assay (CBA) was performed using the LEGENDplex Kit 
(Biolegend, San Diego, CA) and experiments were performed in a V bottom plate. 
As a first step, 25µL of Matrix B were added to the standard wells and 25 µL of 
Assay Buffer to sample wells. The standards were prepared and 25 µL of each 
standard was added to the according wells. Then 25µL of each serum sample 
(undiluted) was added form to the according wells. Finally,  25µL of mixed beads to 
were added to all wells, followed by 25µL detection antibodies. The entire plate was 
covered with aluminum foil to protect the plate from light and shaked at 600 rpm on 
a plate shaker for 2 hours at room temperature. Without washing the plate, 25µL of 
SA-PE were added to each well. The entire plate was packed again with aluminum 
foil and shaked at 600rpm on a plate shaker for 30 minutes at room temperature. 
The plate was then centrifuged at 1,000 x g for 5 minutes, using a swinging bucket 
rotor with microplate adaptor. The supernatant was removed using a multichannel 
pipette and 200µL of 1x Wash Buffer were added to all wells. The beads were 
resuspended by shaking on a plate shaker for 1 minute. The plate was then 
centrifuged again at 1,000 x g for 5 minutes, using a swinging bucket rotor with 
microplate adaptor and the supernatant was removed. 200µL of 1x Wash Buffer 
were then added to each well and the beads were resuspended by pippeting. The 
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samples were read on a FACS Canto II flow cytometer  (BD) with FACS DIVA 
software (BD). Data were compiled using LEGENDplexTM Data Analysis Software.  
 
   Whole Exome Sequencing 
Experiments Experiments have been performed by Alexander Navarini and 
colleagues in London, UK. 
DNA was extracted from AGEP and healthy control PBMC using the QIAamp DNA 
mini kit (Qiagen, Hilden Deutschland) according to manufacturer’s instructions. 
Genomic DNA was fragmented with ultrasonic shearing to fragments of about 150-
200bp. End repair, adenylation of the 3’ end and adaptor ligation was performed 
using the Agilent Sure SelectXT kit according to manufacturer’s instructions. 
Biotinylated RNA (ribonucleic acid) oligos were hybridized in order to select the 
exomic sequences using the Agilent SureSelectXT All exons V5 kit according to 
manufacturer’s instructions. Sequencing was carried out on an Illumina HiSeq 
device using 125bp paired-end sequencing. The sequence reads obtained were 
aligned to the reference human genome (hg19) using BWA sequence aligner. 
Capture efficiency coverage and quality score were determined with R and 
sequence recalibration was performed as per GATK (Genomic Analysis Tool 
Kit https://www.broadinstitute.org/gatk/) guidelines.  
 
   Statistical analysis 
Differences between groups were assessed using one-way Anova followed by 
Turkey’s post-test. Differences were considered significant when: *p≤0.05, ** 










This manuscript in preparation will be shortly submitted for publication. Barbara 
Meier has performed 90% of all experiments in this manuscript including the 
experimental design and has been actively involved in the design and the writing of 
the manuscript.  
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 Enhanced IL36 and IL-8 gene expression in lesional skin of 
AGEP patients 
In a first unbiased approach, we performed gene expression profiling using 
Affymetrix Human Exon 1.0 ST chips. Total RNAs were extracted from lesional skin 
from patients suffering from AGEP (n=8), from patients with maculo-papular rash 
(MPR, n=6), and from healthy skin from individuals undergoing plastic surgery (n=7). 
The hierarchical clustering of genes differentially expressed in AGEP, MPR and 
healthy skin biopsies revealed a perfect segregation of these three conditions based 
on the gene expression profile of individual samples and the magnitude of change 
in gene expression (Fig.10A and Suppl. Table 3). IL-8 has been previously reported 
to be produced by drug-specific T cells in the skin of AGEP patients [185] and in 
accordance with this, IL-8 expression was significantly upregulated in AGEP skin 
biopsies analyzed here when compared to healthy skin (ratio=2.25, p=0.01; Suppl. 
Table 4) but also when compared to MPR (ratio=2.24, p=0.008; Suppl. Table 6). 
Interestingly, the IL-36γ gene (IL1F9) was also found to be significantly 
overexpressed in AGEP skin biopsies when compared to healthy skin (ratio=3.06, 
p=0.0006; Suppl. Table 4) and MPR (ratio=2.54, p=0.005; Suppl. Table 5). RNAseq 
analysis of a second, independent series of AGEP (n=9) and MPR (n=8) patient 
lesional skin biopsies confirmed the overexpression of the IL-36γ gene (ratio=3.12; 
p=0.02) in AGEP (Fig.10B). Although not reaching statistical significance (p=0.12), 
RNAseq analysis also revealed an overexpression of IL-8 (ratio=2.31) in AGEP skin. 
We then confirmed the observed upregulation of IL-36γ and IL-8 by quantitative 
PCR in AGEP (n=16) and MPR (n=16) skin biopsies. In accordance with the gene 
expression array and RNAseq data, expression of IL-36γ was found to be 
significantly upregulated (32-fold, p<0.0001) in AGEP skin biopsies when compared 
to MPR (Fig. 1C). In addition to IL-36γ, IL-36α (15-fold, p<0.0001) and IL-36β (28-
fold, p<0.0001) expression were also upregulated in AGEP skin when compared to 
MPR. The expression of IL-36RN was also found to be higher (4.5-fold, p<0.0001) 
in AGEP skin as compared to MPR, whereas IL-36R expression was similarly 
expressed in both diseases. As previously reported, levels of IL-8 mRNA were 





Fig. 10. IL-36 and IL-8 gene overexpression in AGEP lesional skin. Gene expression hierarchical 
clustering in lesional skin biopsies from patients suffering from AGEP and MPR analyzed using (A) 
Affymetrix Human Exon 1.0 ST chips or (B) RNAseq technology. (C) Quantitative RT-PCR analysis 
of IL-36α, IL-36β, IL-36γ, IL-36R, IL-36RN and IL-8 in lesional skin biopsies of patients suffering from 
AGEP (n=16), MPR (n=16) and normal skin (NS; n=5).  **** p<0.0001. The patient cohorts studied 
in (A), (B) and (C) were independent and all recruited in the Dermatology Department of the 
University Hospital of Zürich (patients no. 1-19).  
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 IL-36α and IL-36γ cytokines are highly expressed in the 
lesional skin of AGEP patients 
Unlike IL-36β, IL-36α and γ were found to be unique for AGEP compared to MPR 
and healthy skin (Suppl. Table 3). Therefore, we further analyzed their expression 
and tissue distribution. To this end, we labeled AGEP and MPR lesional skin 
biopsies with antibodies to both cytokines. IL-36α and γ were found to be highly 
expressed in pustular and peri-pustular regions of AGEP skin biopsies (Fig 11A). 
Both keratinocytes and dermal immune cells infiltrating pustular areas of the 
epidermis were found to produce IL-36α and γ (Fig. 11B).  In contrast, IL-36γ was 
weakly expressed in MPR skin biopsies and IL-36α was barely detectable (Fig. 
11A). In AGEP lesional skin biopsies, IL-36γ was found to be predominantly 
expressed by keratinocytes in the epidermis and by immune cells infiltrating the 
dermis in pustular areas (Fig. 11B). Also, IL-36γ staining intensity was particularly 
important in non-pustular areas of the epidermis surrounding the pustules in AGEP. 
As previously reported [211], IL-36γ was expressed in pustules from patients 
suffering from generalized pustular psoriasis (GPP) and, like in AGEP biopsies, IL-







Fig. 11.  IL-36α and IL-36γ are overexpressed in pustular regions of AGEP lesional skin 
biopsies. (A) Immunohistochemical analysis of lesional skin biopsies revealed that IL-36α and IL-
36γ are overexpressed at the site of pustules in AGEP and PP controls while, in MPR, IL-36α and 
IL-36γ were weakly expressed. Representative pictures of 18 AGEP, 10 PP and 18 MPR cases are 
shown. Neither IL-36α, nor IL-36γ were detectable in normal skin (NS) from healthy donors. (B) Semi-
quantitative evaluation of IL-36α and IL-36γ labeling by immunohistochemistry in the pustular 
epidermis, non-pustular epidermis, and dermis of lesional skin biopsies from patients with AGEP 
(n=18; patients no. 5, 6, 8, 10, 11, 13-17, and 21-28), PP (n=10), MPR (n=18) and normal skin (NS) 
from healthy donors (n=5). Expression levels were qualified as very strong (++++), strong (+++), 
moderate (++), weak (+) or absent (0). *p<0.05; **p<0.01; *** p<0.001; **** p<0.0001. 
 
 
To identify which cell types release IL-36α and γ in AGEP patients’ skin, we co-
labeled AGEP biopsy sections with antibodies to IL-36α and γ and antibodies 
against CD68 to identify macrophages, and against CD3 to identify T-cells (Fig. 12). 
IL-36α was predominantly expressed by CD68+ macrophages (41.17%±4.71 of 
positively labeled cells) and to a lesser extent by epidermal cells (keratinocytes) and 
CD3+ T cells (27.33%±2.17 and 22.33%±2.39 of positively labeled cells 
respectively). IL-36γ was predominantly expressed by epidermal cells 
(keratinocytes) and CD68+ macrophages (44.08%±4.47 and 43.17%±3.31 of 
positively labeled cells, respectively) and to a lesser extent by CD3+ T cells 
(15.17%±1.26 of positively labeled cells). In contrast, IL-36α and IL-36γ were not 







Fig. 12. IL-36 is expressed by keratinocytes and immune cells in AGEP skin. Pustule-containing 
sections of AGEP skin samples were co-labeled with antibodies to CD68 (green), CD3 (green) and 
IL-36α (red) (A) or IL-36γ (red) (B). The percentage of epidermal cells (keratinocytes), CD68 and 
CD3-labeled cells among the IL-36α or IL-36γ-labeled cells was determined (C). Cell nuclei appear 





 Culprit drugs specifically induce rapid monocyte IL-36γ 
secretion in AGEP  
Since our immunofluorescence analyses of AGEP biopsies suggested that, in 
addition to keratinocytes, immune cells may also represent an important source of 
local IL-36γ in the skin, we assessed whether PBMC taken from AGEP patients 
number 8, 9 and 20 at more than 6 months after the CADR – i.e. when in complete 
remission - were still able to respond directly to the causative drug. To this end, 
PBMC from patients having experienced AGEP or MPR were exposed in ELISpot 
plates to the culprit drug or an irrelevant control drug. The number of IL-36γ+ spots 
- indicative of PBMC producing IL-36γ - were then counted after 1, 2, 4, 6 and 8 hrs. 
IL-36γ release was detected in PBMC from AGEP patients already after 1 hr (1.7-
fold more spots than control drug, p<0.001) of culprit drug exposure and reached a 
plateau after 4 hrs (2.7-fold more spots than control drug, p<0.001; Fig. 13A, left 
panel), whereas no increase in IL-36γ production was observed with an irrelevant 
control drug (Fig. 13A, right panel). Furthermore, and in contrast, the culprit drug did 
not induce IL-36γ secretion in MPR as revealed by comparable IL-36γ levels upon 
culprit-, control-drug and vehicle exposure. Similarly, none of the drugs used were 
able to induce IL-36γ secretion in PBMC from healthy blood donors when compared 
to vehicle (Fig 13A). Since immunofluorescence analyses of AGEP skin lesions 
revealed that macrophages and, to a lesser extent, T cells are possible sources of 
IL-36, we sorted CD14+ (monocytes) and CD3+ cells (T cells) from patients’ PBMC 
and exposed them to culprit or control drug to evaluate IL-36γ secretion by ELISpot 
(Fig. 13B). Whereas the control drug did not induce Il-36γ secretion in PBMC or in 
sorted CD14+ and CD3+ cells, the culprit drug was able to induce IL-36γ secretion 
in sorted CD14+ cells at levels similar to those observed with total PBMC. In 
contrast, the culprit drug was not able to induce IL-36γ secretion in CD3+ PBMC. 
Two out of the three tested patients were also analysed for the presence of a 
mutation in the IL-36RN gene (Suppl. Table 2). In both cases, no mutation could be 
determined. These results suggest that PBMC from patients having experienced 
AGEP are able to respond directly and specifically to the causative drug and that 
monocytes/macrophages are an important source of IL-36γ production in response 






Fig. 13. PBMC and monocytes taken from AGEP patients more than 6 months after the ADR 
selectively secrete IL-36γ in response to culprit drug exposure. (A) PBMC from AGEP or MPR 
patients as well as healthy donors were cultured in IL-36γ ELISpot plates for 8 hrs in presence of the 
culprit drug (left panel) or a control drug (right panel). The number of spots was counted 1, 2, 4, 6 
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and 8 hrs after drug exposure. The means±SD of 3 different AGEP patients (no. 8, 10 and 21), 3 
MPR patients and 3 healthy blood donors are shown. ***p<0.001. (B) CD14+ monocytes and CD3+ 
T cells were isolated from AGEP blood with a purity of >96% and were cultured in IL-36γ ELISpot 
plates in presence of the culprit drug or a control drug and compared to total PBMC. The number of 
spots was counted 8 hrs after drug exposure. The mean±SD of 3 different patients (patient no. 8, 9 
and 10) is shown. *p<0.05. 
 
 IL-36 can be induced by culprit drugs in both keratinocytes and 
PBMC from patients having experienced AGEP 
By immunolabeling both keratinocytes and macrophages were shown to be 
positively labeled for IL-36α and γ in pustular areas of AGEP biopsies. To assess a 
possible cross-talk between macrophages and keratinocytes, and the relative 
contribution of each cell type to drug-induced IL-36 secretion, we performed co-
culture experiments using autologous hair follicle-derived keratinocytes and PBMC 
from three patients having experienced AGEP but in remission at the time of blood 
and hair collection (at least 6 months after disappearance of symptoms, patients 8, 
9 and 20). Keratinocytes and PBMC were cultured either alone or together using a 
transwell culture system (Suppl. Fig. 2A). To formally exclude the contamination of 
one cell type by the other, we performed qPCR using primers to CD45 (PBMC 
marker) and Integrin Subunit Alpha 6 (ITGA6, keratinocyte marker) on both PBMC 
and keratinocytes after a 6hr-co-culture (Suppl. Fig. 3). When keratinocytes and 
PBMC were each cultured alone, only PBMC showed elevated IL-36γ mRNA levels 
after exposure to the culprit drug. Interestingly, both keratinocytes and PBMC 
showed culprit drug-specific IL-36γ gene expression when cultured together. In 
contrast, keratinocytes exposed alone to the culprit drug exhibited increased IL-36α 
gene expression (Suppl. Fig. 2B). This increase in gene expression was further 
augmented in keratinocytes co-cultured with PBMC but, nonetheless, remained 
modest when compared to IL-36γ. Indeed, the highest levels of IL-36α mRNA 
measured in keratinocytes corresponded to the lowest gene expression levels 
measured in PBMC (about 10-fold less when compared to IL-36γ). In this in vitro 
co-culture model, the addition of soluble IL-36Ra did not reduce IL-36 expression, 
suggesting that, at the analyzed time point, there is no auto- or paracrine 
amplification and/or induction of IL-36 gene expression by IL-36 released by PBMC 
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or keratinocytes. Taken together, these results indicate that, in culprit drug-induced 
responses of patient-derived keratinocytes and monocytes, IL-36γ is the 
predominant form of IL-36 induced. Furthermore, in response to culprit drug 








Fig. 14. Culprit drugs specifically induce IL-36 in PBMC and keratinocytes and IL-8 in PBMC 
in a co-culture system. Autologous PBMC and keratinocytes (KC) from patients having 
experienced AGEP but in remission at the time of blood and hair collection were cultured either alone 
or together in a transwell system allowing for soluble factor-mediated interactions. Patients’ cells 
were exposed to the culprit drug (Amoxicillin 1mg/ml, patient 8; Letrozole 100nM, patient 9; 
Vancomycin 500µg/ml, patient 20) or a control drug (Metamizole 100µg/ml, patient 8; 
Carbamazepine 10 g/ml, patient 9; Amoxicillin 1mg/ml, patient 20) in presence or absence of IL-
36RA (1µg/ml). After 6 hrs of culture, RNA was extracted from KC (left panels) and PBMC (right 
panels) to measure IL-36γ mRNA levels (A). Relative IL-36γ expression in KC and PBMC cultured 
either alone or in co-culture as indicated and exposed to the culprit drug or a control drug in presence 
or absence of IL-36Ra are shown for each tested patient. Means±SD of 3 replicates are shown. (B) 
Quantitative PCR analysis of IL-8 gene expression in PBMC (upper panels) and KC (lower panels) 
cultured either alone or in co-culture as indicated and exposed to the culprit drug or a control drug in 
the presence or absence of IL-36Ra. Gene expression reported as 2-ΔCT, which represents the target 
gene expression relative to the reference gene (RPL27). Mean±SD of the 3 tested patients is shown. 
The figure illustrates a representative experiment that was repeated 3 times for each patient. 
*p<0.05; **p<0.01; ***p<0.001. 
 
 IL-8 is selectively produced by patients’ PBMC and induced by 
IL-36 
IL-8 has previously been reported to be a key chemokine in AGEP physiopathology 
and has been shown to be inducible by IL-36 [70, 212]. Immunohistochemistry 
analysis confirmed that IL-8 was expressed by cells of the infiltrate in pustular 
regions of AGEP skin (Suppl. Fig. 4). Herein, using the keratinocyte/PBMC co-
culture model described above, we assessed whether IL-36 could promote IL-8 
gene expression, and if so, which cell type could produce IL-8 in response to IL-36. 
We observed that high levels of IL-8 gene expression (4.6-fold increase over control-
drug exposure, p<0.05) occurred exclusively in patients’ PBMC co-cultured with 
autologous keratinocytes selectively in response to culprit drug exposure (Fig. 14B). 
Interestingly, upregulation of IL-8 gene expression in AGEP patients PBMC was 
abrogated by IL-36Ra. IL-8 gene expression was only weakly induced by culprit 
drugs in isolated PBMC cultures, and barely detectable in isolated keratinocyte 
cultures. Taken together, these results indicate that PBMC are the main source of 
culprit drug induced IL-8 production, and that IL-8 gene expression in PBMC is 
dependent on PBMC- and/or keratinocyte-derived IL-36. 
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 IL-1β induces IL-36γ expression in human monocytes and 
keratinocytes   
To determine whether other inflammatory cytokines could regulate IL-36γ 
expression, human keratinocytes and peripheral blood monocytes were treated with 
recombinant cytokines for 6 hours before cells were harvested for RNA isolation. As 
already shown by others [81], recombinant TNF induced a 5.8-fold increase of IL-
36γ expression in keratinocytes as compared to untreated keratinocytes (p<0.001) 
(Fig 15A) and a 3.4-fold increase in monocytes as compared to untreated 
monocytes (p>0.05) (Fig 15B), however not statistically significant. Recombinant 
IFNγ and IL-8 had no impact on IL-36γ expression in both cell types. Intriguingly, IL-
1β induced a dramatic increase in IL-36γ expression in both keratinocytes and 
monocytes with, respectively, a 12-fold (p<0.001) and 57-fold (p<0.001) 






Fig. 15. Regulation of IL-36γ in human cells by inflammatory cytokines. Healthy human 
keratinocytes (A) and human monocytes from peripheral blood (B) were treated with 100g/ml 
recombinant Interferon α (rIFNα), 100ng/ml recombinant Interferon (rIFNγ), 100ng/ml recombinant 
Interleukin-1β (rIL-1β,) 100ng/ml recombinant tumor necrosis factor α (rTNF) 100ng/ml recombinant 
Interleukin-8 (rIL-8). Cells were harvested after 6h inculation at 37°C and RNA was isolated, followed 
by cDNA synthesis and qPCR with primers to the IL-36γ gene. RPL27 served as housekeeping gene. 




 IL-36γ, IL-8, IL-6 and IL-1β can be found at high levels in the 
blood of AGEP patients during acute reaction. 
We next measured cytokines in the serum of AGEP and MPR patients as well as 
healthy blood donors by ELISA and by CBA. While IFNγ, TNF and IL-17A did not 
reveal any difference between all three conditions, IL-6 and IL-8 levels were 
significantly higher in the serum of AGEP patients when compared to MPR and 
healthy donors (Fig. 16). In Swiss, Taiwanese and Japanese patient cohorts, IL-36γ 
was found to be higher in the serum of AGEP and MPR patients when compared to 
healthy donors whereas IL-36α levels were not different. Surprisingly, IL-36γ serum 
levels were not statistically different in AGEP and MPR (Fig. 16A). Additionally, as 
we could show that IL-1β is a positive regulator of IL-36γ, we measured IL-1β levels 
in the serum of AGEP, MPR and healthy donors using cytometric bead assay (CBA). 
Strikingly, we found elevated levels of IL-1β in AGEP when compared to MPR and 
healthy serum, even though not statistically significant (p>0.05). Moreover, when 
comparing IL-23 levels in AGEP serum to serum of MPR or healthy individuals, we 











Fig. 16. IL-36γ, IL-8 and IL-6 are elevated in the serum of AGEP patients. (A) Serum was 
collected from patients with AGEP (n=17) or MPR (n=16) from the Dermatology Department of the 
University Hospital of Zürich and from healthy donors (n=10) and IFNγ, IL-17A, TNF, IL-6, and IL-8 
were measured by ELISA. IL-36α and IL-36γ were measured in patients from the Dermatology 
Department of the University Hospital of Zürich (ZH, n=17; patients no. 6, 8-11, 13-19, 21 and 26-
29) and from the Dermatology Department of Chang Gung Memorial Hospital in Taiwan and the 
Dermatology Department of the Hokkaido University in Japan (ASIA, n=32). *p<0.05; **p<0.01. (B) 
Serum from 17 AGEP, 9 MPR and 5 healthy donors from the Dermatology Department of the 




 IL-1β is highly expressed in the lesional skin of AGEP patients 
Since we found high levels of IL-1β in the serum of AGEP patients in the acute 
phase of disease, we further investigated whether it is also present in lesional skin. 
When comparing IL-1β expression in AGEP and MPR using RNA sequencing, IL-
1β was upregulated in AGEP compared to MPR with a ratio of 1.94 (FDR 0.51), 
even though not statistically significant (p=0.098) (Fig. 10B). qPCR analysis 
confirmed an upregulation of IL-1β in AGEP compared to MPR (3.6-fold), however 
not statistically significant due to high standard deviations. When comparing AGEP 
to healthy skin, a statistically significant upregulation could be observed (52-fold; 
p<0.05). To determine IL-1β protein expression in AGEP skin, 
immunohistochemistry was performed using an antibody against mature IL-1β. 
Notably, a higher amount of IL-1β positive cells could be found in the dermal infiltrate 
and in the pustules of AGEP lesional skin compared to MPR (Fig. 17). In both 
diseases, it was barely expressed in the epidermis. As the antibody used is specific 










Fig. 17. IL-1β gene and protein is expressed in AGEP skin. (A) Quantitative RT-PCR analysis of 
IL-1β in lesional skin biopsies of patients suffering from AGEP (n=11), MPR (n=8) and normal skin 
(NS; n=5). * p<0.05. (B) Immunohistochemical analysis of lesional skin biopsies from AGEP patients 
revealed that mature IL-1β is expressed in the dermal infiltrate and in the pustular region, while it 
was only weakly expressed in MPR. Representative pictures of 10 AGEP and 10 MPR cases are 
shown. IL-1β was not detectable in normal skin (NS) from healthy donors (n=5). 
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 IL-1β can be induced by culprit drugs in PBMC from patients 
having experienced AGEP and can be antagonized by IL-36RA 
To further investigate the role of IL-1β in AGEP, we assessed whether PBMC taken 
from AGEP patients more than 6 months after the adverse reaction were able to 
secrete IL-1β upon stimulation with the causative drug. To this end, PBMC from 
patients having experienced AGEP or MPR were exposed to the culprit drug or an 
irrelevant control drug in ELISpot plates. The number of IL-1β+ spots was then 
counted after 1, 2, 4, 6 and 8 hrs. IL-1β release was detected in PBMC from AGEP 
patients after 4 hrs of culprit drug exposure (3-fold more spots than control drug, 
p<0.01) and reached a plateau after 6 hrs (7-fold more spots than control drug, 
p<0.0001; Fig. 18A, left panel), whereas no increase in IL-1β production was 
observed with an irrelevant control drug (Fig. 18A, right panel). Furthermore and in 
contrast, the culprit drug did not induce IL-1β secretion in MPR PBMC as revealed 
by comparable IL-1β levels upon culprit-, control-drug and vehicle exposure. 
Similarly, none of the drugs used was able to induce IL-1β secretion in PBMC from 
healthy blood donors when compared to vehicle (Fig 18A).  
We then sorted CD14+ (monocytes) and CD3+ cells (T cells) from patients’ PBMC 
and exposed them to culprit or control drug in ELISpot plates to evaluate IL-1β 
secretion by both cell types (Fig. 18B). The culprit drug was able to induce IL-1β 
secretion in sorted CD14+ cells from AGEP patients at levels similar to those 
observed with total PBMC. In contrast, the culprit drug was not able to induce IL-1β 





Fig. 18.  PBMC and monocytes taken from AGEP patients more than 6 months after the ADR 
selectively secrete IL-1β in response to culprit drug exposure. (A) PBMC from AGEP or MPR 
patients as well as healthy donors were cultured in IL-1β ELISpot plates for 8 hrs in presence of the 
culprit drug (left panel) or a control drug (right panel). The number of spots was counted 1, 2, 4, 6 
and 8 hrs after drug exposure. The means±SD of 3 AGEP patients (no. 8, 10 and 21), 3 MPR patients 
and 3 healthy blood donors are shown. **p<0.01, ***p<0.001, ****p<0.0001. (B) CD14+ monocytes 
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and CD3+ T cells were isolated from AGEP blood with a purity of >96% and were cultured in IL-1β 
ELISpot plates in presence of the culprit drug or a control drug and compared to total PBMC. The 
number of spots was counted 8 hrs after drug exposure. The mean±SD of 3 patients (patient no. 8, 
9 and 10) is shown. *p<0.05, **p<0.01.  
 
IL-1β is produced as a proform and needs to be cleaved by caspase-1 to become 
biologically active. To determine whether the secreted IL-1β in our drug stimulation 
experiments is the pro- or mature form, AGEP PBMC were incubated with the 
caspase inhibitor  Z-Val-Ala-Asp fluoromethyl ketone (Z-VAD, 10 µM) for 2 hours 
before and during drug stimulation. Z-VAD was able to abrogate IL-1β secretion in 
PBMC exposed to the culprit drug (p=ns when compared to PBMC exposed to 
vehicle or a control drug), demonstrating that the released IL-1β upon drug 
stimulation represents the active cleaved form of IL-1β. To further investigate 
whether IL-36γ has an effect on IL-1β expression, cells were treated with IL-36RA 
two hours before and during drug stimulation of AGEP PBMC. Interestingly, a partial 
decrease of IL-1β could be observed, suggesting that IL-36γ acts as upstream target 
of IL-1β.  
 
 
Fig 19. IL-1β secretion can be abrogated by the caspase-inhibitor ZVAD and partially 
abrogated by IL-36RA. PBMC from AGEP or MPR patients as well as healthy donors were cultured 
in IL-1β ELISpot plates for 6 hrs in presence of the culprit drug +/- ZVAD, +/- IL36RA and a control 
drug. The number of spots was counted 6 hrs after drug exposure. The means±SD of 3 different 




Taken together, we could show that IL-1β is present in high amounts in AGEP blood 
and skin. Intriguingly, when stimulated with the culprit drug, monocytes secreted 
high amounts of IL-1β, suggesting that it is involved in the early phase of AGEP 
pathogenesis. Blockade of IL-1β secretion by IL36RA further suggests a regulatory 
role of IL-36γ.  
 
 Myeloid cells from AGEP patients exhibit an exacerbated 
response to TLR4 stimulation  
LPS is an agonist of TLR4 and thereby initiates a signaling cascade that leads to 
NF-κB activation and subsequent production and secretion of proinflammatory 
cytokines, including IL-36γ and IL-1β [213]. In in vitro experiments with cytokine 
measurements as experimental output, it is very often used as positive control. For 
this purpose, LPS has also been used in our experimental settings. Strikingly, we 
observed significantly higher responses to LPS in AGEP patients’ PBMC than in 
MPR and healthy control PBMC, which turned out to be statistically significant for 
both IL-36γ (p<0.01) and IL-1β (p<0.001). This observation is suggestive of an 
exacerbated response of AGEP myeloid cells to TLR4 stimulation (Fig. 20). 
 
 
Fig. 20. Higher IL-36γ and IL-1β secretion upon LPS stimulation. PBMC from AGEP or MPR 
patients as well as healthy donors were cultured in IL-36γ and L-1β ELISpot plates for 24 hrs. The 
number of spots was counted 24 hrs after LPS exposure. The mean±SD of 3 different patients 




 AGEP patients do not express higher amounts of TLRs but 
carry polymorphisms in the TLR4 gene 
Given the fact that pure monocyte populations of AGEP patients respond directly to 
the culprit drug and that a strong response to LPS has been observed in AGEP 
PBMC, we hypothesized that AGEP cells show exacerbated TLR-NF-κB activity. To 
investigate whether TLR4 and possibly other TLRs are overexpressed in AGEP 
compared to healthy PBMC, RNA was isolated and qPCR was performed with 
primers to all 10 TLRs. No overexpression of TLRs could be detected in AGEP 
PBMC when compared to MPR and healthy PBMC (Fig. 21). When comparing the 
expression levels of TLRs in AGEP skin compared to MPR skin using RNA 
sequencing, a significant increase of TLR2 (log2-ratio 0.8492 and p<0.05) only was 











































































































































































































Fig. 21. No upregulation of Toll-like receptors in PBMC from AGEPpatients. RNA was extracted 
from AGEP, MPR and healthy PBMC and mRNA expression levels of TLR 1-10 were measured 







Table 6. Expression levels of Toll-like receptors 1-10 measured by RNAseq in AGEP compared 
to MPR skin: 
 
 
As no relevant increase in TLR expression was detectable, we analyzed 96 AGEP 
patients from RegiSCAR [197] for possible genetic changes in genes involved in 
TLR-NF-κB signaling using whole exome sequencing. Interestingly, we found a 
single nucleotide polymorphism (SNP) in TLR4 in a high proportion of AGEP 
patients (Table 7). Indeed, 17/96 AGEP cases (18%) carry one of these 
polymorphisms and 14 out of 17 (14.6%) simultaneously carry two polymorphisms. 
 
Table 7. Polymorphisms in the TLR4 gene in AGEP patients. 
 
 
The SNP 9:120475302_A/G replaces Asp on the position 299 with Gly (D299G) and 
the SNP 9:120475602_C/T replaces Thr at the position 399 with Ile (T339I). The 





 Blockade of TLR pathway signaling molecules prevents IL-
36γ and IL-1β production by AGEP PBMC 
As we suspected an abnormal regulation of the NF-κB pathway in the PBMC of 
AGEP patients, we tested if the blockade of TLR signaling molecules has a 
functional inhibitory effect on the signaling response to culprit drugs in AGEP PBMC. 
To this end, we stimulated AGEP patients’ PBMC with the culprit drug or LPS in the 
presence of inhibitors of the TLR adaptor proteins MyD88, TRIF and TIRAP and 
antagonist antibodies to TLR2 and 4 and to HLA-ABC (MHC-I) and HLA-DR (MHC-
II). Notably, the blockade of MyD88 and TIRAP led to the abrogation of IL-36γ and 
IL-1β production by AGEP patients’ PBMC upon exposure to culprit drugs, further 
supporting an NF-κB-mediated pathogenic reaction to culprit drugs in AGEP 
patients. The blockade of TRIF also decreased the immune response although to a 
lesser extent. On the contrary, blockade of the HLA-molecules did not lead to an 
abrogation of IL-36γ and IL-1β expression, suggesting that the drugs do not bind 
directly to HLA-molecules. When blocking TLR4, we could also inhibit IL-36γ and 
IL-1β production, whereas the inhibition of TLR2 had no effect on culprit drug-
induced IL-36γ and IL-1β (Fig. 22 A and B). However, in one of the four tested 
patients no effect TLR4 blockade could be seen (Fig. 22 C), suggesting that the 





Fig. 22. Blockade of TLR signaling molecules abrogates IL-36γ and IL-1β production by AGEP 
PBMC. PBMC were isolated from AGEP patients and cultured in cell culture (A + C) or ELISpot 
plates (B). Cells were stimulated with the culprit drug in the presence or absence of Tirap-inhibitor 
(25mM), MyD88 inhibitor (25mM), TRIF-inhibitor (25mM), anti-TLR2 antibody (5µg/ml), anti-TLR4 
antibody (5µg/ml), control IgG antibody (5µg/ml), anti-HLA-ABC-antibody (5µg/ml), and anti-HLA-
DR-antibody (5µg/ml). Untreated cells, control drug and upLPS served as controls. (A + C) Cells 
were harvested after 6 hrs incubation at 37°C and RNA was isolated, followed by cDNA synthesis 
and qPCR using primers to IL-36γ and IL-1β gene. RPL27 served as housekeeping gene. Presented 
results are normalized to untreated cells (2-^^CT). (B) Cells were removed from ELISpot plate after 6 
hrs of incubation at 37°C and the number of spots was counted. The means±SD of 3 AGEP patients, 
3 MPR patients and 3 healthy blood donors are shown. n=3 in (A + B); n= 1 in (C). * p≤0.05, ** 




 In certain cases, IL-36γ and IL-1β production by AGEP PBMC 
is dependent on albumin  
When administered in vivo, certain drugs are known to bind to proteins present in 
the serum [215]. Such a drug-protein binding has a direct impact on drug distribution 
and efficacy [216]. Human serum albumin (HSA) is the most abundant plasma 
protein with a concentration of 35-50g/l and many drugs have a high binding affinity 
to HSA [217].  As TLR4 agonists are usually large molecules (e.g. LPS, [218]), we 
hypothesized that small molecules like drugs rather act as drug-protein complex in 
AGEP rather than alone in a free form. To assess whether HSA acts as a mandatory 
partner molecule in AGEP, patients’ monocytes were first exposed to culprit and 
control drugs in the presence or absence of proteins in the culture medium. Notably, 
in two out of three patients, the absence of protein led to the absence of IL-1β and 
IL-36γ production upon culprit drug exposure while LPS stimulation still was still able 
to induce high amounts of both cytokines (Fig. 23). To determine whether HSA is 
involved in a possible hapten-protein complex in AGEP, thereby activating NF-kB 
via TLR4, we added HSA to the protein-free cell suspension. The cytokine 
production in the two patients where IL-1β and IL-36γ production was abrogated by 
absence of proteins, could be restored by the addition of HSA, suggesting that HSA 





Fig. 23. In certain cases IL-36γ and IL-1β production by AGEP PBMC in response to culprit 
drugs is dependent on albumin. PBMC were isolated from AGEP patients (patient 8, 10 and 20) 
and plated in 96-well-plates in complete medium (black histogram), PBS (grey histogram) or PBS + 
human 2.5mg/ml albumin (white histogram). Cells were then stimulated with the culprit drug (pat. 8: 
Amoxicillin 1mg/ml; pat. 18: Terbinafin 100 µg/ml; pat. 10: Amoxicillin 1mg/ml) and LPS and 
incubated for 3 hrs at 37°C. Cells were then harvested and RNA was isolated, followed by cDNA 
synthesis and qPCR using primers to IL-36γ and IL-1β gene. RPL27 served as housekeeping gene. 




4 Discussion & Perspectives 
AGEP is considered to be a severe adverse cutaneous drug eruption in which T 
cells and neutrophils are major players [175, 185]. It has been proposed that upon 
presentation, drugs responsible for causing AGEP elicit drug-specific T cell 
responses, and that these T cells secrete the neutrophil chemoattractant IL-8 [185]. 
Recently mutations in the IL-36RN gene encoding IL-36RA have been reported in 
rare cases of AGEP [197], suggesting that a dysregulation in IL-36 signaling may 
contribute to the physiopathology of AGEP. My data is supportive of this hypothesis, 
showing that culprit drugs can directly induce IL-36 secretion in AGEP patients’ 
monocytes, and indirectly in patients’ keratinocytes in vitro. Analysis of IL-36 gene 
and protein expression in vivo is also supportive of the above, revealing that 
macrophages and keratinocytes are the main producers of IL-36 and are located in 
the pustular areas of AGEP patients’ skin. Among the IL-36 family members, IL-36γ 
was found to be the predominant form expressed in AGEP skin biopsies, and also 
the predominant form induced experimentally by the culprit drug in monocytes and 
keratinocytes in vitro.  
Il-36γ is produced as inactive proform and requires activation by the neutrophil 
proteases elastase, proteinase-3 [73] or by cathespsin S [74]. As AGEP is a pustular 
reaction with abundant neutrophils in the blood and skin, it is very likely that 
neutrophil-derived proteases activate IL-36 cytokines within skin lesions. 
Keratinocytes have been shown to be a major source of IL-36 cytokines in 
cutaneous inflammation, particularly in psoriasis [81]. Our data suggests that 
keratinocytes are also an important source of IL-36 in the skin in AGEP. However, 
co-culture experiments revealed that keratinocytes exposed to culprit drugs were 
only able to produce very little amounts of IL-36α and IL-36γ when cultured alone 
but, interestingly, produced high amounts of IL-36γ when cultured in presence of 
autologous monocytes and culprit drug. This observation suggests that, when 
exposed to the causative drug, patients’ monocytes release a soluble factor that will 
stimulate IL-36γ production by keratinocytes. Unlike what has been reported in 
psoriasis [81], we could not demonstrate evidence of direct IL-36 induction by itself 
within a positive feed-back loop in AGEP patients’ keratinocytes in our co-culture 
model using IL-36RA. However, as more than 6 hours incubation might be needed 
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for induction of its own expression, a self-amplifying effect of IL-36γ cannot be 
excluded and later time-points should be investigated. 
Like in other inflammatory diseases such as psoriasis [219], contact hypersensitivity 
[220] or sunburn [221], keratinocytes may actively participate in the pathogenesis of 
AGEP by secreting IL-36γ, which could contribute to the herein observed and 
previously reported induction of IL-8 gene expression by macrophages. The latter 
likely contributes to the observed neutrophil recruitment to the epidermis in AGEP. 
Indeed, IL-8 expression was more important in culprit drug-exposed PBMC cultured 
with keratinocytes than in PBMC alone and could be blocked by IL-36RA, 
suggesting an additive effect of PBMC- and keratinocyte-derived IL-36 on IL-8 gene 
expression. As previously reported in AGEP patients, neutrophil-attracting IL-8 may 
also originate from drug-specific T cells [185]. Indeed, AGEP is currently seen as a 
delayed type hypersensitivity reaction with T cell involvement. However, the precise 
mechanisms leading to drug-specific T cell priming and recruitment to the skin in 
AGEP have not been elucidated to date. Unlike murine T cells, human T cells do 
not express IL-36R [71]. In AGEP, IL-36 may nevertheless contribute to T cell-
mediated immune responses through its strong stimulatory effects on antigen-
presenting cells [222]. My findings that IL-36 can be induced by a drug very early in 
innate immune cells do not exclude a delayed drug-specific T cell response but 
whether the induction of IL-36 in monocytes by culprit drugs and the activation of 
drug-specific T cells are interdependent events in AGEP pathogenesis or not 
remains to be investigated. 
It has been previously reported that Th17 cells may also be involved in AGEP as 
revealed by their increased frequencies and elevated IL-22 levels in AGEP patients’ 
peripheral blood [193]. Interestingly, we found high levels of IL-23 in the serum of 
our AGEP patients’ cohort. As IL-23 induces the differentiation of naive CD4+ T cells 
into Th17 cells [223], this finding is supportive of a role of Th17 cells in AGEP. IL-
17 has been shown to increase IL-8 secretion by keratinocytes [224] in allergic 
contact dermatitis [225] and in psoriasis [226]. Our in vitro data revealed, however, 
that in response to IL-36, the major source of IL-8 was patients’ monocytes, 
consistent with the elevated expression of IL-36R and potential strong 
responsiveness to IL-36 by dermal myeloid cells [70]. In contrast and although 
keratinocytes also express high levels of IL-36R [70], IL-8 production by 
keratinocytes was marginal as confirmed by qPCR in coculture experiments and 
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immunohistochemistry where IL-8 was only detected in the peri-pustular immune 
infiltrate. 
A key question in this study was why and how a drug induces IL-36 and subsequent 
IL-8 production in immune and/or epidermal cells in a rare disease like AGEP. 
Although mutations in the IL-36RN gene have been identified in rare AGEP patients, 
no other marker(s) of genetic predisposition have been formally identified for AGEP 
to date. My data provide evidence that a dysregulation of the IL-36-IL-8 axis can 
occur independently of IL-36RN mutations in AGEP patients, suggesting that other 
factors influencing the susceptibility to an IL-36-mediated proinflammatory response 
to culprit drugs are at play in AGEP patients.  
To determine whether other inflammatory cytokines are involved in the regulation of 
IL-36γ, healthy monocytes and keratinocytes were treated with several recombinant 
cytokines. Strikingly, IL-1β induced high IL-36γ expression in both monocytes and 
keratinocytes. To investigate a possible role of IL-1β in AGEP, IL-1β levels were 
measured in the serum of AGEP patients in the acute phase. Interestingly, when 
compared to MPR and healthy serum, we found higher levels of IL-1β in AGEP. This 
finding was associated with high amounts of IL-6 which is a known downstream 
target of IL-1β [227, 228]. As IL-1β and IL-6 are known to be strong inducers of fever 
(pyrogens) [229, 230], the elevated levels of these cytokines in AGEP blood might 
be responsible for the fever from which almost all AGEP patients suffer during the 
reaction.  
Moreover, even though not statistically significant, IL-1β was found to be highly 
expressed in AGEP compared to MPR skin, as shown by RNA sequencing. This 
observation has been confirmed by Liang et. al who demonstrated in their recently 
published article that pustular diseases including AGEP show high expression levels 
of IL-1β [231]. Also, immunohistochemistry staining using an antibody against 
mature IL-1β revealed high amounts of IL-1β, showing that the biologically active 
form is present in AGEP skin.  
It has been demonstrated by others that IL-36γ can induce IL-1β expression and 
secretion in human APCs [71]. In turn, IL-36γ can be strongly induced by IL-1β, as 
shown in myelofibroblasts [232]. Interestingly, I could also detect a dramatic 
increase of IL-36γ expression in human keratinocytes and monocytes in vitro upon 
treatment with recombinant IL-1β. ELISpot analysis revealed that IL-1β secretion by 
PBMC could be partly antagonized by IL-36RA, indicating that IL-36γ may be an 
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upstream driver of IL-1β in AGEP. Given that both cytokines can induce the others 
expression, they might act in an amplification loop. As we could not prove in our 
coculture experiment that IL-36 is the soluble factor initiating its own upregulation, 
IL-1β represents a possible candidate for IL-36γ regulation. In order to identify IL-
1β as possible upstream driver of IL-36γ and amplifier, co-culture experiments 
should be repeated with Canakinumab, an antibody against IL-1β, or the IL-1 
receptor antagonist Anakinra.  
Likewise IL-36γ, rapid IL-1β release could be induced by culprit drug treatment of 
monocytes. Moreover, cytokine release from PBMC upon LPS stimulation was 
significantly elevated compared to MPR and healthy cells. The direct activation of 
innate immune cells by culprit drugs and the important response of AGEP PBMC to 
LPS stimulation are suggestive of an exacerbated NF-κB activity in these patients. 
Further supportive of this theory is the very rapid onset of the disease after the first 
intake of a drug, suggesting an early response mediated by the innate immune 
system.  
Using whole exome sequencing of 96 AGEP DNA samples from the RegiSCAR 
cohort compared to 480 DNA samples of healthy individuals, we could identify two 
SNPs in the gene encoding TLR4 that were significantly increased in frequency in 
AGEP compared to healthy individuals. These D299G and T399I SNPs have been 
linked to several human diseases including inflammatory bowel disease, septic 
shock, childhood respiratory syncytial virus infection, and colon and gastric cancers 
[233-236]. Given our in vitro data and the identification of SNPs in the TLR4 gene, 
we hypothesized that dysregulated TLR4 signaling might be involved in the 
pathogenesis of AGEP. 
The D299G and T399I SNPs are localized in the TLR4 ligand binding region for LPS 
and it has been shown that cells carrying these polymorphisms have dysregulated 
TLR4 signaling [214, 237, 238]. Contradicting our results, it was demonstrated that 
D299G and T399I SNPs lead to hyporesponsiveness to LPS stimulation through 
local conformational changes in the ligand binding region. However, even though 
Hold et al. found less NF-κB activity upon LPS stimulation in mutant cells, they also 
demonstrated a significant increase in production of IL-1β, TNF, IL-6 and IL-10 in 
cells from polymorphic TLR4 carriers compared to individuals with WT TLR4 [237]. 
As my data suggest that IL-1β and IL-36 are important players in AGEP, the finding 
of dysregulated cytokine production in cells from D299G and T399I SNP carriers is 
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supportive of our hypothesis that changes in the TLR4 protein might lead to the 
immune response happening in AGEP.  
To functionally prove the impact of TLR4 dysregulation in AGEP, blocking 
experiments were performed. We could show that blockade of TLR4 and its adaptor 
proteins MyD88, TRIF and TIRAP led to an abrogation of IL36γ and IL1β expression 
in three out of four cases. These results indicate that activation of TLR4 has a 
functional impact on the immune activation by drugs in AGEP PBMC. However, the 
number of patients should be increased to emphasize the relevance of these 
findings. Perspectively, it would be of high importance to screen all AGEP patients 
of the Zurich cohort for the detected D299G and T399I SNPs and compare carriers 
and non-carriers in functional experiments. As a first approach, primary monocytes 
from patients harboring either TLR4-D299G or TLR4-T399I or both could be 
transfected with siRNA to TLR4 or to scramble siRNA as control. Transfected cells 
should then be exposed to the culprit drug, a control irrelevant drug and LPS and 
the secretion of IL-36γ and IL-1β could be measured by ELISpot. If a difference in 
cytokine secretion is seen in TLR4-knockdown cells as compared to cells 
transfected with scramble siRNA, the extent of inhibition should be compared 
between cells from patients with either TLR4-D299G, TLR4-T399I or both variants 
to assess a possible hyperresponsiveness due to one of the TLR4 variants. 
To further assess whether the D299G T399I SNPs of TLR4 bestow the receptor with 
the ability to interact with the drugs known to induce AGEP, it would be of interest 
to generate plasmids encoding TLR4 with D299G, T399I or D299G/T399I 
polymorphism mutations, using site-directed mutagenesis. These could then be 
used in in vitro experiments by overexpressing mutants and wild-type TLR4 with an 
NF-κB luciferase reporter construct in Human embryonic kidney cells 293 (HEK293 
cells). As they do not express TLR4 [239], they represent very good candidates for 
TLR4 mutant overexpression experiments. These can then be treated with 
candidate drugs to assess whether, in response to these drugs, receptor variants 
differentially activate NF-κB. This approach would give an indication to whether 
either SNP or both together affect the ability of TLR4 to interact with drugs known 
to cause AGEP. LPS can be used as a control and supernatants could be used to 
measure IL-8, IL-6 and IL-1β production, to further determine whether transcription 
of NF-κB-inducible genes are affected. From another approach, the THP-1 
monocytic cell line stably-transfected with wild-type, D299G, T399I or D299G/T399I 
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TLR4 could be used. These cells could also be co-cultured with primary 
keratinocytes and stimulated with candidate drugs and LPS prior to IL-1β and IL-
36γ expression analysis.  
As SNPs in TLR4 have only been found in 20% of the analyzed AGEP patients, 
other mechanisms leading to the strong drug-induced innate immune response in 
AGEP should be taken into account. Besides genetic changes, also epigenetic 
factors could cause a dysregulation in the signaling pathway of TLR4 or other 
molecules, leading to exacerbated NF-κB activity. It has been shown that epigenetic 
changes in H3K4me1, H3K4me3, H2K27me, or H3K9me2 can result in trained 
immunity of monocytes/macrophages in response to LPS [240-242]. Even though 
most of these changes rather lead to tolerance to certain stimuli, e.g. in bacterial 
infection [243], epigenetic changes in the NF-κB pathway could cause an 
inadequate response to drugs in the case of AGEP and should be further 
investigated. To study epigenetics in AGEP patients, DNA methylation could be 
analysed using high resolution melt analysis (HRM). For this purpose, the DNA 
region of the mutation of interest (e.g. TLR4) should be amplified and the PCR 
product can then be subjected to decreasing temperatures. Thereby the melt 
temperatures and melt curve can be obtained and compared to known standard 
DNA samples to determine the relative levels of methylation. To study DNA/protein 
interactions, a technique known as chromatin immunoprecipitation (ChIP) could be 
used. ChIP assays allow the chromatin structure surrounding a specific DNA 
sequence to be analyzed. Formaldehyde can be used to crosslink DNA and protein, 
followed by immunoprecipitation of DNA–protein complexes. Once the crosslinks 
are reversed, recovered DNA can then be analyzed using PCR [244]. 
Another possible activation mechanism in AGEP may consist of inflammasome 
activation. As mentioned above, mature IL-1β could be found in AGEP lesional skin. 
This is further supported by the fact that the caspase-inhibitor ZVAD could suppress 
IL-1β secretion after culprit drug exposure in ELISpot experiments. However, how 
the activation of IL-1β is initiated, remains unclear to date. IL-1β activation requires 
its cleavage by caspase-1 which is only activated when an inflammasome 
assembles upon stimulation of certain NLRs or the DNA sensor AIM2 [124]. Besides 
IL-1β, activated caspase-1 also cleaves IL-18, another proinflammatory cytokine. 
Thus, to further detect inflammasome activation, it would be interesting to measure 
IL-18 in the AGEP patients’ serum and to perform immunohistochemistry stainings 
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for IL-18 on AGEP lesional skin samples. Intriguingly, it has been demonstrated that 
IL-36 signaling facilitates the activation of the NLRP3 inflammasome [245]. 
Moreover, to detect a possible genetic dysregulation of the inflammasome in AGEP, 
it would be of high interest to screen the whole exome sequencing database of the 
RegiSCAR AGEP patients for SNPs or mutations in inflammasome components.  
Another key question of this study was how drugs can activate TLR4 or other 
receptors in AGEP. We could show that the absence of protein prevented cells from 
AGEP patients to produce IL-36γ and IL-1β upon culprit drug treatment in two out 
of three analyzed cases. This suggests that the drug might act as a hapten and 
activate the receptor only in a drug-protein-complex. However, as the absence of 
protein did not abrogate the immune activation in all cases, TLR4 signaling by drug-
protein complexes may not occur in all patients. As suggested in other adverse drug 
reactions, a direct interaction of a drug with immune receptors – usually T-cell 
receptors - could lead to an immune activation (the so-called pi-concept) [246]. 
Alternatively, other ways of TLR4 activation might be possible. It has been shown 
in the case of nickel, that TLR4 signaling was initiated by direct interaction with the 
molecule [247]. In this study, Schmidt et. al demonstrated that the non-conserved 
histidines 456 and 458 of the human TLR4 are required for hypersensitivity reactions 
by nickel. 
To formally demonstrate that the culprit drug binds - as a drug-protein complex or 
not - to TLR4, we will use a previously published biotinylated-amoxicillin (biot-AMX) 
[248] (amoxicillin is associated to AGEP and has been functionally evaluated in our 
lab for IL-36 induction in patients’ cells). Biot-AMX will be added to THP-1 cells 
stably expressing TLR4D299G, TLR4T399I or TLR4D299G/T399I variants (as described in 
Aim 3) with or without albumin. For each condition, THP-1 cells will be collected 1, 
2 and 4 four hours for protein extraction. Immuno-precipitation will then be 
performed using an anti-TLR4 antibody and the precipitate will be revealed using 
HRP-streptavidin after SDS-PAGE. Alternatively, flow cytometry will be used to 
quantify the binding intensity of the AMX-Biot/albumin complex to TLR4-expressing 
THP-1. 
 
Overall, my work provides the first evidence to date that IL-36 is involved in the 
pathogenesis of the pustular cutaneous adverse drug reaction AGEP, and identifies 
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monocytes and keratinocytes as potential key producers of IL-36 in AGEP. Given 
that monocytes/PBMC of all AGEP patients tested have an enhanced propensity to 
produce IL-36 upon culprit drug exposure, the opportunity to identify predictive 
markers that would help identify patients prone to pathological IL-36 production 
upon exposure to certain medications may be achievable. Moreover, IL-1β 
potentially represents an important player in immune responses to drugs in AGEP. 
This observation may also be of interest for diagnosis and/or culprit drug 
identification together with IL-36γ.  
Strikingly, the possible involvement of TLR4 in the drug-induced inflammation in 
AGEP could be identified in the present work. For the first time, a possible role of 
the innate immune sytem in the early pathogenesis of AGEP could be 
demonstrated, opening new research avenues in the field of cutaneous adverse 
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Suppl. Fig 1. IL-36 Pustule-containing sections 
of AGEP skin samples were co-labeled with anti-myeloperoxidase (MPO, green), and IL-36a (red) 






Suppl. Fig. 2. Culprit drugs induce IL-36a in PBMC and keratinocytes co-culture system. 
PBMC and autologous keratinocytes (KC) from patients having experienced AGEP but in remission 
at the time of blood and hair collection were cultured either alone or together in a transwell system 
allowing for soluble factor-mediated interactions (A). Patients’ cells were exposed to the culprit drug 
(Amoxicillin 1mg/ml, patient 8; Letrozole 100nM, patient 9; Vancomycin 500 µg/ml, patient 20) or a 
control drug (Metamizole 100µg/ml, patient 8; Carbamazepine 10mg/ml, patient 9; Amoxicillin 
1mg/ml, patient 20) in presence or absence of IL-36RA (1µg/ml). After 6 hrs of culture, RNA was 
extracted from keratinocytes (left panels) and PBMC (right panels) to measure IL-36a transcripts (B). 
Relative IL-36a expression in KC and PBMC cultured either alone or in coculture as indicated and 
exposed to the culprit drug or a control drug in presence or absence of IL-36Ra is shown for each 
tested patient. Expression is expressed as 2- ΔCT, which represents the target gene expression 







Suppl. Fig 3. Purity of PBMC and keratinocyte fraction in coculture. After 6 hrs of coculture, 
RNA were extracted from PBMC and autologous keratinocytes using primers to CD45 (PBMC 
marker) and ITGA6 (keratinocyte marker). Expression is expressed as 2- ΔCT, which represents the 








Suppl. Fig 4. IL-8 is expressed in pustular regions of lesional skin biopsies from patients 
suffering from AGEP. Immunohistochemical analysis of lesional skin biopsies revealed that IL-8 is 
expressed at the site of pustules in AGEP in dermal immune cells but not by keratinocytes. 
Representative picture of 18 AGEP cases is shown (upper panels). IL-8 was not detectable in normal 


















32 F 91 10,44 6,68 0,47 36,7 
2 16 M 7,3 24,38 18,31 0,68 36,5 
3 71 M 17 12,45 11,49 0,02 36,5 
4 54 F 35 11,3 7,88 1,18 37,5 
5 58 M 81 11,35 N.A. N.A. N.A. 
6 41 F 61 25,64 23,15 0,01 36,3 
7 81 F 130 21,68 20,57 0,06 N.A. 
8 63 M 106 19,37 18,03 0,7 39,3 
9 49 F 40 10,89 9,92 0,07 38,2 
10 33 F 70 25,04 23,38 0,72 38,8 
11 38 M 60 24,86 22,56 0,37 37,3 
12 72 M 58 19,71 17,17 0,5 N.A. 
13 68 M 233 7,46 6,27 0,12 37,2 
14 85 F 180 17,74 15,09 0 36,5 
15 61 M 272 27,68 26,6 0 38 
16 47 F 119 17 15,1 0,2 38,8 
17 51 F 249 25,53 22,49 0,33 37,3 
18 43 F 59 13,5 12,86 0 37,4 
19 21 F 8,3 9,98 5,9 1,65 37,4 
20 76 F 308 24,36 23,23 0,04 36,1 
21 36 M 34 10,02 8,58 0,37 37,1 
22 74 F 18 8.67 6.65 0.00 36.8 
23 90 F 23 14.29 12.55 0.31 36.3 
24 85 M 69 13.36 10.44 0.43 36.5 
25 77 F N.A. N.A. N.A. N.A. N.A. 
26 56 M 54 12.99 9.72 0.91 N.A. 
27 73 F 23 10.54 8.99 0.05 N.A.  
28 40 F 2.4 11.45 10.83 0.08 37.1 
 
 
in bold: cells from these patients have been used in experiments shown in figures 4, 5 and 









Nr. Patch test Prick LTT Drug IL36RN 
1 N.A. negative negative Amoxicillin n.d. 
2 N.A. N.A. N.A. Terbinafin n.d. 
3 negative negative negative Metformin No mutation 
4 negative negative N.A. unknown  No mutation 
5 positiv positive negative unknown n.d. 




7 N.A. N.A. N.A. unknown n.d. 
8 N.A. N.A. positive Amoxicillin No mutation 
9 N.A. N.A. positive Letrozole n.d. 
10 positive positive positive Amoxicillin No mutation 
11 N.A. N.A. N.A. Amoxicillin n.d. 
12 N.A. N.A. N.A. Floxapen n.d. 
13 negative negative N.A. Ceftriaxon n.d. 





15 N.A. N.A. N.A. Amoxicillin n.d. 
16 positive positive negative Novalgin n.d. 
17 negative negative N.A. 
Ibuprofen / Pure 
Life Cleanse 
No mutation 
18 N.A. N.A. N.A. Terbinafin n.d. 
19 positive positive positive unknown n.d. 
20 N.A. N.A. N.A. Vancomycin n.d. 
21 N.A. N.A. positive Fluconazole n.d. 
22 N.A. N.A. N.A. Unknown n.d. 
23 N.A. N.A. N.A. unknown n.d. 
24 N.A. N.A. N.A. Amoxicillin n.d. 
25 N.A. N.A. N.A. Amoxicillin n.d. 
26 N.A. N.A. positive Acetazolamide n.d. 
27 N.A. N.A. N.A. Cotrimoxazole n.d. 






n.d.: not determined; in bold: cells from these patients have been used in experiments 











Unique for AGEP Common Unique for MPR 
SERPINA1 ALDH1A1 CCL27 
ASPN APOC1 CXCL11 
CD163 DPT CXCL9 
S100A9 FADS2 CA2 
S100A12 FABP9 COL14A1 
S100A8 GAL ELOVL5 
S100A9 ITGBL1 GSDMC 
CA6 LCE3D HERC6 
EIF1AX LPHN3 INSIG1 
PI3 MGST1 CXCL10 
FGFR1 NR4A2 IGHG1 
FLG2 PTN IGKC 
FLG THRSP KRT79 
HEPHL1 SFRP2 LUM 
IL1F6 SOAT1 PLA2G12A 
IL1F9 STMN2 PLA2G2A 
IGKC TCHH PRDX6 
IGHA1 EIF1AX PLA2G7 
IGHA2 EIF1AY IFIT3 
IGKC  SPRR4 
IL-8   
IGHG2   
IGHG4   
KRT16   
KRT2   
KRT6A   
KRT6C   
LTF   
LOR   
MSMB   
POSTN   
ROPN1B   
S100A7A   
SAA1   
SAA2   
SERPINB3   
SERPINB4   
SERPINB13   
SLC6A14   
SPRR2B   
DCT   
TCN1   
EIF1AX   
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Suppl. Table 4. Top 50 upregulated genes in AGEP biopsies (n=8) as compared to normal skin 
(n=7). Affymetrix Human Exon 1.0 ST Array analysis  
 
 
Identifier Gene name log2(ratio) ratio p value 
ENSG00000057149 SERPINB3 3.627 12.36 6.34E-06 
ENSG00000163221 S100A12 3.264 9.609 0.0001602 
ENSG00000196805 SPRR2B 2.507 5.685 2.98E-05 
ENSG00000184330 S100A7A 2.464 5.518 9.88E-05 
ENSG00000124102 PI3 2.462 5.508 9.02E-05 
ENSG00000012223 LTF 2.452 5.474 3.85E-05 
ENSG00000181333 HEPHL1 2.367 5.159 0.0001375 
ENSG00000206073 SERPINB4 2.328 5.022 0.000815 
ENSG00000163220 S100A9 2.245 4.741 0.0002109 
ENSG00000087916 SLC6A14 2.142 4.413 0.000105 
ENSG00000134827 TCN1 1.921 3.788 0.01886 
ENSG00000177575 CD163 1.657 3.153 0.004581 
ENSG00000134339 SAA2 1.623 3.079 0.003722 
ENSG00000136688 IL1F9 1.616 3.064 0.0006775 
ENSG00000163202 LCE3D 1.601 3.033 0.02765 
ENSG00000170465 KRT6C 1.574 2.977 0.04494 
ENSG00000197641 SERPINB13 1.56 2.949 0.0004119 
ENSG00000186832 KRT16 1.515 2.858 0.001006 
ENSG00000148346 LCN2 1.453 2.737 0.001458 
ENSG00000198553 KCNRG 1.371 2.587 0.0001009 
ENSG00000143556 S100A7 1.363 2.572 0.0006319 
ENSG00000129226 CD68 1.358 2.563 0.006454 
ENSG00000189057 FAM111B 1.358 2.562 0.0006161 
ENSG00000110077 MS4A6A 1.351 2.552 0.006225 
ENSG00000147697 GSDMC 1.332 2.517 4.18E-05 
ENSG00000165168 CYBB 1.321 2.499 0.04744 
ENSG00000124107 SLPI 1.321 2.498 0.006837 
ENSG00000155659 VSIG4 1.317 2.492 0.02365 
ENSG00000124491 F13A1 1.31 2.48 0.005231 
ENSG00000185966 LCE3E 1.302 2.465 0.0675 
ENSG00000214787 MS4A4E 1.279 2.427 0.001563 
ENSG00000199004 MIR21 1.26 2.395 0.001729 
ENSG00000165474 GJB2 1.256 2.389 0.0002327 
ENSG00000137462 TLR2 1.253 2.384 0.001919 
ENSG00000006074 CCL18 1.239 2.36 0.1121 
ENSG00000213927 CCL27 1.227 2.341 0.03032 
ENSG00000166535 A2ML1 1.223 2.334 0.012 
ENSG00000198074 AKR1B10 1.217 2.325 0.06558 
ENSG00000149968 MMP3 1.196 2.291 0.1771 
ENSG00000092295 TGM1 1.156 2.228 0.001027 
ENSG00000169429 IL8 1.153 2.225 0.0103 
ENSG00000170688 OR5E1P 1.151 2.221 0.03809 
ENSG00000179477 ALOX12B 1.133 2.193 3.23E-05 
ENSG00000127954 STEAP4 1.132 2.192 0.004494 
ENSG00000062038 CDH3 1.121 2.175 0.002682 
ENSG00000125780 TGM3 1.102 2.147 0.008916 
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ENSG00000205420 KRT6A 1.092 2.132 0.002187 
ENSG00000105427 CNFN 1.09 2.128 0.004554 
ENSG00000149573 MPZL2 1.076 2.108 0.0002388 





Suppl. Table 5. Top 50 upregulated genes in AGEP biopsies (n=8) as compared to MPR skin 





Identifier Gene name log2(ratio) ratio p-value 
ENSG00000057149 SERPINB3 2.798 6.95 0.0009307 
ENSG00000206073 SERPINB4 2.694 6.47 0.001229 
ENSG00000163221 S100A12 2.642 6.24 0.0005447 
ENSG00000012223 LTF 2.497 5.65 0.0003801 
ENSG00000134827 TCN1 2.31 4.96 0.002876 
ENSG00000184330 S100A7A 1.989 3.97 0.004018 
ENSG00000087916 SLC6A14 1.949 3.86 0.0008485 
ENSG00000134339 SAA2 1.907 3.75 0.0223 
ENSG00000153802 TMPRSS11D 1.831 3.56 0.001073 
ENSG00000149968 MMP3 1.588 3.01 0.03996 
ENSG00000196805 SPRR2B 1.56 2.95 0.003465 
ENSG00000148346 LCN2 1.547 2.92 0.002194 
ENSG00000181333 HEPHL1 1.533 2.89 0.009847 
ENSG00000202042 SNORD49B 1.522 2.87 0.003253 
ENSG00000163220 S100A9 1.466 2.76 0.005031 
ENSG00000167755 KLK6 1.421 2.68 0.007998 
ENSG00000167759 KLK13 1.378 2.60 0.007276 
ENSG00000136688 IL1F9 1.346 2.54 0.005832 
ENSG00000075673 ATP12A 1.3 2.46 0.01231 
ENSG00000177575 CD163 1.27 2.41 0.05099 
ENSG00000090382 LYZ 1.266 2.40 0.007701 
ENSG00000124491 F13A1 1.264 2.40 0.03593 
ENSG00000165474 GJB2 1.254 2.39 0.002016 
ENSG00000185275 CD24L4 1.234 2.35 3.24E-05 
ENSG00000139329 LUM 1.224 2.34 0.01131 
ENSG00000105835 PBEF1 1.192 2.28 0.0006817 
ENSG00000176171 BNIP3 1.189 2.28 0.01314 
ENSG00000165168 CYBB 1.167 2.25 0.07221 
ENSG00000169429 IL8 1.161 2.24 0.008632 
ENSG00000169084 DHRSX 1.159 2.23 0.004618 
ENSG00000110077 MS4A6A 1.143 2.21 0.05424 
ENSG00000006074 CCL18 1.129 2.19 0.08582 
ENSG00000173432 SAA1 1.106 2.15 0.05391 
ENSG00000137462 TLR2 1.103 2.15 0.01375 
ENSG00000110079 MS4A4A 1.094 2.13 0.06057 
ENSG00000081041 CXCL2 1.089 2.13 0.0001574 
ENSG00000124102 PI3 1.048 2.07 0.004655 
ENSG00000143556 S100A7 1.03 2.04 0.002713 
ENSG00000121742 GJB6 1.025 2.03 0.0006617 
ENSG00000199004 MIR21 1.017 2.02 0.03609 
ENSG00000087086 FTL 0.986 1.98 0.07913 
ENSG00000129226 CD68 0.971 1.96 0.0579 
ENSG00000129538 RNASE1 0.970 1.96 0.09199 
ENSG00000154175 ABI3BP 0.942 1.92 0.01506 
ENSG00000204020 LIPN 0.933 1.91 0.05536 
ENSG00000166535 A2ML1 0.908 1.88 0.04812 
ENSG00000160593 AMICA1 0.895 1.86 0.04174 
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ENSG00000197930 ERO1L 0.885 1.85 0.01465 
ENSG00000164647 STEAP1 0.879 1.84 0.08395 





Name Meier Barbara 
Academic title Dr. med.  
Date of birth 18.04.1985 
City of birth Munich, Germany 
Nationality German 
Position  MD PhD student / Resident physician 







05/2013 – present MD PhD 
MD PhD program of the University of Zurich  
PhD program in Microbiology&Immunology of the University of Zurich and 
the Swiss Federal Institute of Technology Zurich 
Research group Prof. Dr. Lars E. French 
05/2013 – present Master of Science 
Medical Biology, University of Zurich  
06/2011 Medical state examination 
02/2010 - 01/2011 Practical year of medical studies 
University Hospital Ulm, University Hospital Zurich 
02/2009-04/2015 MD thesis 
Department of Dermatology, University Hospital Ulm 
Research group Prof. Dr. K. Scharffetter-Kochanek 
Scholarship: Experimental Medicine, International Graduate School in 
Molecular Medicine Ulm 
09/2007 - 06/2008 Medical studies 
Faculty of Medicine, University of Franche-Comté Besançon, France 
Scholarship: Erasmus program 
10/2006 Preliminary medical examination 
10/2004 - 02/2011 Medical studies 
Faculty of Medicine, University of Ulm 





05/2013 - present MD PhD student / Resident physician 
Department of Dermatology, University Hospital Zurich 
Research group Prof. Dr. L.E. French 
03/2012 - 02/2013 Resident physician 





2017 Culprit drug specific IL-36 overexpression in Acute Generalized Exanthematous 
Pustulosis. Meier B, Feldmeyer L, Jankovic D, Satoh TK, Mellett M, Yerly D, Navarini 
A, Abe R, Yawalkar N, Chung WH, Contassot E, French LE. Manuscript in preparation. 
10/2016 Pyoderma gangrenosum and Sweet's syndrome: Cutaneous manifestations of 
autoinflammatory disorders. Meier B, Maul JT & French L.E. Hautarzt 2016. 
doi:10.1007/s00105-016-3888 
07/2016 In Situ Mapping of Innate Lymphoid Cells in Human Skin: Evidence for Remarkable 
Differences between Normal and Inflamed Skin. Brüggen MC, Bauer WM, Reininger 
B, Clim E, Captarencu C, Steiner GE, Brunner PM, Meier B, French LE, Stingl G. J 
Invest Dermatol. 2016 Jul 22. pii: S0022-202X(16)32126-1. doi: 
10.1016/j.jid.2016.07.017. 
07/2016 Tumor hypoxia promotes melanoma growth and metastasis via High Mobility Group 
Box-1 and M2-like macrophages. Huber R*, Meier B*, Otsuka A*, Fenini G, Satoh T, 
Gehrke S, Widmer D, Levesque MP, …, Kabashima K, Nonomura Y, Dummer R, 
Contassot E, and French LE. Sci Rep 2016 Jul 18;6:29914 doi: 10.1038/srep29914. 
*These authors contributed equally. 
03/2016 Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Goldinger SM, 
Stieger P, Meier B, Micaletto S, Contassot E, French LE, Dummer R.; Clin Cancer 
Res. 2016 Mar 8. pii: clincanres.2872.2015. 
11/2015 Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Kolios AG*, 
Maul JT*, Meier B*, Kerl K, Traidl-Hoffmann C, Hertl M, Zillikens D, Röcken M, Ring J, 
Facchiano A, Mondino C, Yawalkar N, Contassot E, Navarini AA, French LE. Br J 
Dermatol. 2015 Nov;173(5):1216-23. doi: 10.1111/bjd.14037 *These authors 
contributed equally. 
09/2015 ABCB5 Identifies Immunoregulatory Dermal Cells. Schatton T, Yang J, Kleffel S, 
Uehara M, Barthel SR, Schlapbach C, Zhan Q, Dudeney S, Mueller H, Lee N, de Vries 
JC, Meier B, Vander Beken S, …, Scharffetter-Kochanek K, Murphy GF, Kupper TS, 
Frank NY, Frank MH. Cell Rep. 2015 Sep 8;12(10):1564-74. doi: 
10.1016/j.celrep.2015.08.010. 
03/2015 Severe Sweet's Syndrome with Elevated Cutaneous Interleukin-1β after Azathioprine 
Exposure: Case Report and Review of the Literature. Imhof L, Meier B, Frei P, 
Kamarachev J, Rogler G, Kolios A, Navarini AA, Contassot E, French LE. Dermatology. 
2015;230(4):293-8. doi: 10.1159/000371879. 
01/2015 Propionibacterium acnes promotes Th17 and Th17/Th1 responses in acne patients. 
Kistowska M, Meier B, Proust T, Feldmeyer L, Cozzio A, Kuendig T, Contassot E, 
French LE. J Invest Dermatol. 2015 Jan;135(1):110-8. doi: 10.1038/ jid.2014.290.  
07/2014 Autoinflammatory syndromes-cutaneous manifestations. Meier B, French LE Dtsch 
Med Wochenschr. 2014 Jul;139(28-29):1468-72. doi: 10.1055/s-0034-1370159. 
01/2014 
 
Metastatic melanoma cell lines do not secrete IL-1β but promote IL-1β production from 
macrophages. Gehrke S, Otsuka A, Huber R, Meier B, Kistowska M, Fenini G, Cheng 
P, Dummer R, Kerl K, Contassot E, French LE. J Dermatol Sci. 2014 May;74(2):167-





First of all, I thank Prof. Dr. Lars French for giving me the opportunity to work with 
him and to achieve my PhD in his laboratory. I am very thankful for all your scientific 
and personal support, for constructive discussions on Monday morning and for all 
the knowledge you shared with me. I am really inspired by your enthusiasm about 
research and I am happy that I am able to continue working with you in the future.  
A special thank you goes to Dr. Emmanuel Contassot who was always the first 
contact person for all my concerns. You helped me a lot with the design of 
experiments, the interpretation of my results and the overall understanding of 
scientific topics. Also, you taught me very well how to write scientific manuscripts 
and you were always helping me to improve by giving me constructive feedback. I 
really enjoyed working with you on adverse drug reactions and I am looking forward 
to continue working on it.  
I thank the members of my thesis committee, Prof. Dr. Onur Boyman, Prof. Dr. 
Maries van den Broek, Prof. Dr. Annette Oxenius, and Prof. Dr. Thomas Kündig, for 
their support, for important scientific input to help improving my project, and for 
inspiring discussions during the thesis committee meetings.  
Moreover, I thank my group members Gabriele Fenini, Takashi Satoh, Deepa 
Mohanan and Mark Mellett for great discussions in our lab meetings and for always 
helping out – everyone of you is expert in their own field and I am very thankful to 
be able to exchange our knowledge. 
A special thanks goes to Mark Mellett who has been great help with my new project 
concerning TLR4. I thank you for sharing your knowledge with me and for never 
getting tired to answer all my questions. You are a very good person and a great 
colleague, thank you! 
I thank my former lab member Magdalena Kistowska for introducing me to all the 
important research techniques when I started in the lab four years ago. Moerover, I 
thank Dragana Jankovic for isolating the first set of RNA for the Affymetrix assay 
which was the basis for the start of my project. Also, I want to thank Laurence 
Feldmeyer for collecting samples of adverse drug reactions during many years and 
for helping to start our project. I further thank my former lab member Roman Huber 
 
 116 
for great teamwork and involving me in his melanoma project which I enjoyed very 
much. 
Another thanks goes to the members of Hans-Dietmar Beer’s research group, 
Jenny, Martha, Serena and Gerhard, with who I have shared the benches for many 
years. Thank you for your input in our Friday meetings and for all the good 
„procrastination times“ in our office. 
I thank Alexander Navarini for his support and for giving me insight in his whole 
exome sequencing data. Without you it would have been much more difficult to 
identify genetic changes in AGEP patients. Thank you! 
I want to thank Alaz Özcan Özge for her great help with measuring IL-1β in the blood 
of AGEP patients. A great thanks goes also to her supervisor Dr. Antonios Kolios 
who is always willing to help and to collaborate. 
I want to thank Karin Schnyder for your help with experiments and for being a very 
good colleague with a very good heart. I am happy that you did not give up and that 
we were able to establish the LTT in our Department. 
I thank my parents for always being there for me. You are feeling with me since my 
first day of medical studies and you had to go through even much more in times 
when I worked for my MD thesis title. The cherry of the cake was certainly my 
decision to do a PhD and it was probably not always easy to watch me going through 
times of no sleep and frustration. But you always had an open ear and showed me 
that you are proud of me. Thank you for being wonderful parents! 
I want to thank my sister Stefanie for being a great example in life. I always admired 
your strong personality, your intelligence, your humour and your big heart and I 
couldn’t be any happier to have such great sister!  
Finally, I want to thank my fiancé Oliver for being who he is. You went with me 
through all my moments of happiness, of sadness and frustration. In moments of 
doubts, you cheered me up and convinced me to stand up and continue. I am really 











Culprit drug specific IL-36 overexpression in Acute Generalized Exanthematous 3 
Pustulosis 4 
 5 
Barbara Meier, MD a, Laurence Feldmeyer, MD, PhD b, Dragana Jankovic, PhD a, Takashi K. 6 
Satoh, MD, PhD a, Mark Mellett, PhD a, Daniel Yerly, PhD c, Alexander Navarini, MD, PhD a, 7 
Riichiro Abe, MD, PhD d, Nikhil Yawalkar, MD b, Chung Wen-Hung e, Emmanuel Contassot, 8 
PhD a,# , Lars E. French, MD a,# 9 
 10 
a Department of Dermatology, University Hospital, Zürich, Switzerland 11 
 12 
b Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, 13 
Switzerland 14 
 15 
c Department of Rheumatology, Clinical Immunology and Allergology, Inselspital, Bern 16 
University Hospital, University of Bern, Switzerland 17 
 18 
d Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, 19 
Niigata, Japan 20 
 21 
e Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang 22 
Gung Memorial Hospital, Taipei and Linkou, Taiwan 23 
 24 
# Co-senior authors 25 
 26 
Correspondence: 27 
Lars E. French, Dermatology Department, University Hospital, Gloriastrasse 31, Zürich, 28 
Switzerland. Phone: + 41 44-255 25 50; e-mail: lars.french@usz.ch or Emmanuel Contassot, 29 
Dermatology Department, University Hospital, Gloriastrasse 31, Zürich, Switzerland. Phone: + 30 










Acute generalized exanthematous pustulosis (AGEP) is a severe adverse cutaneous drug 39 
reaction. Although an involvement of drug-specific T cells has been reported, the 40 
physiopathology of AGEP and mechanism of neutrophilic skin inflammation remains 41 
incompletely understood. Recently, mutations in IL-36RN, the gene encoding the IL-36 42 
receptor antagonist, have been reported to be more frequent in AGEP patients and pustular 43 
psoriasis.  44 
 45 
Methods 46 
Gene expression profiling, quantitative RT-PCR and immunohistochemistry in skin lesions 47 
from patients suffering from AGEP were compared to that of patients with maculo-papular rash 48 
(MPR), a benign adverse cutaneous reaction to drugs and healthy skin. The nature of cells 49 
secreting upregulated proinflammatory cytokines in AGEP patients’ skin was assessed using 50 
immunofluorescence. The ability of the causative drug to trigger proinflammatory cytokine 51 
production in AGEP patients’ peripheral blood mononuclear cells and keratinocytes was 52 
assessed using single cell-type cultures or co-culture experiments and subsequent analysis of 53 
cytokine production by ELISPOT or quantitative RT-PCR. 54 
 55 
Results 56 
An unbiased approach revealed significant IL-36 α and γ upregulation in lesional skin of AGEP 57 
patients when compared to MPR. Keratinocytes and macrophages were found to be the source 58 
of IL-36γ in AGEP patients. In vitro, the causative drug specifically induced IL-36γ release 59 
either directly by peripheral blood monocytes, or indirectly in presence of autologous peripheral 60 
blood mononuclear cells by keratinocytes of patients with AGEP. Such culprit drug induction 61 
of IL-36γ secretion in vitro was specific for AGEP and was not observed for MPR. 62 
 63 
Conclusions 64 
Our results demonstrate that IL-36γ secretion by monocytes/macrophages and keratinocytes 65 
in response to culprit drug exposure likely plays a key role in the pathogenesis of AGEP. 66 
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CAPSULE SUMMARY 67 
• IL-36 is overexpressed in lesional skin of patients with acute generalized 68 
exanthematous pustulosis (AGEP) and not in patients with a moderate form of drug 69 
reaction. 70 
• Culprit drugs selectively induce IL-36 secretion in AGEP patients’ monocytes and 71 
keratinocytes. 72 
• IL-36 produced by monocytes and keratinocytes from AGEP patients induce the 73 












AGEP: Acute generalized exanthematous pustulosis; MPR: maculo-papular rash; ADR: 86 
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INTRODUCTION  94 
Acute generalized exanthematous pustulosis (AGEP) is a severe adverse cutaneous drug 95 
reaction (ADR) caused mainly by antibiotics, antimalarials, and antifungals 1. Clinically, AGEP 96 
is characterized by a disseminated eruption of sterile nonfollicular pustules on the background 97 
of a widespread erythematous skin eruption, accompanied with fever and peripheral blood 98 
neutrophilia. The pathophysiology of AGEP remains unclear. However, AGEP is currently 99 
considered as a T cell-mediated disease 2. Indeed, drug-specific T cells are suspected to play 100 
a central role in AGEP as evidenced by the high levels of T cell stimulation induced by 101 
causative (culprit) drugs as measured by the lymphocyte transformation test (LTT) 3. 102 
Furthermore, drug-specific CD4+ and CD8+ T cells have been derived in vitro from AGEP 103 
patients’ peripheral blood. Most of these drug-specific T cells 4 produce IL-8 5, 6, a powerful 104 
neutrophil chemoattractant. IL-8-producing T cells are therefore, considered to be the cause 105 
of neutrophil survival and recruitment to the skin 7. It has also been suggested that Th17 106 
effector cytokines, namely IL-17 and IL-22, stimulate keratinocytes to produce IL-8, and that 107 
keratinocyte-derived IL-8 also contributes to neutrophil accumulation in AGEP patients’ skin 8.  108 
Hence, T cell- and keratinocyte-derived IL-8 has been proposed to be responsible for the 109 
recruitment of neutrophils to the intraepithelial pustules. 110 
AGEP shares certain clinical and histological features with pustular psoriasis. Recently, 111 
genetic studies identified mutations in the IL-36 receptor antagonist gene (IL-36RN) in patients 112 
with general pustular psoriasis 9-12. Interestingly, mutations in IL-36RN have also been reported 113 
in AGEP 13, suggesting that IL-36 signaling dysregulation is involved in the physiopathology of 114 
both diseases. IL-36 receptor antagonist (IL-36Ra) inhibits the binding of IL-36α, β and γ to 115 
their receptor. A mutation in IL-36RN may therefore result in exacerbated IL-36 signaling 116 
leading to the production of IL-1, IL-6 and IL-8 and subsequent neutrophilic skin infiltration with 117 
pustule formation. 118 
IL-36 cytokines have emerged as important cytokines mediating inflammatory responses in 119 
the skin. Indeed, several reports have shown that all IL-36 isoforms are overexpressed in 120 
psoriatic skin 14-17. In keratinocytes, production of IL-36 family members can be induced by 121 
TNF, IL-17 and IL-22, cytokines known to be involved in psoriasis which further supports an 122 
important role for IL-36 in this disease 18. Recently, it has been reported that antigen-presenting 123 
cells located in human skin, express high levels of IL-36R and are responsive to IL-36 124 
cytokines 19, an observation that further supports an important role of IL-36 in skin biology.  125 
Here, we provide evidence that drugs causing AGEP can specifically trigger IL-36 cytokine 126 
production by peripheral blood monocytes and keratinocytes from AGEP patients and 127 
subsequently induce IL-8 by peripheral blood mononuclear cells in an IL-36-dependent 128 
manner. These observations are supportive of a drug-specific dysregulation of IL-36 signaling 129 
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as an important potential driver of AGEP pathogenesis, and identify myeloid cells and 130 






The characteristics of all studied AGEP patients from the Dermatology Department of the 135 
University Hospital of Zürich are presented in Tables 1 and 2. All human samples were 136 
collected after informed written patient consent with approval of Local Ethics Committees and 137 
according to the Declaration of Helsinki Principles. 138 
 139 
Skin biopsy  140 
Skin biopsies were taken from lesional skin of patients in the acute phase of the ADR (4-6mm 141 
punch biopsies). Healthy skin samples were obtained from the Department of Plastic Surgery, 142 
University Hospital of Zürich. For paraffinization, skin samples were fixed in formalin 4% 143 
overnight. For RNA isolation, samples were snap-frozen in liquid nitrogen and stored at -80°C.   144 
 145 
Collection of peripheral blood mononuclear cells  146 
Peripheral blood from patients was taken both in the acute phase of the disease and under 147 
healthy conditions (at least 6 months after the ADR). Healthy controls were obtained from the 148 
Blood Donation Center (Schlieren, Switzerland). Peripheral blood mononuclear cells (PBMC) 149 
were isolated using a density gradient (Ficoll-Paque, Pharmacia, Glattbrugg, Switzerland).  150 
 151 
Monocyte and T cell purification 152 
Where indicated, CD14+ monocytes were sorted from PBMC by positive selection using 153 
magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany). CD3+ cells were sorted from 154 
the CD14- fraction by negative selection using a Pan T Cell Isolation Kit (Miltenyi Biotech) 155 
according to the manufacturer’s instructions. Purity was assessed by flow cytometry 156 
(Facscanto A, Becton-Dickinson) using mouse anti-human CD45-PeCy7 (Biolegend, San 157 
Diego, CA), mouse anti-human CD3-APC (Biolegend) and mouse anti-human CD14-FITC 158 
(Becton-Dickinson, Franklin Lakes, NJ). 159 
 160 
Primary keratinocyte culture 161 
Hair follicles were collected from patients at least 6 months after resolution of the ADR. Hair 162 
follicle extremities containing outer root sheath were cut, washed in complete keratinocyte 163 
medium 20 and incubated for 3 minutes in 1mg/ml Dispase II, followed by three washing steps 164 
in medium. The hair was then plated on J2 feeder cells in complete medium and cultured until 165 
small colonies of keratinocytes become visible. Cells were splitted at 80% confluence and 166 
passaged three times before being used for experiments.   167 
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Gene expression array   168 
Sample processing 169 
Gene expression profiling was performed using Human Exon 1.0 ST Affymetrix chips. Raw 170 
fluorescence intensity values were analyzed using the R packages Affy 21 and Limma of 171 
Bioconductor 22. Data analysis consisted in the following steps: 1. between-array 172 
normalization, 2. probe summary with the rma algorithm, 3. fitting the data to a linear model 173 
and 4. detection of differential gene expression. Quantile-normalization was applied to the 174 
log2-transformed intensity values as a method for between-array normalization, to ensure that 175 
the intensities had similar distributions across arrays 23. To find genes with significant 176 
expression changes between groups, empirical Bayes statistics were applied by moderating 177 
the standard errors of the estimated values. P-values were obtained from the moderated t-178 
statistic and corrected for multiple testing with the Benjamini–Hochberg method 24. The P-value 179 
adjustment guarantees a smaller number of false positive findings by controlling the false 180 
discovery rate (fdr). 181 
 182 
Data analysis 183 
Quality control and gene expression analysis was done using R/Bioconductor software (Fred 184 
Hutchinson Cancer Research Center, Seattle, WA) 22; signal intensity files were summarized 185 
using the robust multi array average (RMA) 23 for processing and quantile normalization. A 186 
modified t-test using limma software (part of the Bioconductor project) 25 was performed to 187 
compare the experimental conditions. P-values and the Benjamini-Hochberg False Discovery 188 
Rate (FDR) are reported. 189 
 190 
RNA-sequencing 191 
Library preparation 192 
RNA quantity and quality were determined with a Qubit® (1.0) Fluorometer (Life Technologies, 193 
California, USA) and a Bioanalyzer 2100 (Agilent, Waldbronn, Germany). The TruSeq 194 
Stranded mRNA Sample Prep Kit (Illumina, Inc, California, USA) was used in the subsequent 195 
steps. Total RNA (1μg) were ribosome depleted and reverse-transcribed into double-stranded 196 
cDNA with Actinomycin added during first-strand synthesis. cDNA samples were fragmented, 197 
end-repaired and polyadenylated before ligation of TruSeq adapters. Adapters contain the 198 
index for multiplexing. Fragments containing TruSeq adapters on both ends were enriched by 199 
PCR. Quality and quantity of the enriched libraries were validated using a Qubit® (1.0) 200 
Fluorometer and the Bioanalyzer 2100. Libraries were normalized to 10nM in Tris-Cl 10mM, 201 




Cluster Generation and RNA Sequencing 204 
The TruSeq PE Cluster Kit v3-cBot-HS (Illumina, Inc., CA) was used for cluster generation 205 
using 8pM of pooled normalized libraries on the cBOT. RNA sequencing was performed on an 206 
Illumina HiSeq with a 2500 paired end approach at 2 X126 bp using the TruSeq SBS Kit v3-207 
HS (Illumina, Inc.). 208 
 209 
Data analysis 210 
Bioinformatic analysis was performed using SUSHI 26. In detail, the raw reads were quality 211 
checked using Fastqc (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and FastQ 212 
Screen (http://www.bioinformatics.babraham.ac.uk/projects/fastq_screen/). Quality controlled 213 
reads (first five bases trimmed, minimum average quality Q20, minimum tail quality Q10) were 214 
aligned to the reference transcriptome (Ensembl GRCh38, not patched) for transcript 215 
abundance estimation using RSEM 27. Differential expression analysis was performed using 216 
edgeR 28. Gene ontology (GO) enrichment analysis was performed using the Bioconductor 217 
packages goseq 29 and GOStats 30, and visualized using ReViGo 31. Enrichment analysis of 218 
other gene sets was performed using Enrichr 32.    219 
 220 
RNA isolation and Real-Time quantitative PCR 221 
Total RNAs were isolated from AGEP, MPR and healthy skin biopsies, as well as from 222 
keratinocytes and PBMC using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to 223 
manufacturer’s instructions, followed by cDNA synthesis by reverse-transcription using the 224 
RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, Watham, MA). Real-Time 225 
quantitative PCR was performed using a LightCycler® 96 (Roche). The primer sequences 226 
were obtained from http://pga.mgh.harvard.edu/primerbank/:  227 
hRPL27 F 5`-ATC GCC AAG AGA TCA AAG ATA A-3' 
hRPL27 R 5`-TCT GAA GAC ATC CTT ATT GAC G-3' 
hIL36a F 5`-CCA GAC GCT CAT AGC AGT CC-3' 
hIL36a R 5`-AGA TGG GGT TCC CTC TGT CTT-3' 
hIL36b F 5`-ATG AAC CCA CAA CGG GAG G-3` 
hIL36b R 5`-TAA TGC TGC GGC TAA GAG GAG-3` 
hIL-36g F 5`-AGG AAG GGC CGT CTA TCA ATC-3' 
hIL-36g R 5`-CAC TGT CAC TTC GTG GAA CTG-3' 
hIL-36R F 5`-CCG AGG TGT TGG AGA GAC AAT G-3' 
hIL-36R R 5`-GGA CCA CAA TGA CAA TCA GCC TC-3' 
hIL36RN F 5`-ACT CGG CAT TGA AGG TGC TTT-3' 
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hIL36RN R 5`-GGG ACC ACG CTG ATC TCT T-3' 
hIL-8 F 5`-TTT TGC CAA GGA GTG CTA AAG A-3' 
hIL-8 R 5`-AAC CCT CTG CAC CCA GTT TTC-3' 
hCD45 F 5'-ACA GCC AGC ACC TTT CCT AC-3' 
hCD45 R 5'-GTG CAG GTA AGG CAG CAG A-3' 
ITGA6 F 5'-TCA TGG ATC TGC AAA TGG AA-3' 
ITGA6 R 5'-AGG GAA CCA ACA GCA ACA TC-3' 
 228 
Real-time quantitative PCR included an initial denaturation at 95°C for 10 min, followed by 40 229 
cycles at 95°C for 30 s, 55°C for 1 min, 72°C for 1 min, and one cycle at 95°C for 1 min, 55°C 230 
for 30 s, 95°C for 30 s. RPL27 was used as a housekeeping gene. 231 
 232 
Immunohistochemistry 233 
Five µm paraffin-embedded AGEP, MPR, PP and healthy skin sections were deparaffinized 234 
and rehydrated. Antigen demasking was performed using pressure cooker heating for 25 min 235 
in Target Retrieval solution (DAKO, Glostrup, Denmark). After permeabilization (0.03% Triton 236 
X for 10 minutes), sections were blocked using 5% BSA in PBS for one hour at room 237 
temperature and washed. 238 
For immunohistochemistry, sections were stained overnight at 4 °C with 0.5µg/ml goat anti-239 
human IL-36α or 0.5µg/ml goat anti-human IL-36γ (both from R&D, Minneapolis, MN), or 240 
2µg/ml rabbit anti-human IL-8 (LSBio, Seattle, WA). A goat IgG isotype antibody (R&D 241 
Systems, Minneapolis, MN) and a rabbit IgG isotype antibody (Abcam, Cambridge, United 242 
Kingdom) at corresponding concentrations were used as controls. Slides were washed with 243 
PBS and a donkey anti-goat secondary antibody (Abcam) for IL-36α and γ and a goat anti-244 
rabbit (Southern Biotech, Birmingham, USA) for IL-8 was added and incubated for 1 hour at 245 
room temperature. Slides were washed with PBS and mounted with an Avidin-Biotin-complex 246 
(Vector Laboratories, Peterborough, UK). After 45 min, slides were washed with PBS and AEC 247 
- HRP substrate (Vector Laboratories) was added. After washing, slides were counterstained 248 
with hematoxylin. Sections were mounted in mounting medium (DAKO) and imaged by using 249 
an Aperio ScanScope (Leica Biosystems, Wetzlar, Germany).    250 
For immunofluorescence, sections were then stained overnight at 4 °C with a) 0.5µg/ml goat 251 
anti-human IL-36α (R&D Systems), together with either 20µg/ml mouse anti-human CD3 252 
(Dako), 20µg/ml mouse anti-human CD68 (Dako) or 20µg/ml rabbit anti-human MPO (DAKO), 253 
or b) with 0.5µg/ml goat anti-human IL-36γ (R&D Systems), together with either 20µg/ml 254 
mouse anti-human CD3 (Dako), 20µg/ml mouse anti-human CD68 (Dako) or rabbit anti-human 255 
MPO (DAKO). Goat IgG isotype (R&D Systems), mouse IgG isotype (Abcam) and rabbit IgG 256 
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isotype (Abcam) antibodies at corresponding concentrations were used as isotype-specific 257 
controls. After washing with PBS, samples were incubated for 60 min at room temperature with 258 
conjugated secondary antibodies as follows: Alexa Fluor® 488 Goat Anti-Mouse IgG or Alexa 259 
Fluor® 488 Donkey Anti-Rabbit and Alexa Fluor® 647 Donkey Anti-Goat IgG (Life 260 
Technologies, Carlsbad, CA). Nuclear staining was performed using 4',6-diamidino-2-261 
phenylindole (DAPI, Thermo Fisher Scientific, Carlsbad, CA). Slides were mounted with 262 
Fluorescence Mounting Medium (DAKO) and analyzed with a Widefield BX61 fluorescence 263 
microscope (Olympus, Tokyo, Japan) using the Analysis Pro software (Soft Imaging Systems, 264 
Münster, Germany).  265 
  266 
ELISPOT 267 
To perform Elispot analysis, PVDF-plates (Merck Millipore, Billerica, MA) were pre-wetted by 268 
70% ethanol for 2 minutes. After washing, plates were coated with 2μg/ml rabbit anti-human 269 
IL-36γ (Peprotech, Rocky Hill, NJ) per well overnight. After removing excess antibody and 270 
washing, a blocking step was performed using RPMI medium containing 10% FBS. After one 271 
hour, medium was removed and 200.000 cells ± culprit drug (Amoxicillin 1mg/ml; Letrozole 272 
100nM) or control drug (Metamizole 100µg/ml; Carbamazepine 10µg/ml) or a vehicle (RPMI 273 
medium containing 10% FBS) were added and incubated at 37°C for the indicated time. After 274 
washing, 2μg/ml rabbit anti-human biotinylated IL-36γ antibody (Peprotech) was added to the 275 
wells and incubated for 2 hours at room temperature, followed by one-hour incubation with 276 
Streptavidin-ALP (Mabtech, Nacka Strand, Sweden). For detection of the protein, BCIP/NBT 277 
substrate (Promega, Dübendorf, Switzerland) was added and developed until distinct spots 278 
emerged. Data was analyzed using the AID Elispot Reader (AID GmbH, Strassberg, 279 
Germany). 280 
 281 
Co-culture experiments 282 
PBMC and keratinocytes used in these experiments were collected at least 6 months after 283 
resolution of the ADR. 70.000 AGEP hair follicle keratinocytes were plated on a 12mm 284 
transwell plate with 0.4µm pore polycarbonate membrane inserts (Corning, NY, USA) 285 
overnight to allow them to adhere. The following day, keratinocyte medium was replaced by 286 
Gibco Opti-MEM medium (Thermo Scientific) and 1x106 PBMC were added inside the inserts, 287 
followed by addition of culprit drug (Amoxicillin 1mg/ml; Letrozole 100nM; Vancomycin 288 
500µg/ml) or control drug (Metamizole 100µg/ml; Carbamazepine 10µg/ml; Amoxicillin, 289 
1mg/ml) or vehicle (RPMI medium containing 10% FBS)  in both compartments at the same 290 
concentration. After 6 hours, cells were harvested and RNA was isolated for quantitative RT-291 




Statistical analysis 294 
Differences between groups were assessed using one-way Anova followed by Turkey’s post-295 
test. Differences were considered significant when: *p≤0.05, ** p≤0.01 and *** p≤0.001 and 296 






Enhanced IL36γ and IL-8 gene expression in lesional skin of AGEP patients 301 
First, we performed gene expression profiling using Affymetrix Human Exon 1.0 ST chips. Total 302 
RNA were extracted from lesional skin from patients with AGEP (n=8) or maculo-papular rash 303 
(MPR, n=6), and from skin from healthy individuals (n=7). The hierarchical clustering of genes 304 
differentially expressed in AGEP, MPR and healthy skin revealed a perfect segregation of 305 
these three conditions based on the gene expression profile of individual samples and the 306 
magnitude of change in gene expression (Fig.1A and Table E1 in the Online Repository). IL-8 307 
has been previously reported to be produced by drug-specific T cells in AGEP patients 6 and 308 
in accordance with this, IL-8 expression was significantly upregulated in AGEP skin when 309 
compared to healthy skin (ratio=2.25, p=0.01; Table E2 in the Online Repository) but also when 310 
compared to MPR (ratio=2.24, p=0.008; Table E3 in the Online Repository). Interestingly, the 311 
IL-36γ gene (IL1F9) was also found to be overexpressed in AGEP skin when compared to 312 
healthy skin (ratio=3.06, p=0.0006; Table E2 in the Online Repository) and MPR (ratio=2.54, 313 
p=0.005; Table E3 in the Online Repository). RNAseq analysis of an independent series of 314 
AGEP (n=9) and MPR (n=8) patient lesional skin confirmed the overexpression of IL-36γ gene 315 
(ratio=3.12; p=0.02) in AGEP (Fig.1B). Although not reaching statistical significance (p=0.12), 316 
RNAseq analysis also revealed an overexpression of IL-8 (ratio=2.31) in AGEP skin. 317 
We then confirmed the observed upregulation of IL-36 and IL-8 by quantitative PCR in AGEP 318 
(n=16) and MPR (n=16) skin biopsies. In accordance with the gene expression array and 319 
RNAseq data, expression of IL-36γ was found to be upregulated in AGEP skin when compared 320 
to MPR (32-fold, p<0.001) and normal skin (3-fold, p<0.001) (Fig. 1C). In addition to IL-36γ, IL-321 
36α expression was also upregulated in AGEP skin when compared to MPR (15-fold, p<0.001) 322 
and normal skin (7-fold, p<0.001). Similarly, IL-36β was upregulated in AGEP when compared 323 
to MPR (28-fold, p<0.001) and normal skin (1.35-fold, p<0.05). The expression of IL-36RN was 324 
found to be higher (4.5-fold, p<0.001) in AGEP skin as compared to MPR whereas it was not 325 
different to that found in normal skin. IL-36R was similarly expressed in both diseases. As 326 
previously reported, levels of IL-8 mRNA were higher in the skin of AGEP patients than in MPR 327 
patients (127-fold, p<0.001) and normal skin (34-fold, p<0.01).  328 
 329 
IL-36α and IL-36γ cytokines are highly expressed in AGEP skin lesions  330 
Unlike IL-36β, IL-36α and γ were found to be unique for AGEP (Table E1 in the Online 331 
Repository). To further analyze their expression and tissue distribution, we labeled AGEP and 332 
MPR lesional skin biopsies with antibodies to both cytokines. IL-36α and γ were found to be 333 
highly expressed in pustular and peri-pustular regions of AGEP skin (Fig.2A). Both 334 
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keratinocytes and dermal immune cells infiltrating pustular areas were found to produce IL-335 
36α and γ (Fig. 2B). In contrast, IL-36γ was weakly expressed in MPR skin biopsies and IL-336 
36α was barely detectable (Fig. 2A). In AGEP lesional skin, IL-36γ was predominantly 337 
expressed by keratinocytes in the epidermis and by immune cells infiltrating the dermis in 338 
pustular areas (Fig. 2B). Also, IL-36γ staining was particularly intense in non-pustular 339 
epidermis surrounding the pustules in AGEP. As previously reported 33, IL-36 was also 340 
expressed in pustules from patients suffering from pustular psoriasis (PP) and, like in AGEP 341 
biopsies, IL-36γ was the predominant form in the epidermis (Fig. 2B). To identify which cell 342 
types release IL-36α and γ in AGEP skin, we co-labeled AGEP biopsy sections with antibodies 343 
to IL-36α and γ and antibodies to CD68 to identify macrophages, and to CD3 to identify T-cells 344 
(Fig. 3). IL-36α was predominantly expressed by CD68+ macrophages (41.17%±4.71 of 345 
positively labeled cells) and to a lesser extent by keratinocytes and CD3+ T cells (27.33%±2.17 346 
and 22.33%±2.39 of positively labeled cells, respectively). IL-36γ was predominantly 347 
expressed by keratinocytes and CD68+ macrophages (44.08%±4.47 and 43.17%±3.31 of 348 
positively labeled cells, respectively) and to a lesser extent by CD3+ T cells (15.17%±1.26 of 349 
positively labeled cells). In contrast, IL-36α and IL-36γ were not expressed by neutrophils 350 
present in pustular areas (Fig. E1 in the Online Repository). 351 
 352 
Culprit drugs specifically induce rapid monocyte IL-36γ secretion in AGEP  353 
Since our immunofluorescence analyses of AGEP biopsies suggested that, in addition to 354 
keratinocytes, immune cells may also represent an important source of IL-36γ in the skin, we 355 
assessed whether peripheral blood mononuclear cells (PBMC) taken from AGEP patients 8, 9 356 
and 20 more than 6 months after the ADR - when in complete remission - were still able to 357 
respond directly to the causative drug. To this end, PBMC from patients having experienced 358 
AGEP or MPR were exposed to the culprit drug or an irrelevant control drug in ELISPOT plates. 359 
The number of IL-36γ+ spots were counted after 1, 2, 4, 6 and 8 hrs. IL-36γ release was 360 
detected in PBMC from AGEP patients already after 1 hr of culprit drug exposure (1.7-fold 361 
more spots than control drug, p<0.001)  and reached a plateau after 4 hrs (2.7-fold more spots 362 
than control drug, p<0.001; Fig. 4A, left panel), whereas no increase in IL-36γ production was 363 
observed with an irrelevant control drug (Fig. 4A, right panel). In contrast, the culprit drug did 364 
not induce IL-36γ secretion in MPR. Similarly, none of the drugs used was able to induce IL-365 
36γ secretion in PBMC from healthy blood donors (Fig 4A). Since immunofluorescence 366 
analyses of AGEP skin lesions revealed that macrophages and, to a lesser extent, T cells are 367 
possible sources of IL-36, we sorted CD14+ (monocytes) and CD3+ cells (T cells) from patients’ 368 
PBMC and exposed them to culprit or control drug to evaluate IL-36γ secretion by ELISPOT 369 
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(Fig. 4B). Whereas the control drug did not induce IL-36γ secretion in PBMC or in CD14+ and 370 
CD3+ cells, the culprit drug was able to induce IL-36γ secretion in CD14+ cells at levels similar 371 
to those observed with total PBMC. In contrast, the culprit drug was not able to induce IL-36γ 372 
secretion in CD3+ PBMC. These results suggest that PBMC from patients having experienced 373 
AGEP are able to respond directly and specifically to the causative drug and that 374 
monocytes/macrophages are an important source of IL-36 production in response to culprit 375 
drug exposure. 376 
 377 
IL-36 can be induced by culprit drugs in keratinocytes and PBMC from patients having 378 
experienced AGEP 379 
By immunolabeling both keratinocytes and macrophages were positively labeled for IL-36α 380 
and γ in pustular areas of AGEP biopsies. To assess a possible cross-talk between 381 
macrophages and keratinocytes, and the relative contribution of each cell type to drug-induced 382 
IL-36 secretion, we performed co-culture experiments using autologous hair follicle-derived 383 
keratinocytes and PBMC from three patients having experienced AGEP but in remission at the 384 
time of blood and hair collection (at least 6 months after disappearance of symptoms, patients 385 
8, 9 and 20). Keratinocytes and PBMC were cultured either alone or together using a transwell 386 
culture system (Figure E2A in the Online Repository). To formally exclude the contamination 387 
of one cell type by the other, we performed qPCR using primers to CD45 (PBMC marker) and 388 
ITGA6 (keratinocyte marker) on both PBMC and keratinocytes after a 6hr-coculture (Fig. E3 in 389 
the Online Repository). When keratinocytes and PBMC were each cultured alone, only PBMC 390 
showed elevated IL-36γ mRNA levels after exposure to the culprit drug. Interestingly, both 391 
keratinocytes and PBMC showed culprit drug-specific IL-36γ gene expression when cultured 392 
together. In contrast, keratinocytes exposed alone to the culprit drug exhibited increased IL-393 
36α gene expression (Fig. E2 in the Online Repository). This increase was further augmented 394 
in keratinocytes co-cultured with PBMC but remained modest when compared to IL-36γ (about 395 
10-fold less). The addition of soluble IL-36Ra did not reduce IL-36 expression, suggesting that, 396 
at the analyzed time point, there was no auto- or paracrine amplification and/or induction of IL-397 
36 gene expression by IL-36 released by PBMC or keratinocytes. Taken together, these results 398 
indicate that, in culprit drug-induced responses of patient-derived keratinocytes and 399 
monocytes, IL-36γ is the predominant form of IL-36 induced. Furthermore, in response to 400 
culprit drug exposure IL-36 is expressed directly by PBMC and indirectly by keratinocytes.   401 
 402 
IL-8 is selectively produced by patients’ PBMC and induced by IL-36 403 
IL-8 has previously been reported to be a key chemokine in AGEP physiopathology and has 404 
been shown to be inducible by IL-36 19, 34. Immunohistochemistry analysis confirmed that IL-8 405 
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was expressed by cells of the infiltrate in pustular regions of AGEP skin (Fig. E4 in the Online 406 
Repository). Using the keratinocyte/PBMC co-culture model described above, we assessed 407 
whether IL-36 could promote IL-8 gene expression, and if so, which cell type could produce 408 
IL-8 in response to IL-36. We observed that high levels of IL-8 gene expression (4.6-fold 409 
increase over control-drug exposure, p<0.05) occurred exclusively in patients’ PBMC co-410 
cultured with autologous keratinocytes selectively in response to culprit drug (Fig. 5B). 411 
Interestingly, upregulation of IL-8 gene expression in AGEP patients PBMC was abrogated by 412 
IL-36Ra. IL-8 gene expression was weakly induced by culprit drugs in isolated PBMC cultures, 413 
and barely detectable in isolated keratinocyte cultures. These results indicate that PBMC are 414 
the main source of drug-induced IL-8 production, and that IL-8 gene expression is dependent 415 
on PBMC- and/or keratinocyte-derived IL-36. 416 




T cells and neutrophils are considered to be major players in AGEP 6, 35. It has been proposed 419 
that drugs causing AGEP elicit drug-specific T cell responses, and that these T cells secrete 420 
IL-8 6. Recently mutations in the IL-36RN gene have been reported in AGEP 13, suggesting 421 
that a deregulation in IL-36 signaling may contribute to the physiopathology of AGEP. Our data 422 
is supportive of this hypothesis, showing that culprit drugs can directly induce IL-36 secretion 423 
in AGEP patients’ monocytes, and indirectly in patients’ keratinocytes in vitro. Analysis of IL-424 
36 gene and protein expression ex vivo is also supportive of the above, revealing that 425 
macrophages and keratinocytes are the main producers of IL-36 in the pustular areas of AGEP 426 
skin. IL-36γ was found to be the predominant form of IL-36 expressed in AGEP skin biopsies, 427 
and also the predominant form induced by the culprit drug in monocytes and keratinocytes in 428 
vitro. Interestingly, causative drugs were able to induce IL-36 and subsequent IL-8 production 429 
in PBMC taken from patients months to years after AGEP resolution whereas these cytokines 430 
could not be induced by drugs in healthy control donors who had never experienced an 431 
adverse drug reaction. This observation suggests that there is a memory of drug sensitization 432 
within AGEP patients’ PBMC and/or that genetic or epigenetic factors rendering AGEP patients 433 
susceptible to drug-induced IL-36 production were already present at the time of first drug 434 
intake. 435 
Keratinocytes are a major source of IL-36 cytokines in cutaneous inflammation, particularly in 436 
psoriasis 18. Our data suggests that keratinocytes are also an important source of IL-36 in the 437 
skin in AGEP. However, co-culture experiments revealed that keratinocytes exposed to culprit 438 
drugs were only able to produce little amounts of IL-36α and IL-36γ when cultured alone but, 439 
interestingly, produced high amounts of IL-36γ when cultured in presence of autologous 440 
monocytes and culprit drug. This observation suggests that, when exposed to the causative 441 
drug, patients’ monocytes release a soluble factor that further stimulates IL-36γ production by 442 
keratinocytes. This factor remains to be identified but our results using IL-36Ra suggest that it 443 
is very likely not IL-36 itself. Indeed, unlike what has been reported in psoriasis 18, we could 444 
not observe any IL-36 induction by IL-36 itself in AGEP patients’ keratinocytes as evidenced 445 
by the lack of effect of IL-36Ra. Like in other inflammatory diseases such as psoriasis 36, 446 
contact hypersensitivity 37 or sunburn 38, keratinocytes may actively participate in the 447 
pathogenesis of AGEP by secreting IL-36α and IL-36γ, which could contribute to the herein 448 
observed and previously reported induction of IL-8 gene expression by macrophages. The 449 
latter likely contributes to the observed neutrophil recruitment to the epidermis in AGEP.  As 450 
previously reported in AGEP, IL-8 may also originate from drug-specific T cells 6. Indeed, 451 
AGEP is currently seen a delayed type hypersensitivity reaction with T cell involvement. 452 
However, the mechanisms leading to drug-specific T cell priming and recruitment to the skin 453 
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in AGEP have not been elucidated to date. Unlike murine T cells, human T cells do not express 454 
IL-36R 39. In AGEP, IL-36 may nevertheless contribute to T cell-mediated immune responses 455 
through its strong stimulatory effects on antigen-presenting cells 40. Our findings that IL-36 can 456 
be induced by a drug very early in innate immune cells do not exclude a delayed drug-specific 457 
T cell response but whether the induction of IL-36 in monocytes by culprit drugs and the 458 
activation of drug-specific T cells are dependent events in AGEP pathogenesis or not remains 459 
to be investigated. 460 
Th17 cells may also be involved in AGEP as revealed by their previously reported increased 461 
frequencies and elevated IL-22 blood levels in AGEP patients 8. IL-17 is known to increase IL-462 
8 secretion by keratinocytes41 in allergic contact dermatitis 42 and in psoriasis 43. Our in vitro 463 
data revealed however that in response to IL-36, the major source of IL-8 was patients’ 464 
monocytes consistently with the previously reported elevated expression of IL-36R and 465 
potential strong responsiveness to IL-36 by dermal myeloid cells 19. Although keratinocytes 466 
also express high levels of IL-36R 19, IL-8 production by keratinocytes was marginal as 467 
confirmed by qPCR in co-culture experiments and immunohistochemistry where IL-8 was only 468 
detected in the peri-pustular immune infiltrate (Fig. E3 in the Online Repository). 469 
Although mutations in the IL-36RN gene have been identified in AGEP patients, no other 470 
marker(s) of genetic predisposition have been formally identified for AGEP to date. 471 
Noteworthy, our data shows that a deregulation of the IL-36-IL-8 axis can occur independently 472 
of IL-36RN mutations in AGEP, suggesting that other factors influencing the susceptibility to 473 
an IL-36-mediated proinflammatory response to culprit drugs are at play in AGEP patients.  474 
Overall, we provide evidence that IL-36 is involved in AGEP pathogenesis, and identify 475 
monocytes and keratinocytes as potential key producers of IL-36 in AGEP. Given that 476 
monocytes/PBMC of all AGEP patients tested have an enhanced propensity to produce IL-36 477 
upon culprit drug exposure, the identification of predictive genetic markers that would help 478 
identify patients prone to pathological IL-36 production upon exposure to certain medications 479 
may be achievable. 480 
 481 
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Figure legends 603 
 604 
FIG 1. IL-36 and IL-8 gene overexpression in AGEP lesional skin. 605 
Gene expression hierarchical clustering in lesional skin biopsies from patients suffering from 606 
AGEP and MPR analyzed using (A) Affymetrix Human Exon 1.0 ST chips or (B) RNAseq 607 
technology. (C) Quantitative RT-PCR analysis of IL-36α, IL-36β, IL-36γ, IL-36R, IL-36RN and 608 
IL-8 in lesional skin biopsies of patients suffering from AGEP (n=16), MPR (n=16) and normal 609 
skin (NS; n=5).  **** p<0.0001. The patient cohorts studied in (A), (B) and (C) were independent 610 
and all recruited in the Dermatology Department of the University Hospital of Zürich (patients 611 
no. 1-19).  612 
 613 
FIG 2. IL-36α and IL-36γ are overexpressed in pustular regions of AGEP lesional skin biopsies.  614 
(A) Immunohistochemical analysis of lesional skin biopsies revealed that IL-36α and IL-36γ are 615 
overexpressed at the site of pustules in AGEP and PP controls while, in MPR, IL-36α and IL-616 
36γ were weakly expressed. Representative pictures of 18 AGEP, 10 PP and 18 MPR cases 617 
are shown. Neither IL-36α, nor IL-36γ were detectable in normal skin (NS) from healthy donors. 618 
(B) Semi-quantitative evaluation of IL-36α and IL-36γ labeling by immunohistochemistry in the 619 
pustular epidermis, non-pustular epidermis, and dermis of lesional skin biopsies from patients 620 
with AGEP (n=18; patients no. 5, 6, 8, 10, 11, 13-17, and 21-28), PP (n=10), MPR (n=18) and 621 
normal skin (NS) from healthy donors (n=5). Expression levels were qualified as very strong 622 
(++++), strong (+++), moderate (++), weak (+) or absent (0). *p<0.05; **p<0.01; *** p<0.001; 623 
**** p<0.0001. 624 
 625 
FIG 3. IL-36γ is expressed by keratinocytes and immune cells in AGEP skin. 626 
Pustule-containing sections of AGEP skin samples were co-labeled with antibodies to CD68 627 
(green), CD3 (green) and IL-36α (red) (A) or IL-36γ (red) (B). The percentage of epidermal 628 
cells (keratinocytes), CD68 and CD3-labeled cells among the IL-36α or IL-36γ-labeled cells 629 
was determined (C). Cell nuclei appear in blue (DAPI). The mean±SD of 12 examined patients 630 
is shown (patients no. 8-10 and 20-28).  631 
 632 
FIG 4. PBMC and monocytes taken from AGEP patients more than 6 months after the ADR 633 
selectively secrete IL-36γ in response to culprit drug exposure. (A) PBMC from AGEP or MPR 634 
patients as well as healthy donors were cultured in IL-36γ ELISPOT plates for 8 hrs in presence 635 
of the culprit drug (left panel) or a control drug (right panel). The number of spots was counted 636 
1, 2, 4, 6 and 8 hrs after drug exposure. The means±SD of 3 different AGEP patients (no. 8, 637 
22 
 
10 and 21), 3 MPR patients and 3 healthy blood donors are shown. ***p<0.001. (B) CD14+ 638 
monocytes and CD3+ T cells were isolated from AGEP blood with a purity of >96% and were 639 
cultured in IL-36γ ELISPOT plates in presence of the culprit drug or a control drug and 640 
compared to total PBMC. The number of spots was counted 8 hrs after drug exposure. The 641 
mean±SD of 3 different patients (patient no. 8, 9 and 10) is shown. *p<0.05. 642 
 643 
FIG 5. Culprit drugs specifically induce IL-36 in PBMC and keratinocytes and IL-8 in PBMC in 644 
a co-culture system. Autologous PBMC and keratinocytes (KC) from patients having 645 
experienced AGEP but in remission at the time of blood and hair collection were cultured either 646 
alone or together in a transwell system allowing for soluble factor-mediated interactions. 647 
Patients’ cells were exposed to the culprit drug (Amoxicillin 1mg/ml, patient 8; Letrozole 648 
100nM, patient 9; Vancomycin 500µg/ml, patient 20) or a control drug (Metamizole 100µg/ml, 649 
patient 8; Carbamazepine 10µg/ml, patient 9; Amoxicillin 1mg/ml, patient 20) in presence or 650 
absence of IL-36RA (1µg/ml). After 6 hrs of culture, RNA was extracted from KC (left panels) 651 
and PBMC (right panels) to measure IL-36γ mRNA levels (A). Relative IL-36γ expression in 652 
KC and PBMC cultured either alone or in co-culture as indicated and exposed to the culprit 653 
drug or a control drug in presence or absence of IL-36Ra are shown for each tested patient. 654 
Means±SD of 3 replicates are shown. (B) Quantitative PCR analysis of IL-8 gene expression 655 
in PBMC (upper panels) and KC (lower panels) cultured either alone or in co-culture as 656 
indicated and exposed to the culprit drug or a control drug in the presence or absence of IL-657 
36Ra. Gene expression reported as 2-ΔCT, which represents the target gene expression relative 658 
to the reference gene (RPL27). Mean±SD of the 3 tested patients is shown. The figure 659 
illustrates a representative experiment that was repeated 3 times for each patient. *p<0.05; 660 
**p<0.01; ***p<0.001. 661 
 662 
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tumour hypoxia promotes 
melanoma growth and metastasis 
via High Mobility Group Box-1 and 
M2-like macrophages
Roman Huber1,*, Barbara Meier1,*, Atsushi Otsuka1,*, Gabriele Fenini1, Takashi satoh1, 
samuel Gehrke1, Daniel Widmer1, Mitchell P. Levesque1, Joanna Mangana1, Katrin Kerl1, 
Christoffer Gebhardt2,3, Hiroko Fujii4, Chisa Nakashima4, Yumi Nonomura4, Kenji Kabashima4, 
Reinhard Dummer1, emmanuel Contassot1,# & Lars E. French1,#
Hypoxia is a hallmark of cancer that is strongly associated with invasion, metastasis, resistance to 
therapy and poor clinical outcome. Tumour hypoxia affects immune responses and promotes the 
accumulation of macrophages in the tumour microenvironment. However, the signals linking tumour 
hypoxia to tumour-associated macrophage recruitment and tumour promotion are incompletely 
understood. Here we show that the damage-associated molecular pattern High-Mobility Group Box 
1 protein (HMGB1) is released by melanoma tumour cells as a consequence of hypoxia and promotes 
M2-like tumour-associated macrophage accumulation and an IL-10 rich milieu within the tumour. 
Furthermore, we demonstrate that HMGB1 drives IL-10 production in M2-like macrophages by 
selectively signalling through the Receptor for Advanced Glycation End products (RAGE). Finally, we 
show that HMGB1 has an important role in murine B16 melanoma growth and metastasis, whereas in 
humans its serum concentration is significantly increased in metastatic melanoma. Collectively, our 
findings identify a mechanism by which hypoxia affects tumour growth and metastasis in melanoma 
and depict HMGB1 as a potential therapeutic target.
Hypoxia is a hallmark of a wide range of advanced solid tumours1 and is often associated with poor prognosis 
in cancer patients2. Up to 60% of advanced solid tumours exhibit large hypoxic areas as a result of an imbal-
ance between their oxygen supply and consumption3. A hypoxic environment, as frequently observed in solid 
tumours, results in focal areas of tumour cell necrosis and the release of damage associated molecular patterns 
(DAMPs) and alarmins, a group of endogenous molecules including hyaluronan fragments, S100 molecules and 
heat shock proteins, amyloid-β , uric acid, IL-1, IL-33 and high-mobility group box 1 protein (HMGB1)4.
The non-histone nuclear protein HMGB1, a highly conserved DNA-binding protein with 98.5% sequence 
homology across mammals5,6, can be actively secreted by immune cells including macrophages or passively 
released upon cell damage. HMGB1 has been shown to engage several different receptors including members 
of the Toll-like receptor (TLR) family7 and the Receptor for Advanced Glycation End products (RAGE), thereby 
inducing an inflammatory response8,9. HMGB1 has been reported to be overexpressed in various solid tumours, 
shown to be released by mesothelial cells exposed to asbestos and erionite and implicated in malignant mesothe-
lioma development in an autocrine manner10–12. HMGB1 has also been implicated in the development of hepato-
cellular carcinoma13 and both colon and inflammation-related skin cancers14,15.
Tumour hypoxia has a major impact on the tumour microenvironment and the subsequent immune response. 
Areas of hypoxia in tumours have been reported to be associated with advanced stage malignancy and resist-
ance to therapy16. Paradoxically, tumour hypoxia promotes the recruitment of leukocytes, which can promote 
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tumour cell proliferation, angiogenesis and metastasis17,18. Among the diverse immune cell populations present 
in the tumour microenvironment, macrophages are the most abundant19 and are referred as Tumour-Associated 
Macrophages (TAMs). Macrophages differentiate or polarize in response to inflammatory stimuli and secrete 
a distinctive set of cytokines and amongst the different types of polarized macrophages described to date, the 
so-called M1-like or M2-like macrophages appear to have opposing effects on tumour progression20. M1-like 
macrophages are associated with type 1 T-cell responses and anti-tumour immune responses, while M2-like mac-
rophages are reported to display tumour-promoting properties including the production of proteolytic enzymes, 
the suppression of anti-tumour immune responses and the promotion of angiogenesis21. Finally, in advanced 
tumours, TAMs have been reported to be preferentially skewed towards an M2-like phenotype22–24.
Given the strong association between tumour hypoxia, tumour progression and poor clinical outcome, deci-
phering the precise molecular mechanisms by which hypoxia regulates tumour behaviour is of great interest and 
relevance. Here, we show that hypoxic melanoma cells release the alarmin HMGB1, which promotes tumour 
growth and metastasis through the accumulation, within tumours, of TAMS bearing an M2-like phenotype.
Results
Serum HMGB1 levels are elevated in metastatic melanoma patients. We first determined whether 
levels of HMBG1 are altered in cancer patients. To this end, we analysed HMGB1 levels in the serum of patients 
with primary melanoma, metastatic melanoma and in age-matched healthy volunteers. Significantly, increased 
levels of HMGB1 were found in the serum of patients with metastatic melanoma when compared to patients with 
primary melanoma and to healthy donors (Fig. 1a). This observation suggests that the extent of HMGB1 release 
correlates with the stage of the disease.
Tumour cell hypoxia drives HMGB1 release in vitro and in vivo. Hypoxia in the context of liver 
ischemia and hepatocellular carcinoma has been previously reported to induce HMGB1 release13,25. To determine 
if metastatic melanoma cells release HMGB1 in response to hypoxia, we analysed metastatic melanoma cell-lines 
grown in hypoxic versus normoxic conditions in vitro. When compared to their counterparts grown in normoxic 
conditions, all tested melanoma cell-lines (n = 7) released enhanced levels of HMGB1 when grown in hypoxic 
conditions in which increased expression of the hypoxia target gene VEGF-A was also observed26 (Fig. 1b,c). 
Notably, under the hypoxic conditions tested no increase in cell mortality was observed as revealed by the con-
sistently low levels of LDH release. The induction of HMGB1 expression by hypoxia in melanoma cells in culture 
was only significantly induced after 72 hours of hypoxia, but not at shorter exposure times to hypoxia.
Under physiologic conditions, HMGB1 is known to be sequestered in the nucleus, whereas cytoplasmic relo-
calization of HMGB1 has been reported to occur prior to active secretion or passive HMGB1 release11. First, we 
observed that melanoma metastasis cell lines expressed both cytosolic and nuclear HIF1α when cultured under 
low oxygen conditions, whereas HIF1α was not detectable when cells were kept in normoxic conditions. The 
co-labelling with an anti-HMGB1 antibody revealed that HMGB1 is located in the cytosol of HIF1α -positive 
cells in hypoxic conditions whereas HMGB1 was confined to the nucleus of cells kept in normoxic conditions 
(Fig. S1). When the intracellular localization of HMGB1 was assessed in tissue sections of nevi, primary mela-
noma (superficial spreading melanoma) and melanoma metastases, nuclear HMGB1 staining was observed in 
nevi and primary melanomas, whereas in melanoma metastases large areas of the tumour were composed of 
cells with cytoplasmic HMGB1 staining (Fig. 2a). Interestingly, the latter areas were also Hif1α -positive indi-
cating that HMGB1 is released within hypoxic areas of metastatic melanomas (Fig. 2a). Co-labelling with an 
anti-melanosome antibody (clone HMB-45) showed that, in metastasis, HMGB1 is released by HMB-45+ mel-
anoma cells in contrast to primary tumours where HMGB1 was exclusively found in the nucleus of HMB-45+ 
melanoma cells (Fig. 2b). These observations indicate that HMGB1 is released by hypoxic tumour cells within 
metastases in melanoma patients.
HMGB1 release is partly dependent on HIF1α in cells in hypoxic condition. To assess whether 
HMGB1 release under hypoxic culture condition was dependent on HIF1α or not, we knocked HIF1α down 
using siRNA in two human melanoma cell lines. After seventy-two hours under low oxygen conditions, increased 
levels of stabilized HIF1α were detected in both cell lines, either unmodified or transfected with a control siRNA 
(and Fig. 3a). In contrast, little or no expression of HIF1α was detected in both cell lines transfected with 2 inde-
pendent HIF1α sequences (Fig. 3a). Interestingly, a reduced HMGB1 secretion under hypoxia was observed in 
both cell lines transfected with both HIF1α -siRNA as measure by ELISA (Fig. 3b,c). Under the hypoxic condi-
tions tested, no increase in cell mortality was observed as revealed by the consistently low levels of LDH release 
and VEGFA was always found to be upregulated (Fig. 3b). Notably, HMGB1 secretion decrease was of only 50%, 
suggesting that mechanisms, other than HIF1α , are involved (Fig. 3b,c). By inhibiting oxygen-sensitive prolyl 
hydroxylases (PHDs) with DMOG, we observed that the resulting increased stabilization of HIF1α (Fig. 3d) was 
associated with a higher HMGB1 release in melanoma cell lines (Fig. 3e). DMOG exposure of siRNA-transfected 
melanoma cells did not result in significant increase of HMGB1 release (Fig. 3e), therefore reinforcing the role of 
the hypoxia/HIF1α axis in HMGB1 secretion.
HMGB1 promotes melanoma growth and metastasis. To assess whether HMGB1 plays a functional 
role in melanoma progression, we diminished HMGB1 expression in B16 melanoma cells using shRNA technol-
ogy. Four HMGB1-specific shRNA sequences and 2 lamin-specific shRNA sequences were transduced into B16 
cells. B16 cells showing the highest downregulation of HMGB1 expression (shRNA sequence 5, Fig. S2a, top panel) 
were subsequently cloned by limiting dilution and expanded under selection pressure (puromycin). B16 cells 
transduced with shRNA to lamin showing no variation in HMGB1 expression when compared to wild-type B16 
cells (shRNA sequence 2 to lamin, Fig. S2a, top panel) were chosen as controls and were also cloned by limiting 
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dilution and expanded under selection pressure. The silencing of HMGB1 was highly stable during in vitro expan-
sion (Fig. S2b) and after 13 days of in vivo growth (Fig. S2c). The B16 clones transduced with HMGB1-specific 
Figure 1. HMGB1 is increased in the serum of patients with metastatic melanoma and released by 
melanoma cells under hypoxic conditions. (a) HMGB1 was measured by ELISA in the serum of healthy 
individuals (n = 10), and patients with primary (n = 9) or metastatic melanoma (n = 11). Data are expressed as 
the mean + /− SEM are presented. * * * P < 0.001 using ANOVA followed by Turkey test. (b) Cell-lines derived 
from human melanoma metastases were cultured under normoxic or hypoxic conditions for 72 h. As a marker 
of hypoxia, VEGF-A expression was assessed by qPCR (top panels). Cell viability was assessed in cell culture 
supernatants with an LDH release assay (middle panels) and HMGB1 release measured by ELISA (bottom 
panels). (c) Statistical representation and analysis of the data presented in (b). Data expressed as the mean  
+/− SEM are presented. A paired Student t-test was performed. * P < 0.05, * * P < 0.01.
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Figure 2. HMGB1 is released by tumour cells in hypoxic tumour areas of human metastatic melanoma. 
(a) Immunofluorescence labelling, using antibodies to HIF1α (red) and HMGB1 (green), was performed on 
healthy skin, nevi, primary cutaneous melanoma and metastases as indicated (n = 5/group; representative 
pictures are presented). (b) Immunofluorescence labelling using antibodies to human melanosome (clone 
HMB-45, red) and HMGB1 (green) was performed on healthy skin, nevi, primary cutaneous melanoma and 
metastases as indicated (n = 5/group; representative pictures are presented).
www.nature.com/scientificreports/
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Figure 3. HMGB1 release is dependent on HIF1α. (a) HIF1α expression was assess by Western blotting in 
two human metastatic melanoma cell lines (MM130421 and MM000921) transfected with 2 sequences of siRNA 
to HIF1α and incubated for 72 hrs in normoxic or hypoxic conditions. (b) MM130421 and MM000921 were 
cultured under normoxic or hypoxic conditions for 72 hrs. As an hypoxia target gene, VEGF-A expression was 
assessed by qPCR (bottom panels). Cell viability was assessed in cell culture supernatants with an LDH release 
assay (middle panels) and HMGB1 release measured by ELISA (top panel). (c) HMGB1 release summary and 
statistical analysis of the data presented for individual cell lines in (b). Data expressed as the mean + /− SEM 
are presented. A paired Student t-test was performed. * * * * P < 0.0001. (d) HIF1α expression was assessed by 
Western blotting in two human metastatic melanoma cell lines (MM130421 and MM131112) transfected with 2 
sequences of siRNA to HIF1α and exposed to DMOG or incubated for 72 hrs in normoxic (Nor, N) or hypoxic 
conditions (Hyp, H). (e) HMGB1 release was measured by ELISA (top panels). Cell viability was assessed in cell 
culture supernatants with an LDH release assay (middle panels) and VEGF-A expression was assessed by qPCR 
(bottom panels).
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shRNA exhibiting the highest HMGB1 knockdown (Fig. S2a, bottom panel) and the clones transduced with 
lamin-shRNA showing similar HMGB1 expression when compared to wild-type B16 were then injected s.c. 
in C57BL/6 mice. Following sub-cutaneous injection, mice implanted with HMGB1-shRNA-transduced B16 
clones exhibited significantly reduced tumour growth when compared to mice implanted with the same num-
ber of lamin-shRNA-transduced B16 clones (Fig. 4a). Importantly, the transduction of lamin-shRNA did not 
alter the in vivo growth kinetics of B16 tumours when compared to wild-type B16 cells (Fig. S3). Since such 
a reduced growth was reproducibly obtained irrespective of the shRNA sequence and clonal selection of B16 
cells, all experiments described below were performed with one B16 clone transduced with HMGB1-specific 
shRNA and one B16 clone transduced with lamin-specific shRNA (HMGB1 clone 17 (sequence 5) 
and lamin clone 1 (sequence 2), respectively). This growth delay was neither due to an intrinsic effect of shRNA 
transduction or HMGB1 knockdown on growth or apoptosis as revealed by the identical in vitro growth and 
apoptosis of HMGB1- and lamin-shRNA-transduced B16 cells (Fig. S4). To further validate the above observation 
and assess the contribution of released extracellular HMGB1 on tumour growth, we next treated mice implanted 
subcutaneously with lamin-shRNA-transduced B16 cells with either a recombinant HMGB1 inhibitor (BoxA, 
50 µ g i.p. every 3 days) or vehicle (PBS) in an independent set of in vivo experiments. In accordance with results 
observed with HMGB1 silencing using shRNA, systemic treatment of tumour-bearing mice with the HMGB1 
inhibitor BoxA also resulted in significantly delayed tumour growth compared to mice exposed to vehicle alone 
(Fig. 4b).
Figure 4. HMGB1 promotes tumour growth and metastasis, and is released by hypoxic tumour cells in vivo. 
(a) Tumour growth in C57BL/6 mice subcutaneously injected with 1 × 105 B16 clones transduced with shRNAs 
specific to HMGB1 or lamin and (b) tumour growth in C57BL/6 mice subcutaneously injected with 1 × 105 B16 
cells transduced with lamin-shRNA (cl1s2: clone 1, shRNA sequence 2) and treated i.p. every 3 days from day 0 
with 50 µ g a recombinant HMGB1 inhibitor (BoxA). (c) 1 × 105 B16 cells transduced with HMGB1- or lamin-
shRNA were injected i.v. to C57BL/6 mice and lung metastases were counted after 13 days. A macroscopic view 
of 5 representative lungs from each group and the numeration of metastases in the lungs (n = 9) are shown. 
Results are expressed as the mean + /− SEM. * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001.
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We next evaluated the role of HMGB1 in metastasis by injecting either HMGB1-shRNA-transduced 
B16 cells or lamin-shRNA-transduced B16 cells i.v. into wild type mice. After 13 days, mice injected with 
HMGB1-shRNA-transduced B16 cells also exhibited significantly less lung metastases when compared to mice 
injected with lamin-shRNA-transduced control cells (Fig. 4c).
To determine whether HMGB1 release in this mouse model of melanoma was reminiscent of what was 
observed in human melanoma metastases, we assessed the intra-cellular localization of HMGB1 in tumours of 
mice implanted s.c. with lamin-shRNA-transduced B16 cells. Large areas where HIF was stabilized were found 
mainly in the centre of B16 tumours, as revealed by immunocytochemistry using a HIF1α antibody (Fig. 5a). 
Within HIF1α -positive tumour areas, large numbers of tumour cells displaying cytoplasmic HMGB1 expression 
were observed and double-labelling experiments identified numerous cells co-expressing HMGB1 and HIF1α 
(Fig. 5b). In contrast, nuclear HMGB1 localisation was predominantly observed in HIF-1α -negative areas of the 
tumour, and no evident co-labelling of anti-HMGB1 and HIF1α antibodies was observed in such areas. These 
observations are in line with data from human melanomas. Altogether, these results suggest that HMGB1 released 
by hypoxic tumour cells promotes melanoma growth and metastasis.
HMGB1 promotes the accumulation of tumour-associated M2-like macrophages. To further 
investigate the tumour-promoting effects of HMGB1 release, as a consequence of tumour hypoxia and given the 
absence of evidence for a direct effect of HMGB1 on tumour cell growth or apoptosis in vitro, we analysed the 
immune cell infiltrate within the tumour microenvironment. Analysis of dissociated tumours by flow-cytometry 
revealed a significant increase in the total number of TAMs and a slight but significant decrease in the total 
number of neutrophils in HMGB1-shRNA-transduced B16 tumours (Fig. 6a). To assess the phenotype of these 
TAMs, we analysed the in vivo expression of markers discriminating M1-like and M2-like macrophage subpopu-
lations27. Quantitative PCR of macrophages accumulating at the tumour site revealed that the downregulation of 
HMGB1 in B16 cells was associated with a significant induction of the expression of the M1 macrophage marker 
CD8028, whereas lamin-shRNA-transduced B16 tumours were associated with a significant upregulation of the 
Figure 5. HMGB1 is released in hypoxic regions of B16 tumours. (a) Immunohistochemistry using a  
HIF1α − specific antibody was performed on 200 mm3 tumours and revealed large HIF1α + hypoxic areas in 
the center (C) and HIF1α − normoxic areas in the periphery (P). Representative pictures of 10 tumours are 
presented. (b) Immunofluorescence analysis of B16 tumours transduced with lamin-shRNA using antibodies 
to HIF1α (red) and HMGB1 (green) showed nuclear HMGB1 localization in normoxic (HIF1α −) areas and 
cytoplasmic HMGB1 localization in hypoxic (HIF1α +) areas. Representative pictures of 10 tumours are 
presented.
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M2 markers YM1, Fizz1, and IL-10 (Fig. 6b). These results suggest that HMGB1 expression and release within 
tumours favours the accumulation of M2-like macrophages in the microenvironment.
HMGB1 induces IL-10 in M2-like macrophages through RAGE. Given the reported role of the 
cytokine milieu of the tumour microenvironment on tumour progression29,30, we evaluated the effect of HMGB1 
on TAM cytokine expression. While HMGB1 had no effect on IL-6, TNF or IL-1β expression, it significantly 
increased IL-10 expression in bone marrow-derived M2-like macrophages (BMM2, Fig. 7a). Furthermore, 
HMGB1-induced upregulation of IL-10 expression was not observed in BMM2 from RAGE−/− mice while it was 
retained in TLR2- and TLR4-deficient BMM2 (Fig. 7b), suggesting that HMGB1 induces IL-10 in TAMs through 
RAGE-dependent signalling. To assess the effect of IL-10 on tumour development in the model used herein, mice 
implanted with lamin-shRNA transduced B16 tumours were treated with an anti-IL-10 neutralizing antibody. 
Similar to mice in which tumour expression of HMGB1 was silenced or inhibited with recombinant BoxA, mice 
treated with anti-IL-10 exhibited significantly delayed tumour growth compared to controls, whereas anti-IL-10 
did not significantly affect the growth of HMGB1-shRNA-transduced B16 tumours (Fig. 7c). Collectively, these 
results indicate that HMGB1-dependent production of IL-10 by tumour-associated M2-like macrophages con-
tributes to tumour progression in our mouse melanoma model. In further support for a potential role of TAMs 
and IL-10 in melanoma is the presence of IL-10-producing TAMs in human melanoma metastases as revealed 
by the presence of CD163+ IL-10+ cells infiltrating human metastases in areas with high cytoplasmic HMGB1 
expression (Fig. 7d). In contrast, lower expression and nuclear localisation of HMGB1 in nevi was associated with 
a very discrete presence of CD163+ cells and an absence of IL-10 production. Taken together, these results are 
supportive of a tumour-promoting role for HMGB1 dependent on its ability to induce IL-10 secretion by M2-like 
macrophages in a RAGE-dependent manner.
Discussion
Tumour-associated macrophages (TAMs) have emerged as key components of the tumour microenvironment 
with a crucial role in tumour progression31. TAMs are reported to be associated with poor prognosis in several 
types of cancer32–35, and it has been proposed that monocytes, which continuously infiltrate tumours, once polar-
ized to M2-like macrophages preferentially accumulate in hypoxic tumour areas36–40. By promoting angiogenesis 
Figure 6. Tumour-derived HMGB1 induces the accumulation of macrophages harbouring an M2-like 
phenotype. (a) Macrophage and neutrophil infiltrates were quantified in 200 mm3 tumours. Representative 
flow cytometry pictures (left panels) and quantification (right panels) of total macrophages and neutrophils 
in tumours of mice implanted with B16 cells transduced with lamin- (n = 6) or HMGB1-shRNA (n = 6). 
(b) Quantification of M1- and M2-specific gene expression by qPCR in size-matched (200 mm3) primary 
tumours from mice implanted with B16 cells transduced with HMGB1- (shHMGB1, n = 5) or lamin-shRNA 
(shLamin, n = 5). Results are presented as the mean + /− SEM. * P < 0.05, * * P < 0.01.
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and metastasis, M2-polarized TAMs can “assist” the tumour in overcoming a hostile hypoxic environment and 
thus sustain its progression24,41. Therapeutic targeting of this process in cancer is currently limited by an inade-
quate understanding of factors released by hypoxic cells that may be associated with M2-like macrophage accu-
mulation in the tumour microenvironment. Here, we show that the alarmin HMGB1, which is released from 
Figure 7. HMGB1 and RAGE-dependent IL-10 production by TAMs favour melanoma growth. (a) IL-6, 
TNF, IL-10 and IL-1β mRNA expression, relative to housekeeper RPL27, in in vitro-generated murine M2-like 
macrophages in the presence or absence of recombinant HMGB1. (b) IL-10 mRNA expression in in vitro-
differentiated M2-like macrophages from wild-type (WT), Tlr2−/−, Tlr4−/− and Rage−/− mice stimulated with 
recombinant HMGB1. Expression is relative to untreated WT M2-like macrophages. (c) Tumour growth 
in C57BL/6 mice having received 1 × 105 B16 cells transduced with either HMGB1- or lamin-shRNA and 
treated with an anti-IL-10 blocking antibody or a control isotype (n = 7 mice/group). (d) Immunofluorescence 
analysis of human biopsies of nevi and melanoma metastases using anti-CD163, anti-HMGB1 and anti-IL-10 
antibodies (n = 5/group) revealing IL-10 secretion by TAMs in regions with cytoplasmic (secreted) HMGB1. 
Representative pictures are shown.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:29914 | DOI: 10.1038/srep29914
tumour cells under hypoxic conditions, plays a critical role in promoting tumour progression by triggering the 
accumulation of M2-like TAMs. We demonstrate that HMGB1 released by hypoxic tumour cells favours the accu-
mulation of M2-like macrophages at the tumour site and their secretion of IL-10. The relevance of the in vitro and 
in vivo data generated in this mouse model of melanoma is substantiated by the observation that HMGB1 release 
also occurs in human melanoma cell-lines under hypoxic conditions in vitro, particularly in Hif-1α -positive areas 
within human melanoma metastases and by the fact that melanoma metastases but not benign melanocytic nevi 
are infiltrated by CD163+ IL-10+ TAMs.
Areas of hypoxia in tumours have been reported to be associated with advanced stage malignancy and resist-
ance to therapy16. Whether hypoxia and its by-products directly induce an M2-like phenotype in TAMs remains 
unclear. Our data suggest that, although HMGB1 clearly contributes to the accumulation of M2-like macrophages 
within tumours, it does not appear to be directly involved in M2 polarization. Indeed, and in line with a previous 
report showing that hypoxia is not a driver of the differentiation of TAMs37, we were not able to differentiate 
macrophages towards an M2-like phenotype in vitro using recombinant HMGB1 alone. However, a recent study 
showed that lactic acid, produced by tumour cells as a by-product of hypoxic glycolysis, has a critical function in 
tumour development by inducing VEGF expression and M2-like polarization of TAMs in a HIF1α -dependent 
manner42. Furthermore, oncostatin M and eotaxin have been suggested to promote breast cancer metastasis by 
favouring M2 polarization and tumour infiltration43. Recent evidence also suggests that HMGB1 may directly act 
on progenitor cells to favour the induction of myeloid-derived suppressive cells44.
Mechanistically, hypoxia-induced HMGB1 release seems to be associated with several tumour-promoting 
events. In advanced hepatocarcinomas, hypoxia has also been shown to be associated with the release of 
HMGB145, and it has been suggested that HMGB1, via RAGE, induces the expression of NF-κ B-dependent 
pro-angiogenic factors including VEGF46 and the matrix metalloproteinases MMP2 and MMP947. It has 
also been observed that HMGB1 released from dying cells in prostate cancer induces the accumulation of 
tumour-infiltrating T cells and the expression of lymphotoxin-α 1β 2 on their surface, which in turn recruits mac-
rophages to the tumour and supports angiogenesis48. Noteworthy, tumour cells or tumour-infiltrating immune 
cells seem not to be the sole source of HMGB1. Indeed, UVB radiation of the skin has been shown to induce 
HMGB1 release from epidermal keratinocytes, resulting in a neutrophilic inflammatory response that stimulate 
angiogenesis and promotes melanoma metastasis in mice49.
We also observed that HMGB1 directly induced the production of IL-10 in TAMs and that blockade of IL-10 
with a neutralizing antibody led to delayed tumour growth in the B16 mouse melanoma model. As we cannot, at 
present, technically and specifically delete IL-10 in TAMs, the relative role of HMGB1-induced IL-10 in TAMs 
remains incompletely elucidated in our model. It is known that regulatory T cell-mediated/IL-10-dependent sup-
pression of CD8+ T cells can be blocked by removal of tumour-derived HMGB150, which is consistent with our 
observation that HMGB1 inhibition leads to delayed tumour growth although via an alternate mechanism. It is 
likely that IL-10, which can also be produced by melanoma cells51 and tumour-associated myeloid-derived sup-
pressor cells44 may favour immunoregulatory responses by inducing the downregulation of molecules involved in 
antigen presentation to CD8+ T cells52, by inducing regulatory T cells53,54 and/or by supressing the production of 
pro-inflammatory cytokines including TNFα , IFN-γ and IL-2 by T cells55. In accordance with this, elevated IL-10 
production levels in melanoma patients are associated with poor prognosis56.
HMGB1 can signal by binding to TLR2, -4 and -9 as well as RAGE. According to our data, TLR signalling 
was not required for HMGB1-dependent induction of IL-10, the latter being selectively dependent on RAGE 
signalling. The potential importance of the HMGB1-RAGE interaction in promoting tumour progression is sup-
ported by a recent report showing that RAGE and HMGB1 are associated with the progression of prostate cancer 
and poor patient outcome57. However, since our data shows that HMGB1 downregulation or the use of a soluble 
inhibitor did not lead to complete inhibition of tumour growth, it is very likely that signalling by other alarmins 
through TLRs or RAGE also have the ability to induce a tumour-promoting microenvironment58. In addition, 
we do not exclude an incomplete inhibition of the effect of HMGB1 in our model or other HMGB1-independent 
mechanisms of tumourigenesis.
In conclusion, we demonstrate that HMGB1, derived from hypoxic tumour cells, significantly contrib-
utes to melanoma progression by favouring the accumulation of IL-10-secreting TAMs within the tumour. 
Tumour-derived HMGB1 released as a consequence of focal intra-tumoural hypoxia thus directly contributes 
to tumour progression and likely represents an attractive therapeutic target for tumour therapy as demonstrated 
here in the case of melanoma.
Methods
Biological samples from melanoma patients and healthy donors. Serum and tumour biopsies were 
collected from patients with primary melanoma or metastatic melanoma (stage IIIB to IV) in the Department of 
Dermatology of the University Hospital of Zürich. Characteristics of patients with primary and metastatic mel-
anoma are reported in Tables 1 and 2, respectively. Serum was obtained from healthy blood donors and healthy 
skin was obtained as excess skin resulting from aesthetic/reconstructive procedures in the plastic surgery unit at 
the University Hospital of Zürich. All human biological samples were collected after written informed consent of 
the patient and with approval of Local Ethics Committee (Kantonale Ethikkommission Zürich, KEK-ZH author-
ization Nr. 2014-0425) in accordance to GCP guidelines and the Declaration of Helsinki.
Mice. Six to 8-week-old female C57BL/6 mice (Harlan, Venray, Netherlands) were used in this study. 
TLR2−/− C57BL/6 mice were kindly provided by Prof. Marc Donath (Department of Biomedicine, University 
Hospital Basel, Switzerland), TLR4−/− C57BL/6 mice were kindly provided by Prof. Markus G. Manz (Division 
of Haematology, University Hospital Zürich, Switzerland) and RAGE−/− C57BL/6 mice were kindly provided 
by Prof. Peter P. Nawroth (Department of Internal Medicine and Clinical Chemistry, University of Heidelberg, 
www.nature.com/scientificreports/
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Germany). All experimental procedures were approved by the Veterinary Office of Zürich and the institutional 
animal care officer and were carried out in accordance to the approved guidelines.
Generation of HMGB1-shRNA-transduced B16. B16-F10 mouse melanoma cell-lines stably express-
ing shRNA specific to Lamin or HMGB1 were generated by transducing B16-F10 cells with a lentiviral vector. 
Briefly, specific shRNA were generated by inserting oligonucleotides targeting Lamin or HMGB1 into the pSU-
PER vector (Oligoengine, Seattle, WA) and subsequent cloning into the lentiviral vector pSP-93 (Oligoengine). 
Second-generation packaging plasmids pMD2-VSVG and psPAX2 (kindly provided by Prof. J. Tschopp, 
Biochemistry Institute, Lausanne, Switzerland) were used for lentivirus production and infection. For each tar-
get molecule, the procedure was performed with different shRNA sequences. ShRNA-transduced B16 cells were 
subsequently cloned by limiting dilution under selection pressure (puromycin). For each shRNA, one clone was 
chosen according to knock-down efficiency and stability as well as in vitro properties (Figs S1 and S3).
Generation of HIF1α-siRNA-transduced human melanoma cell lines. siRNA transfection of metastatic 
melanoma cells was carried out using INTERFERin transfection solution according to the manufacturer’s pro-
tocol (Polyplus Transfection, Illkirch, France). Cells were transfected with 10 nM of siRNA to Hif1α two hours 
before hypoxia treatment for 72 hours before supernatant was harvested and RNA or protein was extracted. 
All-Star negative siRNA sequence (Qiagen) was used as control siRNA. The following siRNAs were used:
siHIF-1α #1: Hs_HIF1A_5 (NM_001530; S102664053, Qiagen FlexiTube).
siHIF-1α #2: Hs_HIF1A_6 (NM_001530; S102664431, Qiagen FlexiTube).
Tumour growth and metastasis experiments. Lamin-shRNA-transduced or HMGB1-shRNA- 
transduced B16 cells (1 × 105) were injected subcutaneously in 100 µ l PBS into the flank of wild-type mice. 
Where indicated, mice were treated with 50 µ g BoxA (HMGBiotech, Milano, Italy), one of the highly conserved 
DNA-binding domains of HMGB1, which antagonizes HMGB1 binding to its receptor RAGE. In independ-
ent sets of experiments, 50 µ g anti-IL-10 antibody or control isotype (Biolegend, San Diego, CA) was injected 
intraperitoneally every 3 days in 100 µ l PBS. Mice were monitored every other day and tumour size was meas-
ured using a microcaliper (Mitutoyo, Kawasaki, Japan). Tumour volume is expressed as (long diameter × shorter 
diameter2) × π /6. Lung metastases were generated by tail vein intravenous injection of 1 × 105 B16 cells in 100 µ 
l of PBS. Mice were sacrificed 13 days after tumour cell inoculation and the number of macroscopically visible 
melanoma metastases on the surface of the lungs was counted in a blinded manner by two different investigators.
Patient number Date of Birth Gender Melanoma type Localization Breslow (mm)
1 24.04.1941 M NMM Right upper arm 1.6
2 19.05.1945 M NMM Left lower arm 3
3 13.01.1980 M SSM Left upper arm 0.9
3 10.08.1944 M SSM Left-side chest 1.42
4 12.05.1957 F SSM Left upper arm 1.77
5 23.09.1956 F SSM Right shoulder blade 1.06
6 14.10.1935 M SSM Right lower leg 4
7 14.09.1968 F SSM Right shoulder blade 0.82
8 04.03.1980 M SSM Abdomen 0.68
9 02.05.1946 F SSM Back 1.1
Table 1.  Characteristics of patients with primary cutaneous melanoma. All the patients were Caucasian. 
(SSM: superficial spreading melanoma; NMM: nodular melanoma).
Patient number Date of birth Gender Stage
1 01.05.1934 M IV
2 02.05.1964 M IV
3 24.11.1961 M IV
4 17.07.1958 M IIIB
5 09.10.1960 M IV
6 17.04.1971 M IIIC
7 25.10.1938 M IV
8 30.06.1947 F IV
9 21.11.1979 M IV
10 09.05.1943 M IV
Table 2.  Characteristics of patients with metastatic melanoma. All the patients were Caucasian.
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Flow cytometry analysis of tumour-infiltrating cells. Minced tumours were incubated at 37 °C for 
60 min in complete RPMI containing 1.5 mg/ml collagenase D (Roche Diagnostics, Rotkreuz, Switzerland). The 
resulting cell suspensions were filtered through a 40 µ m cell strainer (Corning Inc., New York, NY) and stained 
with anti-mouse 7/4 antibody (Abcam, Cambridge, UK), anti-mouse CD11b and CD45 antibodies (Biolegend). 
The absolute numbers of each cell subset were calculated by flow cytometry and presented are the numbers per 
mm3 of tumour. Flow-cytometry analysis was performed with a FACS Canto II (Becton-Dickinson, Franklin 
Lakes, NJ) and FACS DIVA software (Becton-Dickinson).
Immunohistochemistry and immunofluorescence. To analyze Hif-1α expression in immunohis-
tochemistry, 2 µ m paraffin-embedded sections were stained overnight at 4 °C with a monoclonal anti-mouse 
Hif-1α Ab (Abcam) or an isotype IgG control Ab (Abcam). Samples were incubated for 60 min at room tem-
perature with biotinylated goat anti-mouse IgG (Abcam) coupled to streptavidin-alkaline phosphatase (Vector 
Laboratories, Burlingame, CA) for 45 min at room temperature. Alkaline phosphatase activity was revealed with 
the DAKO real detection system (DAKO, Glostrup, Denmark) following the manufacturers’ instructions. After 
counter-staining with Haematoxylin solution (Sigma, Zug, Switzerland), slides were mounted with Fluorescence 
Mounting Medium (DAKO) and scanned with a digital slide scanner (Hamamatsu Photonics, Hamamatsu, 
Japan). Pictures were analysed with the ImageJ software (open source from the National Institutes of Health). For 
immunofluorescence analyses, 2 µ m paraffin-embedded sections were stained overnight at 4 °C with 1 µ g/ml rab-
bit polyclonal anti-mouse HMGB1 Ab (Abcam) and 10 µ g/ml mouse monoclonal anti-mouse Hif-1α Ab (Abcam) 
or alternatively 714 µ g/ml monoclonal anti-human melanosome (clone HMB-45, DAKO) or with control IgG 
antibodies (Abcam) at corresponding concentrations. To determine IL-10 and CD163 expression together with 
HMGB1sections were stained overnight at 4 °C with rabbit polyclonal anti-human IL-10 (R&D Systems), mono-
clonal anti-human CD163 (Leica Biosystems, Wetzlar, Germany) and HMGB1 (Abcam) or with respective con-
trol IgG antibodies. Samples were then incubated for 60 min at room temperature with conjugated secondary 
antibodies as follows: Alexa Fluor® 546 Goat Anti-Rabbit IgG (Life Technologies) for HMGB1 and IL-10, and 
DyLight® 650 Goat Anti-Mouse IgG (Abcam) for Hif-1α and CD163, and Alexa Fluor® 647 Donkey Anti-Goat 
IgG H&L (Abcam) for IL-10. Slides were mounted with Fluorescence Mounting Medium (DAKO) and analysed 
with a Widefield BX61 fluorescence microscope (Olympus, Tokyo, Japan) using the Analysis Pro software (Soft 
Imaging Systems, Münster, Germany).
Cell culture in hypoxic conditions and treatment with DMOG. To determine the release of HMGB1 
under hypoxic conditions in vitro, primary cell cultures from metastatic melanoma patients were cultured under 
hypoxia. One million cells were cultured in 2.5 ml complete RPMI medium. After an overnight incubation in 
standard conditions allowing the cells to adhere, cells were incubated in a MIC-101 Modular Incubator Chamber 
(Billups-Rothenberg, Del Mar, CA), flushed with 20 l/min of certified pre-mixed gas composed of 1% O2, 5% CO2, 
and 94% N2 (Carbagas, Guemligen, Switzerland). The O2 concentration inside the chamber was measured with a 
disposable VTI-122 Polaro-graphic oxygen cell oxygen sensor (Vascular Technology, Nashua, NH). The hypoxia 
chamber was placed in an incubator at 37 °C for 72 h and samples were harvested on ice for analysis.
Alternatively, to stabilize HIF1α expression in metastatic melanoma cells, cells were treated with 1 mM 
Dimethyloxalylglycine (DMOG, Sigma-Aldrich, St Louis, MO) for 72 hours.
Quantitative PCR analysis and quantitative PCR array. For tumour mRNA isolation, tumours 
excised from mice were cut into small pieces and incubated for 60 min in lysis buffer (Qiagen, Hilden, Germany) 
with iron beads. RNA was isolated using an RNeasy kit (Qiagen). For mRNA isolation from in vitro cell cultures, 
supernatants were discarded and cells were washed twice with cold PBS. RNA was isolated using an RNeasy kit 
(Qiagen) according to the manufacturers’ instructions. Total RNA was converted into cDNA with the RevertAid 
First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA). Quantitative RT-PCR was performed 
with a ViiA™ 7 Real-Time PCR System (Life Technologies, Carlsbad, CA) using FastStart Universal SYBR Green 
Master (Roche). The PCR included an initial denaturation at 95 °C for 10 min, followed by 40 cycles of 95 °C for 
10 s and 58 °C for 30 s. After 15 s at 95 °C, 20 s at 60 °C and 15 s at 95 °C, samples were kept at 4 °C. Expression of 
mRNA (relative) was normalized to the expression of RPL27 mRNA by the change in cycling threshold (∆ CT) 
method and calculated as 2−∆∆CT. The following primers were used:
Human RPL27: forward 5′ -ATCGCCAAGAGATCAAAGATAA-3′ , reverse 5′ -TCTGAAGACATCCTTA 
TTGACG-3′ , Human VEGF-α : forward 5′ -TACCTCCACCATGCCAAGTG-3′ , reverse 5′ -GATGATTCTGCC 
CTCCTCCTT-3′ , Mouse CD80: forward 5′ -TCAGTTGATGCAGGATACACCA-3′ , reverse 5′ -AAAGACGAATCA 
GCAGCACAA-3′ , Mouse Fizz1: forward 5′ -CCAATCCAGCTAACTATCCCTCC-3′ , reverse 5′ -ACCCAGTAG 
CAGTCATCCCA-3′ , Mouse HMGB1: forward 5′ -GGCGAGCATCCTGGCTTATC-3′ , reverse 5′ -GGCTGCTT 
GTCATCTGCTG-3′ , Mouse IL-1β : forward 5′ -ATCTTTTGGGGTCCGTCAACT-3′ , reverse 5′ -GACAGCACACA 
TTTGCAGCTC-3′ , Mouse IL-6: forward 5′ -TAGTCCTTCCTACCCCAATTTCC-3′ , reverse 5′ -TTGGTCCT 
TAGCCACTCCTTC-3′ , Mouse IL-10: forward 5′ -GCTCTTACTGACTGGCATGAG-3′ , reverse 5′ -CGCAGCTCT 
AGGAGCATGTG-3′ , Mouse RPL27: forward 5′ -AAAGCCGTCATCGTGAAGAAC-3′ , reverse 5′ -GCTGTCAC 
TTTCCGGGGATAG-3′ , Mouse TNF-α : forward 5′ -CCCTCACACTCAGATCATCTTCT-3′ , reverse 5′ -GCTACG 
ACGTGGGCTACAG-3′ , Mouse Ym1: forward 5′ -AGAAGGGAGTTTCAAACCTGGT-3′ , reverse 5′ -GTCTTGCT 
CATGTGTGTAAGTGA-3′ .
Detection of HMGB1 by ELISA. To determine the concentration of HMGB1 in the serum of healthy 
donors, primary melanoma patients and melanoma patients with metastasis, serum samples were analysed using 
the HMGB1 ELISA kit (IBL International, Hamburg, Germany) according to the manufacturers’ instructions. 
To determine the concentration of released HMGB1 from in vitro cell cultures, supernatants were centrifuged at 
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1,500 g for 5 min at 4 °C and analysed using the HMGB1 ELISA kit (IBL International) according to the manu-
facturers’ instructions.
In vitro differentiation of M1- and M2-like macrophages from bone marrow cells. Recombinant 
cytokines were all from Peprotech (Rocky Hill, NJ). To generate of M1 and M2 macrophages, bone marrow cells 
from the tibia and fibula of C57BL/6 mice (Harlan) were cultured at 37 °C in 5% CO2 in RPMI supplemented 
with 1% L-glutamine and 10% foetal bovine serum with 10 ng/ml mouse M-CSF. Medium was replaced on days 
3 and 6 and cells were harvested on day 8. For M1 phenotype induction, cells were stimulated for 24 h with 10 ng/
ml M-CSF and 100 ng/ml IFN-γ and for an additional 24 h with 10 ng/ml M-CSF and 20 ng/ml ultra-pure LPS 
(Invitrogen, Carlsbad, CA). For M2 phenotype induction, cells were stimulated twice for 24 h with 10 ng/ml 
M-CSF and 20 ng/ml IL-4. To determine the effect of HMGB1 on M1 and M2 macrophages, culture medium used 
to induce M1- or M2-like macrophages was supplemented with 1 µ g/ml recombinant HMGB1 (HMGBiotech).
Statistical analyses. Unless otherwise indicated, data are presented as the means ± standard error of the 
mean (SEM) and are representative of three independent experiments. Statistical analyses were performed using 
the Prism Software (GraphPad Software, San Diego, CA). P-values were calculated with paired or unpaired 
Student’s t test. Where indicated, statistical analyses where performed using ANOVA test followed by a Tukey 
test. Differences were considered significant when: * P ≤ 0.05, * * P ≤ 0.01, * * * P ≤ 0.001 and * * * * P ≤ 0.0001.
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Propionibacterium acnes Promotes Th17 and
Th17/Th1 Responses in Acne Patients
Magdalena Kistowska1, Barbara Meier1, Tatiana Proust1, Laurence Feldmeyer2, Antonio Cozzio1,
Thomas Kuendig1, Emmanuel Contassot1,3 and Lars E. French1,3
Propionibacterium acnes is a Gram-positive commensal bacterium thought to be involved in the pathogenesis of
acne vulgaris. Although the ability of P. acnes in the initiation of pro-inflammatory responses is well documented,
little is known about adaptive immune responses to this bacterium. The observation that infiltrating immune cells
consist mainly of CD4þ T cells in the perifollicular space of early acne lesions suggests that helper T cells may be
involved in immune responses caused by the intra-follicular colonization of P. acnes. A recent report showing
that P. acnes can induce IL-17 production by T cells suggests that acne might be a T helper type 17 (Th17)-
mediated disease. In line with this, we show in this work that, in addition to IL-17A, both Th1 and Th17 effector
cytokines, transcription factors, and chemokine receptors are strongly upregulated in acne lesions. Furthermore,
we found that, in addition to Th17, P. acnes can promote mixed Th17/Th1 responses by inducing the concomitant
secretion of IL-17A and IFN-g from specific CD4þ T cells in vitro. Finally, we show that both P. acnes-specific Th17
and Th17/Th1 cells can be found in the peripheral blood of patients suffering from acne and, at lower
frequencies, in healthy individuals. We therefore identified P. acnes-responding Th17/Th1 cells as, to our
knowledge, a previously unreported CD4þ subpopulation involved in inflammatory acne.
Journal of Investigative Dermatology (2015) 135, 110–118; doi:10.1038/jid.2014.290; published online 14 August 2014
INTRODUCTION
Propionibacterium acnes (P. acnes) is a Gram-positive normal
skin commensal bacterium present in all individuals. The
intra-follicular colonization and proliferation of P. acnes
has been associated with the pathogenesis of acne, the
most common human inflammatory skin disorder (Leeming
et al., 1988; Leyden et al., 1998). It has been proposed that
P. acnes contributes to the development of inflammatory
lesions by releasing chemotactic substances and attracting
polymorphonuclear leukocytes to the site of inflammation.
Infiltrating cells are locally activated and release pro-inflam-
matory cytokines including IL-6, tumor necrosis factor-a, IL-12,
IL-8, and IL-1b (Kim et al., 2002; Kalis et al., 2005; Nagy et al.,
2005; Kistowska et al., 2013). Surprisingly, in early acne
lesions, infiltrating cells consist mainly of CD4þ T cells (Norris
and Cunliffe, 1988; Layton et al., 1998). These memory/effector
CD4þ T cells are detected in close proximity to macrophages
and are also present in uninvolved follicles from acne patients
but not in non-acne controls (Jeremy et al., 2003). In addition,
P. acnes has been shown to induce T-cell proliferation (Jappe
et al., 2002), and reactive P. acnes-specific CD4þ T cells have
been isolated from early inflamed acne lesions (Mouser et al.,
2003). These T cells have the capacity to secrete IFN-g, but not
IL-4, upon stimulation with P. acnes and have therefore revealed
to be Th1 cells.
CD4þ T helper (Th) cells have a key role in the regulation
of adaptive immune responses by secreting cytokines and
chemokines that activate and/or recruit effector cells. Because
of the discovery of an IL-17-producing T-cell subset, known as
Th17, numerous studies have revealed IL-17 as a pro-inflam-
matory cytokine involved in the pathogenesis of autoimmune
disorders as well as in response to certain pathogens at both
the barrier site and at a systemic level (O’Connor et al., 2010;
Miossec and Kolls, 2012). Th17 cells have a role in the
protection against extracellular bacteria and fungi (Zhu and
Paul, 2008; Zhu et al., 2010), particularly those colonizing the
respiratory and gastrointestinal tracts and the skin (Peck and
Mellins, 2010). The protective effects of IL-17-producing cells
have been demonstrated in patients with hyper-immuno-
globulin E syndrome, who suffer from recurrent infections
with Candida albicans (C. albicans) and Staphylococcus
aureus (S. aureus) due to the impairment in Th17 develop-
ment (Milner et al., 2008; Puel et al., 2011). In addition to
their protective effect, Th17 have also been reported to be
pathogenic. Indeed, Th17 cells are associated with many
autoimmune and inflammatory disorders including Crohn’s
disease, colitis, psoriasis, multiple sclerosis, rheumatoid
arthritis, and chronic graft-versus-host disease (Wilke et al.,
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2011; McGeachy, 2013). Moreover, Th17 cells are suspected
to have a role in cutaneous inflammatory disorders, including
psoriasis, allergic contact dermatitis, or atopic dermatitis
(Asarch et al., 2008). In a recent report, Agak et al. (2013)
showed that the secretion of IL-17 by naı̈ve CD4þ T cells can
be induced by P. acnes, thus suggesting that both Th1 and
Th17 responses may be involved in responses to this
bacterium.
In this work, we show that, in addition to IL-17A, both Th1
and Th17 effector cytokines, transcription factors, and che-
mokine receptors are strongly upregulated in acne lesions. We
also observed that, besides Th17, P. acnes can promote mixed
Th17/Th1 responses by inducing the concomitant secretion of
IL-17A and IFN-g from specific CD4þ T cells in vitro. Finally,
we show that both P. acnes-reactive Th17 and Th17/Th1 cells
can be found in the peripheral blood of patients suffering from
acne and, at lower frequencies, in healthy individuals. Our
data suggest that, in addition to Th17, Th17/Th1 T cells may
have a role in acne pathogenesis.
RESULTS
T cells of Th1 and Th17 phenotypes are found in acne lesions
We first assessed the expression of Th effector cytokines in
human acne biopsies. We detected significantly increased
levels of IFN-g and, in line with the recent report from Agak
et al. (2013), IL-17A mRNA in human acne samples when
compared with normal skin. IL-21, an essential cytokine for
the differentiation and homeostasis of Th17 cells (Korn et al.,
2007; Weaver et al., 2007; Wei et al., 2007), was also found
to be highly expressed in acne biopsies (Figure 1a). In
accordance with previous studies (Mouser et al., 2003; Agak
et al., 2013), the levels of IL-4 mRNA were not higher in acne
lesions compared with those in normal skin (Figure 1a). IL-22
mRNA levels were also not increased in acne lesions in
comparison with normal skin (Figure 1a). Noteworthy, we
observed a correlation between the mRNA levels of IL-17A
and IFN-g in acne biopsies (Figure 1b). The immunohisto-
chemical analysis of acne biopsies not only confirmed a strong
expression of IL-17A but also revealed strong IFN-g expression
in the same areas of the immune cell infiltrates (Figure 1c).
Differentiation of Th subsets is tightly regulated by master
transcription factors, signaling transducers, and activators of
transcription (signal transducer and activator of transcriptions
(STATs)). Th1 differentiation depends on STAT4 and T-bet
(TBX-21), whereas Th2 cells require STAT5a and GATA3, and
RAR-related orphan receptor gamma (ROR-gt) (RORC) and
STAT3 are critical factors for Th17 subset differentiation (for
review (Zhu et al., 2010)). In acne biopsies, increased levels of
Th1 and Th17 transcription factor mRNA were observed,
whereas transcription factors required for Th2 cells remained
unchanged when compared with normal skin (Figure 1d).
Analysis of chemokine receptors in skin biopsies revealed
elevated CXCR3, CCR4, and CCR6 mRNA levels in acne
lesions when compared with normal skin (Figure 1e). These
receptors are preferentially expressed in Th1 (CXCR3) or Th17
(CCR4 and CCR6) subsets (Bromley et al., 2008; Brodie et al.,
2013). In contrast, the expression of the Th2 chemokine
receptor CRTh2 in acne lesions was not different from the
one of normal skin. Our detailed analysis of CD4þ T-cell subset
markers further supports the presence of cells of Th1 and Th17
in inflammatory lesions of patients suffering from acne.
P. acnes triggers Th17 and mixed Th17/Th1 responses in vitro
To further characterize Th responses to P. acnes, peripheral
blood mononuclear cells (PBMCs) from healthy donors were
exposed to live P. acnes, at different multiplicities of infection
(MOI). After 24hours, we observed a strong secretion of Th1
and Th17 polarizing cytokines: namely IL-12 (Th1) and IL-1b,
IL-6, and IL-23 (Th17) (Supplementary Figure S1a online).
Moreover, we could confirm that, after 6 days of incubation, a
robust release of Th1 and Th17 effector cytokines, namely
IFN-g and IL-17A, respectively, could be detected, whereas P.
acnes failed to induce the secretion of IL-4 and IL-22 from
PBMCs (Supplementary Figure S1b online). However, using
intracellular stainings and flow-cytometric analysis, we
observed that IL-17A was secreted by two distinct cell
populations upon P. acnes exposure. In accordance with the
recent report from Agak et al. (2013), we also found a first
population secreting IL-17A alone. Interestingly, we identified
a second cell population secreting IL-17A and IFN-g con-
comitantly (Figure 2a). In line with ELISA data, we did not
detect cells producing IL-4 or IL-22 upon stimulation with
P. acnes. The induction of P. acnes-reactive IL-17Aþ IFN-g
and IL-17Aþ IFN-gþ cells was significant in 100% of the
tested healthy donors (Figure 2b). In contrast, induction of
IL-17A IFN-gþ cells was observed in only 40% of the
tested donors (Figure 2b). Nearly 100% of the P. acnes-
induced IL-17Aþ cells were CD4þ (Figure 2c). Taken
together, these data show that P. acnes not only induces
Th17 (IL-17Aþ IFN-g ) but also Th17/Th1 (IL-17Aþ IFN-gþ )
responses.
P. acnes-exposed monocytes activate CD4þ T cells in an major
histocompatibility complex II-dependent manner
These findings prompted us to further characterize the CD4þ
T-cell response to P. acnes. Therefore we isolated CD4þ
T cells from PBMCs from healthy donors and stimulated them
with live bacteria in the presence of autologous monocytes.
After 6 days, we assessed the production of IL-17A and IFN-g
by intracellular staining. Flow-cytometric analysis showed that
both IL-17Aþ IFN-g and IL-17Aþ IFN-gþ CD4þ cells are
strongly induced in response to P. acnes (Figure 3a and b).
In about 50% of tested donors also IL-17A IFN-gþ T cells
were increased upon P. acnes exposure (Figure 3b). It has
been previously shown that human leukocyte antigen-DR
(HLA-DR) is upregulated in acne lesions and that HLA-DR-
expressing cells are present in close association with CD4þ
T cells surrounding the lesions (Layton et al., 1998). We
addressed the role of major histocompatibility complex (MHC)
class II in the induction of T-cell response upon P. acnes
exposure by blocking its function with a neutralizing antibody.
Treatment with an anti-HLA-DR antibody, but not with an
irrelevant control antibody, led to a significant decrease in
IL-17A single producers as well as IL-17A and IFN-g double
producers in all analyzed donors (Figure 3c and d). Anti-HLA-
DR also led to a decrease in the number of T cells producing
M Kistowska et al.
P. acnes Promotes Th17 and Th17/Th1 Responses
www.jidonline.org 111
only IFN-g in about 80% of the donors, as shown in Figure 3d.
However, for unknown reasons, the extent of this reduction
was not as strong as the one obtained in IL-17A single
producer or IL-17A and IFN-g double-producer reduction
and was not statistically significant. Moreover, the blockade
of MHC II resulted in a strong reduction of T-cell proliferation
upon P. acnes exposure (Figure 3e). These data demonstrate
that proliferation and cytokine secretion by CD4þ T cells
upon P. acnes exposure are dependent on MHC II.
IL-1b and IL-12/IL-23 modulate the T-cell response to P. acnes
The IL-1 family cytokines and STAT activators are able to
influence effector cytokine production from differentiated Th
subsets. IL-12 activates STAT4 and, together with IL-18,
induces IFN-g production from Th1 cells (Guo et al., 2009).
Secretion of IL-17A from Th17 cells can be promoted by IL-1
and STAT3 activators, including IL-6, IL-21, and IL-23 (Chung
et al., 2009; Guo et al., 2009). The observation that IL-1b,
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Figure 1. Cells with T helper type 1 (Th1) and Th17 profile are found in acne lesions. (a) Th cell effector cytokine gene expression in acne lesions (AV, n¼ 12)
and normal skin (NS, n¼6) measured by quantitative reverse transcriptase in real time (qPCR). (b) Scatter plot showing the correlation (Spearman’s rank
correlation) between IL-17A and IFN-g mRNA expression in human acne biopsies. (c) Immunohistochemical analysis of IL-17 and IFN-g in an acne lesion
compared with healthy skin (scale bar¼500mm). (d) Transcription factors and (e) chemokine receptor gene expression in acne lesions (AV, n¼ 12) and normal
skin (NS, n¼ 6) measured by qPCR. The relative mRNA abundance of indicated genes against ribosomal protein L27 (RPL27) mRNA levels was analyzed and
normalized with the average of normal skin. *Pp0.01, **Pp0.001, and ***Pp0.0001 by the Mann–Whitney two-tailed test for acne lesions compared with
normal skin. Presented are mean and SEM.
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exposure (Supplementary Figure S1a online) prompted us to
investigate whether these cytokines may have a role in
shaping T-cell responses. Sorted CD4þ T cells were stimu-
lated with live P. acnes in the presence of various neutralizing
mAb. The inhibition of IL-1b resulted in a reduction in
IL-17Aþ IFN-g and IL-17Aþ IFN-gþ T cells, whereas the
neutralization of the IL-12/23-p40 common subunit alone
reduced the response of IL-17Aþ IFN-gþ cells but did not
affect IL-17Aþ IFN-g T cells unless used together with anti-
IL-1b (Figure 4). The effect of anti-IL-12/23 blocking mAb on
IL-17Aþ IFN-gþ T cells was further enhanced when used in
combination with anti-IL-1b mAb. In contrast, tumor necrosis
factor-a inhibition did not significantly affect the T-cell
response to P. acnes. These results suggest that the stimulation
of P. acnes-induced Th17 and Th17/Th1 T cells can be
efficiently prevented by blocking IL-12/23-p40 and IL-1b,
whereas the responses of IL-17A IFN-gþ cells are less
susceptible to the blockade of these cytokines.
Acne patients exhibit stronger Th17 and Th17/Th1 responses to
P. acnes
The presence of P. acnes-reactive T cells in the blood of
healthy individuals raised the question whether these cells
could be detected at higher frequencies in acne patients.
To address this question and assess the specificity of respond-
ing CD4þ T cells, the ability of P. acnes to induce Th17 and
Th17/Th1 responses was compared with Staphylococcus
aureus (S. aureus). As S. aureus could not be used in its live
form, cells were stimulated with bacterial lysates. P. acnes
lysates induced comparable number of IL-17Aþ IFN-g as
well as IL-17Aþ IFN-gþ cells as live bacteria (Supplementary
Figure S2 online). Then, we compared the response to
P. acnes and S. aureus in healthy donors and in acne
patients. In healthy donors, both P. acnes and S. aureus
induced, at a similar extent, a discrete increase of IL-17Aþ
IFN-g as well as IL-17Aþ IFN-gþ CD4þ cells (Figure 5). In
contrast, P. acnes was able to induce a dramatic increase in
both IL-17Aþ IFN-g and IL-17Aþ IFN-gþ CD4þ cells,
whereas the induction of both CD4þ subsets remained
discrete and comparable with that of healthy donors
upon exposure to S. aureus lysates (Figure 5). Neither P. acnes
nor S. aureus was able to induce IL-17A IFN-gþ cells in
both healthy individuals’ and acne patients’ cells.
Altogether, these data show that acne patients have increased
frequencies of circulating P. acnes-specific Th17 and
Th17/Th1 cells.
DISCUSSION
In the present study, we have investigated the adaptive
immune response to the skin commensal bacterium P. acnes.
Previous studies have shown that P. acnes-specific Th1 are
cells present in early inflamed acne lesions (Mouser et al.,
2003). In addition to IFN-g, we have found significantly








































































































































Figure 2. P. acnes induces production of IL-17A and IFN-c by CD4þ T cells. Peripheral blood mononuclear cells (PBMCs) were exposed to P. acnes (multiplicity
of infection (MOI)¼3) or incubated with medium. On day 6, cells were stimulated for 4.5hours with phorbol 12-myristate 13-acetate (PMA) and ionomycin,
fixed, permeabilized, and stained with antibodies against CD4, IL-17A, and IFN-g or IL-22 or IL-4. (a) Representative flow-cytometric analysis. (b) Percentages of
IL-17Aþ IFN-g , IL-17Aþ IFN-gþ , and IL-17A IFN-gþ detected in PBMCs from healthy donors untreated (K) or stimulated with P. acnes (J) (n¼12). Each
symbol represents a unique donor. ***Pp0.0001 and ****Pp0.00001 by two-tailed paired Student’s t-test for P. acnes-exposed PBMCs compared with medium-
exposed PBMCs. (c) Representative flow-cytometric analysis of CD4 expression among IL-17Aþ PBMCs stimulated with P. acnes.
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biopsies. In vitro, we demonstrated that P. acnes has the
ability to induce the secretion of IL-17A and IFN-g, therefore
confirming the recent observation by Agak et al. (2013) that
P. acnes induces Th17 differentiation. However, in contrast to
the data reported in the same study, we show that IL-17A is
produced by two distinct subsets of T cells producing either
IL-17A alone or in conjunction with IFN-g. We also observed
that Th1 cells could be induced in only 40% of the tested
donors, whereas Th17 and Th17/Th1 cells could be induced
by P. acnes in 100% of them. This is also in apparent contra-
diction with the recent study by Agak et al. (2013), who
concluded that both Th17 and Th1 cells could be induced in
100% of the tested PBMC donors. In fact, we show here that,
in addition to Th17 and Th1 cells, a third subset secreting both
IL-17A and IFN-g may be involved in the inflammatory
response to P. acnes. Interestingly, our data suggest that the
use of anti-IL-1b and anti-IL-12/IL-23 may represent an effi-
cient strategy for the targeting of Th17/Th1 cells. While
anti-IL-1b had a discrete but significant effect on the
induction of IL-17Aþ /IFN-g cells, an anti-IL-12/IL-23-p40
antibody alone did not impact the response of these cells,
suggesting that, in this setting, the induction of Th17 cells by
P. acnes does not require IL-23, as previously reported (Agak
et al., 2013). In contrast, anti-IL-1b and anti-IL-12/IL-23-p40
had pronounced additive inhibitory effects on cells producing
both IL-17 and IFN-g, suggesting that IL-1b and IL-12 or/and
IL-23 are key cytokines in the differentiation of these cells. We
also found elevated levels of IL-21 mRNA in acne lesions,
whereas, surprisingly, IL-22 mRNA levels were similar to those









































































































































































Figure 3. Major histocompatibility complex II (MHC II)-dependent response of CD4þ T cells to P. acnes infection. (a, b) Freshly isolated CD4þ T cells
from healthy donors were left untreated or exposed to P. acnes in the presence of autologous monocytes. On day 6, cells were stimulated with P/I and stained with
antibodies against CD4, IL-17A, and IFN-g. (a) Representative flow-cytometric analysis. (b) Percentages of IL-17Aþ IFN-g , IL-17Aþ IFN-gþ , and IL-17A IFN-gþ
within CD4þ T cells untreated (K) or stimulated with P. acnes (J) (n¼ 12). (c, d) IL-17A and INF-g production by CD4þ T cells stimulated with P. acnes in the
presence of irrelevant or anti-HLA-DR-neutralizing mAb determined by intracellular staining following P/I stimulation on day 6. (c) Representative flow-cytometric
analysis. (d) Percentages of IL-17Aþ IFN-g , IL-17Aþ IFN-gþ , and IL-17A IFN-gþ within CD4þ T cells stimulated with P. acnes in the presence of
irrelevant mAb (K) or anti-HLA-DR mAb (J) (n¼ 10). (e) Carboxyfluorescein succinimidyl ester (CFSE) profile of CD4þ T cells stimulated with autologous
monocytes exposed to P. acnes in the presence of irrelevant mAb or anti-HLA-DR mAb. Data are representative of at least three different experiments. (b, d) Each
symbol represents an individual donor. ***Pp0.0001 and ****Pp0.00001 by two-tailed paired Student’s t-test. HLA-DR, human leukocyte antigen-DR;
P/I, phorbol 12-myristate 13-acetate (PMA)/ionomycin.
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Figure 4. T helper type 17 (Th17) and Th17/Th1 responses are prevented by blocking differentiation cytokines. Freshly isolated CD4þ T cells from healthy
donors (n¼ 5) were left untreated or exposed to P. acnes in the presence of autologous monocytes. On day 6, cells were stimulated with phorbol 12-myristate
13-acetate (PMA) and ionomycin and stained with antibodies to CD4, IL-17A, and IFN-g. Percentages of IL-17Aþ IFN-g , IL-17Aþ IFN-gþ , and IL-17A IFN-gþ
within CD4þ T cells stimulated with P. acnes in the absence or presence of the indicated blocking antibodies. **Pp0.001 and ***Pp0.0001 by two-tailed paired













































































































































































































HD, n =12 AP, n =12 HD, n =12 AP, n =12 HD, n =12 AP, n =12
IFNγ
Figure 5. Acne patients have enhanced T-cell responses to P. acnes. Freshly isolated peripheral blood mononuclear cells (PBMCs) from healthy donors (HD,
n¼ 12) and acne patients (AP, n¼12) were exposed to bacterial lysates from P. acnes or S. aureus or incubated with medium. On day 6, cells, after 4.5 hours
stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin, were subjected to intracellular staining with antibodies against CD4, IL-17A, and IFN-g.
(a) Representative flow-cytometric analysis. (b) Percentages IL-17Aþ IFN-g , IL-17Aþ IFN-gþ , and IL-17A IFN-gþ detected among CD4þ cells from healthy
donors and acne patients untreated or stimulated with P. acnes or S. aureus. **Pp0.001 and ****Pp0.00001 by two-tailed unpaired Student’s t-test for HD-PBMCs
compared with AP-PBMCs exposed to indicated bacteria.
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Th17 effector cytokines, IL-17 and IL-22, have the capacity
to stimulate the production of various antimicrobial peptides
(Peck and Mellins, 2010). Moreover, IL-17 induces the
production of neutrophil-recruiting chemokines such as
IL-8 (CXCL8) in epithelial cells (Laan et al., 1999; Ye et al.,
2001; Annunziato et al., 2012). It has been previously
shown that neutrophils infiltrate late-stage acne lesions
(Norris and Cunliffe, 1988) and that the expression levels of
IL-8 in acne biopsies are elevated (Trivedi et al., 2006). In
addition to its ability to induce pro-inflammatory cytokine
secretion in the perifollicular area, P. acnes is thought to
produce low-molecular weight chemotactic factors, resulting
in the accumulation of neutrophils at the site of acne
comedones. Our observation that IL-17A is found in acne
lesions and that P. acnes has the ability to induce IL-17-
secreting CD4þ T cells supports an additional T-cell–
dependent role of this bacterium in the recruitment of
neutrophils at the site of acne lesions.
The coproduction of IFN-g and IL-17 has been previously
observed in memory T cells residing in the gut of patients
with Crohn’s disease (Annunziato et al., 2007) and in T cells
responding to the mycobacterial antigen purified protein
derivative (Acosta-Rodriguez et al., 2007). Moreover, it has
been shown that Candida albicans-specific T cells have the
capacity to produce IL-17A in combination with IFN-g and co-
express ROR-gt and T-bet (Zielinski et al., 2012). These cells
with a mixed Th17/Th1cytokine profile most likely derive from
Th17 subsets exhibiting a certain plasticity and can acquire
functional characteristics of Th1 cells (Muranski and Restifo,
2013).
Alhough Th17 cells have been extensively studied, the
precise role of Th17/Th1 cells in host defense and diseases
remains to be investigated. The development of these mixed
T-cell subset depends on the cytokine microenvironment
(Zielinski et al., 2012) but also might be induced by chronic
stimulation of Th17 cells (Dileepan et al., 2011).
In the present work, we also demonstrate that recall
responses could be elicited by P. acnes and that such
responses are mainly mediated by Th17 and Th17/Th1 cells.
Interestingly, the Th17- and Th17/Th1-mediated recall
responses could be observed in all the healthy donors tested
(n¼ 12), suggesting that such a pool of memory cells is present
in a majority of healthy individuals. The increased responses
of IL-17A- and IL-17A/IFN-g-producing CD4þ cells found in
individuals with an active disease revealed higher frequencies
of circulating P. acnes-specific T cells in acne patients.
In contrast, responses to S. aureus were not enhanced in
PBMCs from patients with acne when compared with healthy
individuals.
Altogether, our data suggest that CD4þ T cells harboring a
Th17 and Th17/Th1 cytokine profile may be involved in the
inflammatory response associated with acne. The targeting of
effector cytokines—namely, IL-17 and IFN-g—or differentia-
tion cytokines—namely, IL-1b and IL-23—may represent a
new therapeutic approach for the treatment of acne. However,
a better knowledge of the precise contribution of these T-cell
subsets in the pathogenesis of this common skin disease
remains to be further investigated.
MATERIALS AND METHODS
Human samples
All human skin biopsies and peripheral blood samples were collected
with informed written consent upon approval from Local Ethical
Committees and were conducted according to the Declaration of
Helsinki Principles. All acne patients included in this study had a
moderate form of acne vulgaris. All of them were 19–25-year-old
men who were not treated at the time of biopsy.
Cell sorting
PBMCs were isolated from buffy coats (obtained from healthy donors,
Blood Donation Center, Schlieren, Switzerland) and from peripheral
blood from acne patients using a density gradient (Ficoll-Paque,
Pharmacia, Glattbrugg, Switzerland). CD4þ T cells were sorted from
PBMCs by negative selection using magnetic beads (CD4þ T Cell Iso-
lation Kit II, MACS, Miltenyi Biotech, Bergisch Gladbach, Germany)
with a purity of 97% (determined by staining with CD3 and CD4
antibodies and flow-cytometric analysis). Monocytes were sorted with
anti-CD14-labeled magnetic beads according to the manufacturer’s
instructions (MACS, Miltenyi Biotech). The purity was over 96% as
determined by CD14 staining and flow-cytometric analysis.
Bacteria
P. acnes (DSM 1897, DMSZ, Braunschweig, Germany) was cultured
under anaerobic conditions as previously described (Kistowska et al.,
2013). Bacteria were harvested by centrifugation at 5,000 r.p.m. for
10minutes, washed, and suspended in phosphate-buffered saline (PBS)
or medium for experiments. To prepare bacterial lysates, bacterial
pellets were resuspended in PBS and heat inactivated for 1hour at
65 1C and then subjected to five freeze–thaw cycles followed by two
rounds of sonication (5minutes each). Protein concentration was mea-
sured using the bicinchoninic acid assay (BCA Protein Assay Reagent,
Pierce, Rockford, IL) according to the manufacturer’s instructions.
T-cell–stimulation assays
Cells were cultured in RPMI 1640 medium (Invitrogen, Basel,
Switzerland), supplemented with 5% human serum (Blood Donation
Center, Schlieren, Switzerland), 1% Antibiotic-Antimycotic (Invitro-
gen, Life Technologies, Zug, Switzerland), 1mM sodium pyruvate
(Invitrogen), and 2mM GlutaMAX solution (Invitrogen). PBMCs from
healthy donors and patients were exposed to live P. acnes at the
indicated MOI or to bacterial lysates (2.5mg ml 1) for 6 days. Sorted
CD4þ T cells were cocultured for 6 days with autologous monocytes
(ratio 2:1) pre-exposed to live P. acnes at the indicated MOI. In some
experiments, T-cell activation was performed in the presence of the
following neutralizing antibodies (all at 10mgml 1): anti-human
leukocyte antigen HLA-DR (L243, kindly provided by Prof G. De
Libero, Basel, Switzerland), irrelevant mouse IgG2a (MG2a-53,
Biolegend, San Diego, CA), anti-IL-1b (Canakinumab, Novartis, Basel,
Switzerland), anti-IL-12/IL-23 (Ustekinumab, Janssen Biotech, Zug,
Switzerland), and tumor necrosis factor-a inhibitor (5mgml 1 Etaner-
cept, Pfizer, Zürich, Switzerland).
Cytokine analysis
Cell culture supernatants were collected at indicated time points, and
the following cytokines were measured by ELISA: IL-1b IL-6, IL-17A,
IFN-g IL-22 (R&D Systems, Minneapolis, MN), IL-4, IL-12p70
(Biolegend), and IL-23 (eBioscience, San Diego, CA). All ELISAs were
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performed according to the manufacturer’s instructions. For intracel-
lular cytokine stainings, cells were stimulated at indicated
time points for 4.5 hours with phorbol-12-myristate-13-acetate
(50ngml 1, Sigma-Aldrich, Buchs, Switzerland) and ionomycin
(500ngml 1, Sigma-Aldrich) in the presence of brefeldin A
(5mgml 1, Sigma-Aldrich). Cells were fixed with paraformaldehyde
(2%, Sigma-Aldrich), permeabilized with saponin (0.1%, Sigma-
Aldrich), and stained with anti-IL-17A (BL168), anti-IFN-g (B27),
anti-IL-4 (MP4-25D2), and anti-IL-22 (BG/IL-22) (all from Biolegend)
and were analyzed by flow cytometry (FacsCanto A, Becton-Dickinson,
Basel, Switzerland). Flow-cytometric data were analyzed by FlowJo
(Tree Star, Ashland, OR).
Gene expression analysis
Total RNA was isolated from human skin samples obtained from
healthy donors (n¼ 6) or from acne patients (n¼ 12) using the RNeasy
Fibrous Tissue Kit (Qiagen, Basel, Switzerland) according to the manu-
facturer’s instructions. RNA was converted into cDNA by standard
reverse transcription with the RevertAid First Strand cDNA Synthesis Kit
(Thermo Scientific, Life Technologies, Carlsbad, CA). Quantitative PCR
was performed using Power SYBR Green PCR Master Mix (Applied
Biosystems, Life Technologies). The following primers were used:
RPL27: forward 50-ATCGCCAAGAGATCAAAGATAA-30, reverse
50-TCTGAAGACATCCTTATTGACG-30
IFN-g: forward 50-TCGGTAACTGACTTGAATGTCCA-30, reverse
50-TCGCTTCCCTGTTTTAGCTGC-30
IL-4: forward 50-CCGTAACAGACATCTTTGCTGCG-30, reverse
50-GAGTGTCCTTCTCATGGTGGCT-30
IL-17A: forward 50-CAATCCCACGAAATCCAGGATG-30, reverse
50-GGTGGAGATTCCAAGGTGAGG-30
IL-21: forward 50-CCAAGGTCAAGATCGCCACATG-30, reverse
50-TGGAGCTGGCAGAAATTCAGGG-30
IL-22: forward 50-GCTTGACAAGTCCAACTTCCA-30, reverse
50-GCTCACTCATACTGACTCCGTG-30
STAT3: forward 50-CTTTGAGACCGAGGTGTATCACC-30, reverse
50-GGTCAGCATGTTGTACCACAGG-30
STAT4: forward 50-CAGTGAAAGCCATCTCGGAGGA-30, reverse
50-TGTAGTCTCGCAGGATGTCAGC-30
STAT5a: forward 50-GTTCAGTGTTGGCAGCAATGAGC-30, reverse
50-AGCACAGTAGCCGTGGCATTGT-30
RORC: forward 50-GAGGAAGTGACTGGCTACCAGA-30, reverse
50-GCACAATCTGGTCATTCTGGCAG-30
TBX-21: forward 50-ATTGCCGTGACTGCCTACCAGA-30, reverse
50-GGAATTGACAGTTGGGTCCAGG-30
GATA3: forward 50-ACCACAACCACACTCTGGAGGA-30, reverse
50-TCGGTTTCTGGTCTGGATGCCT-30
CXCR3: forward 50-ACGAGAGTGACTCGTGCTGTAC-30, reverse
50-GCAGAAAGAGGAGGCTGTAGAG-30
CRTh2: forward 50-TGGAGTCATCCTCTTCGTGGTG-30, reverse
50-AGTAGGTGAAGAAGGGCAGGGA-30
CCR4: forward 50-CTCTGGCTTTTGTTCACTGCTGC-30, reverse
50-AGCCCACAGTATTGGCAGAGCA-30
CCR6: forward 50-CTGAACCCTGTGCTCTACGCTT-30, reverse
50-CACAGGAGAAGCCTGAGGACTT-30
The real-time PCR included an initial denaturation at 95 1C for
10minutes, followed by 40 cycles of 95 1C for 30 seconds, 55 1C for
1minute, and 72 1C for 1minute, and one cycle of 95 1C for 1minute,
55 1C for 30 seconds, and 95 1C for 30 seconds.
Immunohistochemistry
Human acne skin samples (n¼ 12) and normal skin samples (n¼ 3)
from distinct individuals were cross-sectioned, and immunohistochem-
istry stainings were performed. After deparaffinization by heat and
ascending alcohol series, the slides were stored in Retrieval Solution
(DAKO, Agilent Technologies, Santa Clara, CA) and heated under
pressure in a pressure cooker for 25minutes for antigen demasking.
Unspecific binding sites were blocked by incubation in 5% (wt/v)
BSA and 5% (v/v) normal goat serum (DAKO) in PBS for 1hour.
Antibodies against IFN-g (Abcam, Cambridge, UK) and Interleukin-17
(Abcam) were diluted in antibody diluent (DAKO S0809), and
an appropriate isotype control antibody was substituted for
every primary antibody on a separate section. Slides were washed
with PBS, and secondary antibody goat anti-rabbit (Southern Biotech,
Birmingham, AL) was added and incubated for 1hour at room
temperature. Slides were again washed with PBS and mounted
with an Avidin–Biotin complex (Vectastain, Vector Laboratories,
Burlingame, CA). After 45minutes, incubation slides were washed
with PBS and mounted with (3,30-diaminobenzidine) HRP substrate
(Vectastain) to produce a brown reaction product. After the washing
steps, a counterstain with hematoxylin was performed. The sections
were mounted in mounting medium (DAKO) and imaged using Aperio
ScanScope (Leica, Nussloch, Germany).
Statistics
The statistical analysis for quantitative reverse transcriptase in real
time on human samples was performed using the Mann–Whitney
two-tailed test. Data obtained from in vitro experiments were
subjected to two-tailed paired or unpaired Student’s t-test as indi-
cated. Differences were considered significant when *Pp0.05,
**Pp0.001, ***Pp0.0001, and ****Pp0.00001. All statistical ana-
lyses were performed using GraphPad Prism software (La Jolla, CA).
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In Situ Mapping of Innate Lymphoid Cells in
Human Skin: Evidence for Remarkable
Differences between Normal and
Inflamed Skin
Marie-Charlotte Brüggen1,2,6, Wolfgang M. Bauer1,6, Bärbel Reininger1, Eduard Clim3,
Catalin Captarencu4, Georg E. Steiner5, Patrick M. Brunner1, Barbara Meier2, Lars E. French2
and Georg Stingl1
Although innate lymphoid cells (ILCs) have recently been identified also in skin, their role in this organ
remains poorly understood. In this study, we aimed at developing a technique to assess ILCs in situ and to
determine their topographical distribution in human skin. We collected lesional skin biopsies from patients
with atopic dermatitis and psoriasis (both n ¼ 13) and normal human skin from healthy controls. After
establishing immunofluorescence ILC in situ stainings, we developed an analysis approach (gating combined
with manual validation) to reliably identify ILCs. Topographical mapping was obtained by automated calcu-
lations of the distances between ILCs and different cellular/structural elements of the skin. Whereas normal
human skin harbored a very scarce ILC population (mostly ILC1s and AHRþILC3s), atopic dermatitis and
psoriasis skin was infiltrated by clearly visible ILC subsets. We observed atopic dermatitis skin to contain not
only ILC2s but also a prominent AHRþILC3 population. Conversely, we encountered almost equal proportions
of ILC1s and RORCþILC3s in psoriasis skin. Distance calculations revealed ILCs to reside near the epidermis
and in close proximity to T lymphocytes. ILC mapping in situ will provide valuable information about their
likely communication partners in normal and diseased skin and forms the basis for the appropriate mecha-
nistic studies.
Journal of Investigative Dermatology (2016) 136, 2396e2405; doi:10.1016/j.jid.2016.07.017
INTRODUCTION
The skin is a barrier organ directly exposed to the outside
world. As such, it often faces environmental challenges
ranging from immunogenic haptens to invading microbes.
Protection from such danger signals is provided by a highly
complex cutaneous immune network consisting of both
innate and adaptive components (Modlin et al., 2012).
Among the latter, a population of skin-resident T cells has
been recognized as an important player (Clark, 2015). A
novel subset of innate immune cells has more recently
entered the stage of immune defense (Kim, 2015), namely
innate lymphoid cells (ILCs). These leukocytes require IL-7
for their development and, thus, uniformly express the IL-
7 receptor alpha chain CD127. They do not express any
lineage (Lin) markers of other leukocyte populations and
lack a recombinant antigen recognition receptor (Spits and
Cupedo, 2012). What they do share with T-cell subsets,
however, are striking similarities regarding their transcrip-
tion factor (TF) and, hence, cytokine profiles. Based on the
latter, three groups of noncytotoxic human ILCs can be
defined (De Obaldia and Bhandoola, 2015; Eberl et al.,
2015). Group 1 ILCs depend on the TF TBET, and
generate IFN-g and tumor necrosis factor-a, but no cyto-
toxic molecules. Group 2 ILCs express high levels of the
GATA3 and produce T helper type 2 (Th2) cytokines (IL-4,
IL-5, and IL-13). Group 3 ILCs constitute a group of cells
displaying heterogeneous expression of the TFs’ nuclear
receptor gamma (RORC), the AHR, and TBET (Serafini et al.,
2015). Functionally, ILC3s produce variable amounts of
IFN-g, IL-22, and IL-17 (Eberl and Littman, 2004). This
apparent heterogeneity of ILC3s, rather than being indica-
tive of their multifocal origin, seems to be a sign of their
plasticity imposed by different types of stimuli in their
environment.
All ILCs have in common the capacity of immediately
responding to different, often epithelial cell-derived media-
tors, mostly by cytokine production (Sonnenberg and Artis,
1Department of Dermatology, Division of Immunology, Allergy and
Infectious Diseases, Medical University of Vienna, Vienna, Austria;
2Department of Dermatology, Zurich University Hospital, Zurich,
Switzerland; 3Department of Application Support and Image Processing,
TissueGnostics srl, Iasi, Romania; 4Department of Product Development,
TissueGnostics srl, Iasi, Romania; and 5TissueGnostics GmbH, Vienna,
Austria
6These authors contributed equally to this work.
Correspondence: Georg Stingl, Department of Dermatology, Division of
Immunology, Allergy and Infectious Diseases, Medical University of Vienna,
Waehringer Guertel 18-20, 1090 Vienna, Austria. E-mail: georg.stingl@
meduniwien.ac.at
Abbreviations: AD, atopic dermatitis; IF, immunofluorescence; ILC, innate
lymphoid cell; Lin, lineage; NHS, normal human skin; Pso, psoriasis; TF,
transcription factor; Th, T helper
Received 8 April 2016; revised 28 June 2016; accepted 14 July 2016;
accepted manuscript published online 22 July 2016; corrected proof
published online 9 September 2016
ORIGINAL ARTICLE
Journal of Investigative Dermatology (2016), Volume 136 ª 2016 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.2396
2015). This innate response is not only biologically important
by itself, but can also initiate and orchestrate adaptive immune
responses (Eberl et al., 2015; Sonnenberg and Artis, 2015).
Dependent on the type of ILC subset involved, the complex
functional interplay of ILCs with other leukocyte populations
may either result in inflammation or in the downregulation of
inflammatory events. In addition, ILCs play an important role
in tissue repair and, as described for a special subset of ILC3s,
in the histogenesis of secondary lymphoid tissues (Eberl and
Littman, 2004; Yoshida et al., 1999).
It is not entirely clear whether and, if so, how ILCs are
embedded in the cutaneous immune network. Most data
currently available on the occurrence of ILCs in skin are
derived from the murine system. These point to the existence
of a small ILC population in normal skin and suggest an
involvement of ILC2s (Imai et al., 2013; Kim et al., 2013;
Roediger et al., 2013; Salimi et al., 2013) and ILC3s
(Pantelyushin et al., 2012) in mouse models of atopic
dermatitis (AD) and psoriasis (Pso), respectively. Our
knowledge about cutaneous ILCs in humans is currently
limited to a few studies conducted on single cell suspensions
isolated from skin (Dyring-Andersen et al., 2014; Salimi
et al., 2013; Teunissen et al., 2014; Villanova et al., 2014).
In this study, we sought to develop an in situ approach
allowing to detect and quantify ILCs in the skin, and,
importantly, to obtain a detailed topographic description of
these cells in the cutaneous microenvironment. By doing so,
we hoped to gain new insights into the role of ILCs in skin
biology under physiologic (normal human skin [NHS]) and
pathologic conditions (AD and Pso).
RESULTS
In situ identification of ILCs in human skin by a newly
developed two-step validation algorithm
Our first aim was to establish multicolor immunofluores-
cence (IF) in situ stainings for ILC subsets in human skin. We
used a microscope equipped with four filters capable of
discriminating DAPI, green fluorescent protein, Cy3, and Cy5
fluorescence.
A major requirement for the identification of ILCs is to
reliably exclude the expression of markers for any other
leukocyte population (Eberl et al., 2015), especially T cells.
We implemented this by including the relevant Lin markers
(i.e., for natural killer cells [CD16, CD94], Th cells (CD3,
CD4), B cells (CD20), Langerhans cells (CD1a), myeloid
dendritic cells (CD11c), monocytes (CD14), stem/endothelial
cells (CD34), neutrophils (CD15), plasmacytoid dendritic
cells (CD123), and mast cells (CD203c); Supplementary
Figure S1a online) in a single fluorescence channel.
Another channel was used for the identification of TFs that
are known to be a prerequisite for the development and
functional specialization of, on the one hand, different ILC
subpopulations (TBET for ILC1, GATA3 for ILC2, RORC, and
AHR for ILC3), and, on the other, Th-cell subtypes (Shih et al.,
2014). TF stainings were established using differentiated,
sorted Th-cell subsets (Supplementary Figure S1b and c).
GATA3 expression in keratinocytes (Kaufman et al., 2003)
served as an additional positive validation. We then followed
either of two staining strategies to unequivocally identify ILCs
in situ (Supplementary Table S1 online). In staining protocol
A, we deliberately counterstained with CD3 for the precise
exclusion of T cells and also for comparison of Th cell and
ILC subtypes. In staining protocol B, we included CD3 in the
lineage cocktail and used the third and remaining channel for
the depiction of CD45 or of prototypic ILC markers (CD127,
CD161, chemoattractant receptor-homologous molecule
expressed on T helper type 2, CD117, NKp44, and NKp46).
When examining tissue sections of NHS stained in this way
by conventional (i.e., eye based) epiluminescence micro-
scopy, we were able to occasionally identify Line TFþ cells
classified as ILCs but could not grasp the complete picture.
The paucity of ILCs and small field of views were the main
limiting factors. To overcome this problem, we scanned and
recorded the entire skin sections. We then used analysis
software (TissueFAXS) to apply an automated algorithm on
the scanned images measuring the mean IF intensities of the
stained markers in cells (identified with DAPI). Software
analysis allowed graphical depiction of the cells as events in
dot plots, allowing for gating strategies similar to conven-
tional FACS data assessment. Concerned that the slightest
“contamination” of the ILC gate with falsely positive cells
would bias results, we implemented a manual validation step
in our software. This algorithm cropped out all cells auto-
matically identified as ILCs on a single-cell basis (Figure 1a,
Supplementary Figure S2 online) allowing for the manual
reassessment of the different fluorescence channels and the
cells’ morphologic shape. Each cell was manually confirmed
or rejected by two observers (Figure 1a).
Using these measurements, we reliably identified a very
small population of LineCD3e cells expressing one of the ILC-
associated TFs (Figure 1a). Similar numbers of LineTFþ cells
were encountered when we used staining protocol B, in
which we assessed the expression of phenotypic ILC markers
in the LineCD3eTFþ cell population (Figure 1b). We were
thereby able to show that these cells are indeed ILCs, as evi-
denced by their positive expression of CD45, CD127, CD161,
or CRTH2 in the case of GATA3þILC2s (Figure 1beh and
Supplementary Figure S3aec online).
NHS harbors a sparse dermal ILC population
In a first set of experiments, we searched for ILCs residing in
epidermal, upper dermal, and hypodermal areas of NHS. This
analysis revealed a very sparse ILC population in the upper
dermis (Figure 2a), whereas hypodermal areas as well as the
epidermis were essentially devoid of CD45þLine cells
expressing ILC TFs (data not shown). Approximately half of
upper dermal ILCs belonged to the group 1 subset (TBETþ).
AHR-expressing ILC3s accounted for the second most
prominent subgroup in NHS followed by RORCþILC3s,
whereas hardly any GATA3þILC2s were identified. With the
exception of ILC2, this composition of ILC subpopulations
corresponds to what we and others observed using
FACS analysis of dermal cell suspensions (Supplementary
Figure S4 online).
Next, we sought to assess the spatial arrangement of ILCs
within the skin, especially their topographical distribution
with regard to the epidermis and to vascular structures.
Therefore, we developed and applied an algorithm calculating
the distance of each validated ILC to the epidermis aswell as to
the nearest blood vessel. These measurements (Figure 2b)
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revealed all ILCs to reside in a close (<30 mm) distance to the
epidermis. In contrast, ILCs did not occupy the perivascular
areas of the dermis (Figure 2c).
Diverse ILC subsets infiltrate cutaneous AD versus Pso
lesions
We next asked which changes in number and composition
the cutaneous ILC population would undergo in AD and Pso,
both inflammatory skin diseases driven by distinct T-cell
subsets (Nograles et al., 2009). When compared with NHS,
we found considerably increased numbers of ILCs
(Figures 2deg and 3a) in both AD and Pso skin lesions (both
n ¼ 13). In AD, this numerical increment mainly affected
GATA3þILC2s and AHRþILC3s (Figures 2g and 3a).
AHRþILC3s even represented the most prominent ILC subset
in AD. In Pso skin, by contrast, we observed an expansion of
Figure 1. In situ identification of ILCs. (a) Illustration of the gating strategy and validation algorithm. The ILC gating strategy was based on mean fluorescence
measurements. Line cells were gated for CD3eAHRþ cells. In the implemented validation step, each cell in the target gate (e.g., LineCD3eAHRþ) was
automatically cropped out and back-gated in the section, allowing a manual validation. Validated cells (n ¼ 3) were displayed in a “confirmation gate.”
(b) Alternative gating strategy (of the same sample, consecutive section) for LineCD127þAHRþ cells yielding the same number of confirmed ILCs. (ceh)
Representative image of IF multicolor stainings. The following marker combinations are displayed (all with DAPI): (c) CD45/AHR/Lin, scale bar¼ 5 mm, (d) CD3/
GATA3/Lin, scale bars ¼ 100 mm and 20 mm, (e) CD45/GATA3/Lin, (f) CD127/GATA3/Lin, (g) CD161/GATA3/Lin, and (h) CRTH2/GATA3/Lin, scale bar¼ 10 mm.
CRTH2, chemoattractant receptor-homologous molecule expressed on T helper type 2; IF, immunofluorescence; ILC, innate lymphoid cell; Lin, lineage.
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both ILC1s and ILC3s (Figures 2def and 3a), but hardly of
ILC2s.
When determining the topographical relationship be-
tween ILCs and the skin’s structural components, in AD and
Pso lesions, we found an almost random distribution of
these cells within the upper dermis with no signs of peri-
vascular clustering (Figure 3b and c). In fact, none of the
subsets was located in a close distance (Figure 3f) from
blood vessels but rather far (80 mm) or very far (150 mm)
away from them (Figure 3d). As far as their topographic
relationship to the epidermis is concerned, ILC subsets in
AD and Pso were found to reside at an intermediate distance
(50e60 mm; Figure 3e and f, Supplementary Figure S5
online) from the basal cell layer. With the exception of
RORCþILC3s, this distribution was similar to that observed
in NHS.
Figure 2. Distinct ILC infiltrates in NHS, AD, and Pso. (a) Results from the automated and validated quantitative in situ analysis of ILCs in the upper dermis of
abdominal NHS (n ¼ 10). Data are displayed as mean absolute numbers of cells  SD per mm basement membrane (BM). (b, c) Distance measurements in NHS
(n ¼ 10) of ILC subsets to (b) the epidermis and to (c) BVs. Data are shown as mean minimal distance (mm)  SD. (deg) Representative images of IF multicolor
stainings. The framed areas are displayed in a higher magnification in the lower panel of the respective images. (d) ILC3 (LineCD3eRORCþ) in Pso, scale bar ¼
100 mm, (e) CD117 expression in RORCþILC3s, scale bar ¼ 10 mm, (f) ILC1s (LineCD3eTBETþ) in Pso, (g) AHRþILC3s (LineCD3eAHRþ) in AD, scale bars ¼
100 mm and 20 mm. AD, atopic dermatitis; AHR, aryl hydrocarbon receptor; BV, blood vessel; IF, immunofluorescence; ILC, innate lymphoid cell; Lin, lineage;
NHS, normal human skin; Pso, psoriasis.
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ILCs are in intimate contact with T cells
On the basis of the observation that murine ILCs engage in a
biologically relevant functional interaction with T lympho-
cytes (Halim et al., 2014), we studied the localization of
human skin ILCs vis-à-vis their T-cell counterparts.
Strikingly, our analyses revealed a close proximity
(maximal distance: 30 mm) between ILCs and T cells in both
AD and Pso (Figure 4a and b, Supplementary Figure S6aec
online). Even in NHS, ILCs were found not further than
70e80 mm away from T cells (Figure 4b). A particularly
intimate relationship (<10 mm) was observed between ILC1s
and T cells in Pso lesions.
We next investigated the contribution of T cells to the
closest cellular environment of ILCs. We developed an
analysis algorithm for this purpose, in which the whole
cellular content of the upper dermal area was screened to
calculate the percentage of T cells in a defined radius
around validated ILCs (Figure 4c). Direct cell-cell contact
Figure 3. No perivascular ILC clustering in Pso and AD lesions. (a) Results from the in situ analysis of ILCs in AD and Pso skin lesions (both n ¼ 13) as well as in
abdominal NHS (n ¼ 10). (b) Illustration of the vessel detection algorithm used: detected vessels (white areas, upper row) and “screening” (color gradient, lower
row) of their surroundings for ILCs, scale bars ¼ 100 mm. (c) Distances between ILCs and the nearest BV in AD, Pso (both n ¼ 13) and NHS (n ¼ 10). (d, f)
Scheme showing a distance scale as well as the terms used in the text to describe/interpret distance measurements. (e) Distances between ILCs and the epidermis
in AD, Pso (both n ¼ 13) and NHS (n ¼ 10). *P < 0.05, **P < 0.01, ***P < 0.001. AD, atopic dermatitis; BV, blood vessel; ILC, innate lymphoid cell; NHS,
normal human skin; Pso, psoriasis.
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corresponded to an analysis radius of 3 mm. The “inner
circle” of the ILC microenvironment was arbitrarily defined
with a 9 mm radius (Figure 4d). The percentage of T cells
directly adjacent to all ILCs ranged between 3% and 30%,
with the notable exception of AHRþILC3s of AD skin,
which were surrounded by a dense mantle of T cells
(Figure 4e, Supplementary Figure S6def). We ensured that
our results were not biased by overlapping cells; the
analysis of a 3 mm and a 5 mm (corresponding to our
section thickness) radius yielded essentially the same
results (data not shown). The proportion of T cells within
the radius of 9 mm ranged between 15% and 50% and did
not differ greatly between the various ILC subsets
(Figure 4f).
ILC and Th-cell patterns in AD and Pso are similar but not
identical
The close vicinity between ILCs and T cells prompted us to
ask whether the TF-based composition of ILCs mirrored the
one of their Th cell counterparts in AD and Pso. The
Figure 4. Close proximity between
ILCs and T cells. (a) Distance
measurements between the different
ILC subsets and T cells in AD, Pso
(both n ¼ 13) and NHS (n ¼ 10).
(b) ILC2 (LineCD3eGATA3þ)
surrounded by two T cells (CD3þ),
scale bar ¼ 20 mm. (c) Scheme of the
applied software algorithm layer
assessing the cellular environment of
ILCs. The entire cellular content of the
upper dermis was screened and
assessed as to its distance to validated
ILCs. Scale bars ¼ 50 mm and 10 mm.
(d) The cellular environment was
assessed in a radius of 3 mm (direct
cell-cell contact) and 9 mm (closest
cellular environment), scale bar ¼
5 mm. (e, f) Percentage of T cells
among total cells in an environmental
radius of (e) 3 mm or (f) 9 mm around
validated ILCs for AD, Pso (both n ¼
13) and NHS (n ¼ 10). *P < 0.05,
**P < 0.01, ***P < 0.001. AD, atopic
dermatitis; GATA3, trans-acting T-cell-
specific transcription factor GATA-3;
ILC, innate lymphoid cell; Lin,
lineage; NHS, normal human skin;
Pso, psoriasis.
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analysis of IF stainings for Th-cell subsets (Figure 5a)
revealed GATA3þTh2 cells to clearly predominate the
CD3þCD4þ T-cell infiltrate in AD (see also Figure 5b).
AHRþ, putative Th22 cells were the second most prominent
subset in AD, followed by TBETþTh1 and RORCþTh17
cells. Pso lesions, on the other hand (Figure 5a, c, and d),
contained considerable numbers of Th1 as well as Th17
cells.
A comparison of the relative ILC and Th-cell subset
composition in NHS, AD, and Pso skin (Figure 5c) showed
no absolute correlation between TF-defined ILC and Th-cell
lineages. In AD, Th2 cells and AHRþILC3s predominated
within the Th-cell and ILC infiltrate, respectively. In Pso,
we found an RORCþ/AHRþILC3 predominance among
ILCs juxtaposed to a Th17 pattern among CD4þ T lym-
phocytes. TBET expression was prevailing in both ILCs and
T cells of NHS. A sizable proportion of AHR-positive cells
were only found in the ILC, but not the Th-cell fraction of
NHS.
Next, we were interested in whether T cells in close
proximity (9 mm and 3 mm) to ILCs belong to the
respective “mirror” subsets. Overall, this was surprisingly not
the case (Figure 5e and f, Supplementary Figure S6). Only
3e5% of the cells surrounding ILCs belonged to their
respective adaptive T-cell counterparts. Exceptions to this
were Th2 cells/ILC2s in AD; in both a 3 mm and 9 mm radius,
we found them to make up for 10e20% of all neighboring
cells.
Figure 5. Characteristic Th-cell
infiltrates in AD versus Pso skin
lesions. (a) Automated quantitative in
situ analysis of the Th-cell infiltrate in
AD and Pso skin lesions as well as in
NHS. (b) Representative image of a
multicolor IF staining of Th2 cells in
AD (CD3þCD4þGATA3þ), scale
bars ¼ 100 mm and 50 mm. (c) Pie
charts displaying the relative
composition of ILC and Th-cell
populations in AD, Pso and NHS,
respectively. (d) Representative image
of a multicolor IF staining Th17 cells
in Pso (CD3þCD4þRORCþ), scale
bars ¼ 100 mm and 50 mm. (e, f)
Percentage of the respective T-cell
subsets among total cells in an
environmental radius of 3 mm or 9 mm
around validated ILCs for AD, Pso
(both n¼ 13) and NHS (n¼ 10). **P<
0.01, ***P < 0.001. AD, atopic
dermatitis; GATA3, trans-acting T-cell-
specific transcription factor GATA-3;
IF, immunofluorescence; ILC, innate
lymphoid cell; NHS, normal human
skin; Pso, psoriasis; Th, T helper.
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DISCUSSION
Although previous human studies have used flow cytometric
approaches to identify ILCs in peripheral organs, our aim was
to provide an in situ characterization of ILCs in skin under
homeostatic (NHS) and inflammatory conditions (AD and
Pso). We established an IF staining panel for ILCs and
developed a computed analysis algorithm allowing enumer-
ation and topographic assessment of ILCs on a single-cell
basis. Our analysis of ILC subpopulations was based on the
fact that the expression of certain TFs is a prerequisite for the
differentiation of ILCs into distinct lineages (Eberl et al.,
2015). The same TFs are responsible for the polarization of
Th-cell subsets (Shih et al., 2014), allowing us to subse-
quently compare these two lymphocyte populations in situ. A
limiting factor in choosing this approach is the known plas-
ticity of ILCs and in part overlapping TF expression. GATA3,
for example, is not only expressed by ILC2 and Th2 cells but
is also required early during ILC lineage specification and
ILC3 homeostasis (De Obaldia and Bhandoola, 2015; Yagi
et al., 2014). RORCþ/AHRþILC3s can differentiate into
TBETþILC1s under special conditions (Bernink et al., 2013).
In addition, some controversy as to the assignment of ILC3 to
a distinct lineage still exists (Hughes et al., 2014). These ca-
veats should be kept in mind when snap-shot analyzing ILC
subsets either by FACS or IF.
Our investigations revealed a very sparse ILC population in
NHS consisting almost exclusively of TBETþILC1s and
AHRþILC3s. In contrast, inflamed skin harbored much larger
numbers of ILCs. AD was found to mainly host AHRþILC3s
and GATA3þILC2s. In Pso lesions, TBETþILC1s and ILC3s
predominated, whereas GATA3þILC2s were almost absent.
Topographically, ILCs were mainly clustered beneath the
dermoepidermal junction and exhibited a very close spatial
relationship to T lymphocytes.
Some of our data on NHS, that is, the presence of ILC3s
and ILC1s, correspond to those obtained by Teunissen et al.
and Villanova et al. in flow cytometric studies. In contrast,
these authors as well as our own group (Supplementary
Figure S4a) identified approximately 10% of all ILCs in
dermal cell suspensions as ILC2s by FACS analysis, but we
hardly found any GATA3þILC2s in tissue sections by IF. Kim
et al. (2013), in contrast, were not able to demonstrate
CRTH2 expression on ILC2s in NHS or patients with AD by
FACS. The reasons for this discrepancy are not entirely un-
derstood and may include: (i) differences in ILC density in
different body locations, as it has been reported for T cells
(Foster et al., 1990); (ii) phenotypic alterations during isola-
tion and purification procedures; (iii) differences in the
sensitivity of the staining and detection method. The high
threshold of detection applied in our study together with
lower mean fluorescence intensities measured by IF in
comparison to FACS and the paucity of ILCs in NHS may
have led to a slight underestimation of the actual number of
ILCs in NHS.
The role of ILCs in NHS escapes us at the present time.
Intriguingly, certain ILC3s are involved in fetal development
of secondary lymphoid tissues (Yoshida et al., 1999). One
could speculate that ILCs, in addition to forming a first line of
antimicrobial defense (Klose et al., 2014), contribute to skin
histogenesis/organogenesis. This raises questions about the
time point at which ILCs start populating this organ and
whether in adults ILCs are permanently residing/renewing in
skin or transiting from the blood. The previously described
expression of cutaneous lymphocyte-associated antigen on
circulating ILCs suggests their entry from blood (Teunissen
et al., 2014; Villanova et al., 2014). Further studies are
needed to investigate the time of entry of ILCs into the skin
and their possible role in antimicrobial defense or as pro-
moters of tissue remodeling/repair (Dudakov et al., 2015).
As opposed to the rare occurrence of ILCs in NHS, we
found AD lesions to be prominently populated by
AHRþILC3s and GATA3þILC2s. Their adaptive Th-cell
counterparts consisted mostly of Th2, and, to a lesser
extent, of Th22 cells.
Concerning ILC2s, our results are in keeping with obser-
vations by other investigators demonstrating this leukocyte
subset in cell suspensions isolated from human AD lesions
and murine AD-like skin (Bonefeld and Geisler, 2016).
Concerning the latter, mostly keratinocyte-derived cytokines
(e.g., thymic stromal lymphopoietin) activate ILC2s. Their
main effector function in AD seems to be the release of cy-
tokines further accentuating epidermal barrier breaching
(Salimi et al., 2013). Particularly striking regarding the po-
tential role of ILCs in AD was our observation that among T
cells directly adjacent to ILC2s, the majority belonged to the
Th2 subset. This may indicate that ILC2s modulate the Th2
response in AD. Studies in murine allergic asthma models
support a Th2-promoting role of ILC2s (Halim et al., 2014,
2016).
An unexpected finding of our investigations was the
identification of substantial amounts of AHRþILC3s in AD
skin. The TF AHR is known to be not only an important
modulator of IL-22 production of ILC3s but is also necessary
for their development and maintenance (Cella and Colonna,
2015; Hughes et al., 2014; Mjosberg et al., 2012). In analogy
to the role of Th22 cells in AD (Czarnowicki et al., 2015;
Nograles et al., 2009), IL-22 producing ILC3 could be core-
sponsible not only for inflammation but also for lichen-
ification of the skin, a hallmark of AD (Zheng et al., 2007).
The question whether AHRþILC3s and ILC2s act in concert
with their Th-cell counterparts and thus, to which extent they
contribute to the pathogenic process in a given situation,
remains to be elucidated. Because cytokine release by ILCs
occurs in an antigen-independent fashion, one may hypoth-
esize that ILCs play an important role especially in the
intrinsic form of AD, which, as opposed to the extrinsic one,
is not associated with allergen sensitization and/or elevated
IgE levels (Weidinger and Novak, 2016).
When compared with NHS, Pso skin sections were found
to harbor substantially increased numbers of ILC1s as well as
of ILC3s. ILC2s, in contrast, were only rarely encountered.
Again, all ILCs showed a preferential topographic distribution
near the epidermis. Strikingly, all ILC subsets were found to
reside close to T lymphocytes, which, as reported by others,
consisted mainly of Th1 and Th17 cells (Kryczek et al., 2008;
Lowes et al., 2008).
As far as the ILC3 subset is concerned, our in situ data are
complementary to FACS studies published previously
(Dyring-Andersen et al., 2014; Teunissen et al., 2014;
Villanova et al., 2014) pointing to the existence of an ILC3
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population in Pso skin. In contrast to findings by others
(Teunissen et al., 2014), we observed an abundance of
TBETþILC1s in cutaneous Pso lesions. Although we cannot
exclude the possibility that these cells directly originate from
the common ILC precursor, we should not forget that ILC3s
can downregulate RORC and, reciprocally, increase the
expression of TBET. Concurrent with these changes, the cells
acquire the capacity to produce IFN-g and tumor necrosis
factor-a at the expense of IL-17 and IL-22 secretion (Serafini
et al., 2015). It is currently unknown whether TBETþILC1s
play a disease-promoting role in Pso. A possible argument
against this possibility is the recently published finding that
neutralization of IL-17A is even more efficient in the treat-
ment of moderate-to-severe plaque Pso than the blockade of
IL-12/IL-23p40 (Thaci et al., 2015). Whether TBETþILC1s
may have perhaps a dampening effect on their neighboring
Th17 populations remains to be determined.
In summary, we have developed an algorithm-based in situ
analysis technique enabling us to reliably quantify and,
importantly, topographically characterize ILCs in human
skin. As opposed to flow cytometric studies conducted so far,
our approach additionally allows us to accurately describe
the structural and cellular environment of ILCs on a single-
cell basis. Deeper insights into the nature of cutaneous ILC
subpopulations and their surroundings in human skin will
constitute a solid basis for future analyses of the functional
relationship between ILCs and other constituents of the
cutaneous immunological microcosmos.
MATERIALS AND METHODS
Study design, skin sampling, and processing
We collected lesional biopsies from patients with Pso (n ¼ 13) and
AD (n ¼ 13) treated at Division of Immunology, Allergy and Infec-
tious Diseases, Dermatology Department of Vienna’s Medical Uni-
versity, or at the Dermatology Department of the University Hospital
Zurich between 2009 and 2015. NHS (n ¼ 10) was obtained as
tissue discarded from abdominoplasties. Patient characteristics are
displayed in Supplementary Table S2 online. Details of skin sam-
pling and processing are given in the Supplementary Material and
Methods online.
The study was approved by the Ethics Committees of the Medical
University of Vienna (EK700/2009) and of the University of Zurich
(EK 647/2006) and conducted according to the Declaration of Hel-
sinki. All study subjects participated voluntarily and gave written
informed consent.
IF stainings, section scanning
A complete list of antibodies used in this study is shown in
Supplementary Table S3 online. Details of the performed multicolor
IF stainings and the scanning of sections are given in the
Supplementary Material and Methods.
Images displayed in the figures were taken with Zeiss LD Plan-
Neofluar objectives (primary objective 20/0.4, ocular
objective 10) using a PC pixelfly camera (Carl Zeiss Inc, Jena,
Germany) and exported from the StrataQuest software as TIFF im-
ages. Some images were processed in Adobe Photoshop CS6 (Adobe
Systems, San Jose, CA).
Automated analysis of IF stainings, validation step
The computed analysis of skin sections was performed using Stra-
taQuest V64 (TissueGnostics GmbH, Vienna, Austria). A detailed
description of the created algorithms and analysis layers is given in
the Supplementary Material and Methods and Supplementary
Figure S2. Briefly, a first set of analysis layers was applied to auto-
matically differentiate between epidermal, upper dermal, and hy-
podermal areas and detected regions manually validated. ILCs were
gated based on the IF mean intensity of the respective channels;
cutoffs were adapted to isotype controls.
A specific tool was developed to manually validate/reject all
events (ILCs) on a single cell basis in the gates of interest regarding
their staining as well as the cell shape. The validation step was
performed by two independent observers.
Topographic analyses
Two additional analysis layers were created in the program to
explore the topographic distribution of manually validated cells. In
the first topography layer, the shortest distance of each ILC nucleus
in the dermal area to (i) the epidermis and to (ii) other cells of interest
was calculated (precision: 0.31 mm). The second topography layer
calculated the distance between validated ILCs and the closest blood
vessel. Blood vessel detection was based on their morphological
shape (i.e., endothelial-shaped cells surrounding a lumen) and the
mean intensity of green fluorescent protein expression (CD34
included in the lineage cocktail) followed by manual corrections.
Proximity analysis
This algorithm layer was created to more precisely assess the cellular
environment of validated ILCs by screening the complete cellular
content of the upper dermis with regard to its distance to every
validated ILC. The percentage of T cells in a defined radius (3 mm
and 9 mm) of validated ILCs was calculated.
Statistical analysis
All statistical analyses were performed using GraphPad Prism soft-
ware (Graphpad, San Diego, CA). For comparison of means between
more than two groups (NHS, AD, and Pso), one-way analysis of
variance with the Tukey post-test was used for all experiments. A P
value <0.05 was considered statistically significant.
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Cancer Therapy: Clinical
Cytotoxic Cutaneous Adverse Drug Reactions
during Anti-PD-1 Therapy
Simone M. Goldinger, Pascale Stieger, Barbara Meier, Sara Micaletto,
Emmanuel Contassot, Lars E. French, and Reinhard Dummer
Abstract
Purpose: Immunotherapy has experienced impressive prog-
ress in cancer treatment. Antibodies against PD-1 improved
survival in different types of cancer including melanoma. They
are generally well tolerated. However, skin toxicities including
pruritus, rashes, and vitiligo are reported. Although frequent,
they have not been characterized further yet. In this analysis, we
aimed to systematically assess and characterize the adverse
cutaneous reactions observed in patients with melanoma trea-
ted with anti-PD-1 antibodies.
Experimental Design: Patients with melanoma were treated
with anti-PD-1 antibodies within clinical trials and an early-
access program. Adverse cutaneous eruptions that emerged in
our melanoma patient cohort were systematically investigated
and classified using histology and gene expression profiling in
comparison with maculopapular drug rash, cutaneous GVHD,
and the severe drug eruption toxic epidermal necrolysis
(TEN).
Results: Between February 2013 and September 2015, 68
patients with stage IV melanoma were treated at the University
Hospital Zurich (Zurich, Switzerland); 15 patients (22%) devel-
oped cutaneous reactions and 10 (15%) vitiligo. The cutaneous
reactions ranged from small erythematous papules with mild
pruritus to disseminated erythematous maculopapular rashes
(MPR) without signs of epidermal involvement to severe MPRs,
including epidermal detachment and mucosal involvement.
Although skin involvement varied from mild rash to bullous
drug eruptions, gene expression profiling pathogenically classi-
fied all investigated cases as TEN-like reactions.
Conclusions: As predicted by the PD-1 knockout mouse, anti-
PD-1 antibodies frequently cause adverse cutaneous reactions.
Gene expression profiling reminds in all cases of a TEN-like
pattern, suggesting that PD-1/PD-L1 interaction is required to
preserve epidermal integrity during inflammatory skin reactions.
Clin Cancer Res; 22(16); 4023–9. 2016 AACR.
Introduction
Antibodies against PD-1, a checkpoint in the effector phase of
cytotoxic T cells, have been successfully used in cancer immuno-
therapy (1–3). Through the binding to PD-1, its ligands, namely
PD-L1 and PD-L2, inhibit T-cell–mediated immune responses.
By preventing the binding of PD-L to PD-1, the FDA-approved
antibodies, pembrolizumab and nivolumab, promote T-cell–
mediated cytotoxic responses, which result in tumor regression
in a variety of cancers (2). In several randomized pivotal studies,
pembrolizumab and nivolumab demonstrated improved over-
all response rates and progression-free survival compared with
chemotherapy or the anti-CTLA-4 antibody ipilimumab (4–7).
Besides efficacy, the introduction of anti-PD-1 antibodies led to
a new benchmark for treatment tolerability in cancer being a
treatment with very few adverse events. Adverse cutaneous reac-
tions have however been reported. These include skin exanthe-
mas with a frequency of 10% to 25% and vitiligo in 9% to 11%
of the treated patients (2, 4, 5). Hua and colleagues hypothesize
that vitiligo is associated with a favorable outcome of anti-PD-1
therapy (8). Moreover, one case of bullous pemphigoid in asso-
ciation with pembrolizumab (9) and one case of psoriasiform
exanthema under nivolumab (10) have been published. The ad-
verse cutaneous reactions observed under the treatment with anti-
PD-1 antibodies have not been characterized in detail so far.
Stevens–Johnson syndrome (SJS) and toxic epidermal necro-
lysis (TEN) are severe cutaneous drug eruptions characterized by
widespread macules, papules, and/or targetoid lesions with vary-
ing degrees of epidermal necrolysis clinically presenting as skin
detachment and/or bullous skin lesions with mucosal erosions
(11). Common drugs inducing SJS/TEN include allopurinol,
trimethoprim–sulfamethoxazole, carbamazepin, lamotrigine,
nevirapine, NSAIDs, phenobarbital, and phenytoin (12). The
molecular events that cause potentially fatal SJS and TEN are
only partially understood, although "drug"-specific adaptive
immune responses in the effector phase of TEN are well docu-
mented (13). In the skin, T-cell–mediated immune responses
occurring during SJS/TEN result in a massive keratinocyte apo-
ptosis mediated by cytolytic molecules, including FasL (14),
perforin/granzyme B (15), annexin A1 (16), and granulysin
(17). Histologically, SJS and TEN are characterized by full-thick-
ness epidermal necrolysis due to extensive keratinocyte apoptosis
associated with varying degrees of inflammation and epidermal
infiltration by CD8þ lymphocytes.
In this study, we aimed to systematically assess and character-
ize the adverse cutaneous reactions observed in patients with
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advanced melanoma treated with anti-PD-1 antibodies using
gene expression profiling and compared the data with other
clinical types of drug eruptions.
Patients and Methods
Patients with advanced melanoma were treated with either
the anti-PD-1 antibody pembrolizumab (2 or 10 mg/kg) or with
nivolumab (3 mg/kg) within clinical trials (clinicaltrials.gov
NCT01704287, NCT01721746, and NCT02156804; refs. 4, 7)
and an early-access program. The first 68 patients with melano-
ma treated with pembrolizumab or nivolumab at the University
of Zurich (Zurich, Switzerland) were systematically investigated
for adverse skin reactions by board-certified dermatologists ex-
perienced in immunotherapy and familiar with associated ad-
verse events (S.M. Goldinger and/or R. Dummer).
Complete and accurate skin examinations were performed
before and during immunotherapy. Previously selected untreated
skin eruptions of eight patients emerging during therapy were
biopsied and analyzed by histology. The decision to take a biopsy
was based on whether the lesion was new (i.e., not apparent prior
treatment start), on the severity (grade 2 or greater), on the
localization and distribution (favoring multiple and disseminat-
ed lesions), and on the clinical characteristics (palpable or scaling
presentation). In general, the most infiltrated lesion was chosen
andbiopsied provided patient's consent and that the lesionwas in
a region of the body that allowed proper wound healing. Expres-
sion of PD-1 on skin-infiltrating T cells (eBioscience) and PD-L1
(Immunobiology Yale, Yale University, New Haven, CT) on
keratinocytes at the foci of lymphocytic epidermal infiltration
was assessed by IHC.
Gene expression analyses of five of these eight skin biopsies
during anti-PD-1 therapy with pembrolizumab were in addition
analyzed and compared with expression profiles of skin biopsies
from patients with maculopapular rashes (MPR; n ¼ 8), SJS/TEN
(n ¼ 5), and cutaneous GVHD (n ¼ 9). RNA was isolated from
patients' skin (n¼ 5) and from healthy control skin (n¼ 4) using
a Qiagen RNeasy Kit (Qiagen) following the manufacturer's
instructions, and total RNAwas converted into cDNA by standard
reverse transcription using a RevertAid RT Reverse Transcription
Kit (Thermo Scientific). Quantitative PCR was performed using
Power SYBR Green PCRMaster Mix (Applied Biosystems). Primer
sequences were obtained from http://pga.mgh.harvard.edu/pri-
merbank/. The real-time PCR included an initial denaturation
at 95C for 10 minutes, followed by 40 cycles of 95C for
30 seconds, 56C for 1 minute, and 72C for 1 minute and one
cycle of 95C for 1 minute, 56C for 30 seconds, and 95C for
30 seconds. Moreover, we performed gene expression arrays
(Affymetrix) on the skin of patients with MPR (n ¼ 8), patients
with SJS/TEN (n ¼ 5), patients with GVHD (n ¼ 9), and healthy
donors (n ¼ 8) as controls. Healthy skin was obtained from
healthy individuals undergoing plastic surgery. All human skin
biopsies were collected with informed written consent upon
the approval of local ethical committees and were conducted
according to the Declaration of Helsinki Principles (KEK nr. 647).
On the basis of the results of the gene expression arrays, we
selected a set of genes that could be used as a specific signature
for TEN as opposed toMPR and GVHD (Fig. 2A). Using quantita-
tive RT-PCR, we determined the expression levels of the gene set
specific for SJS/TEN in the skin of patients with an adverse
cutaneous reaction occurring during anti-PD-1 therapy.
Results
Between February 2013 and September 2015, 68 patients
were treated with either pembrolizumab (2 and 10 mg/kg;
every 3 weeks) or nivolumab (3 mg/kg; every 2 weeks)
in different clinical trials (clinicaltrials.gov NCT01704287,
NCT01721746, and NCT02156804; refs. 4, 7) and an early-
access program. Of the first 68 patients with stage IV melanoma
treated with pembrolizumab (n ¼ 54) or nivolumab (n ¼ 14)
at the University Hospital of Zurich (Zurich, Switzerland), 15
patients (22%) developed a cutaneous inflammatory reaction,
and 10 (15%) developed vitiligo. Clinically, the adverse cuta-
neous reactions ranged from small erythematous papules with
mild pruritus to disseminated erythematous MPRs without
major clinical signs of epidermal involvement to severe MPRs,
including epidermal detachment and mucosal involvement
(Table 1). Histology performed on selected lesional skin biop-
sies of eight patients at the onset of the adverse cutaneous
reaction revealed different manifestation grades of apoptotic
keratinocytes and even focal full-thickness necrosis of the
epidermis in two cases in the histology (Table 1). In particular,
a 77-year-old patient presented with a generalized unspecific
MPR predominantly affecting the trunk with focal areas of
epidermal detachment a few days after the first pembrolizu-
mab infusion (Fig. 1A, <10% of the body surface area). His-
tology showed epidermal damage with apoptotic keratino-
cytes, subepidermal lymphocytic infiltrates, and dermo-epider-
mal cleavage (Fig. 1B). One week later, mucosal involvement
and genital ulcerations developed. Taken together, these fea-
tures led to a diagnosis of SJS, and pembrolizumab therapy was
discontinued.
Skin biopsies from six patients were also analyzed by IHC and
revealed in all cases an accumulation of CD8þ cells at the dermo-
epidermal junction and some CD8þ exocytosis within the epi-
dermis, as well as keratinocyte apoptosis suggestive of a cytotoxic
etiology. Expression of PD-1 on skin-infiltrating T cells and
keratinocytes at the foci of lymphocytic epidermal infiltration
was also assessed by IHC (Fig. 1C andD).Despite topical steroids,
the lesions of this patient subsequently evolved into persistent
polygonal flat erythematous papules, clinically suggestive of
Translational Relevance
Antibodies against PD-1 have revolutionized cancer immu-
notherapy. This article describes relevant skin toxicities emerg-
ing upon treatment with antibodies against PD-1, such as
nivolumab andpembrolizumab. Skin toxicities were classified
using histology and gene expression profiling in comparison
with mild maculopapular drug rashes and severe drug erup-
tions, such as toxic epidermal necrolysis (TEN). Although the
clinical picture was variable, ranging frommild to severe, gene
expression profiling resembled in all cases to severe cytotoxic
SJS/TEN–like patterns. This suggests that the PD-1/PD-L1
interaction is involved in the preservation of epidermal integ-
rity during inflammatory skin reactions. We advocate a careful
examination of the skin of patients treated with immunother-
apy in the near future, as these adverse cutaneous reactions can
imply a loss of epidermal integrity.
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lichen planus (Fig. 1E). Accumulation of cytotoxic CD8þ lym-
phocytes in the junction zone and in the epidermis, causing
apoptotic cell death of keratinocytes, classical for lichen planus,
was confirmed by histology (Fig. 1F). PD-L1 expression on
keratinocytes was clearly detectable by IHC in the proximity of
T cells (Fig. 1G and H).
In all cases, none of the concomitant medications taken by
patients had been recently started or were known to cause SJS/
TEN (Table 1). Furthermore, lymphocyte transformation tests
to the concomitant medication taken by patient 1 did not pro-
vide evidence for a "drug"-specific immune response (data not
shown; Table 1).
Treatment included systemic steroids (prednisone 1 mg/kg,
tapered for 4 weeks), systemic steroids (over a course of 4 weeks),
disinfectant agents when necessary, and rehydration of the skin.
Treatment with pembrolizumab could be continued in six of
eight cases and did not further affect the skin.
Gene expression profiling of RNA extracted from lesional skin
of validated cases of MPR (eight cases), SJS/TEN (five cases), and
cutaneous GVHD (nine cases) enabled us to identify a set of 18
genes for which the expression levels enable differentiation
among the three diagnostic categories (Fig. 2A). Analysis of the
level of expression of these 18 geneswas performed in the lesional
skin biopsies of five patients and revealed a gene expression
profile reminiscent of SJS/TEN (Fig. 2B). Both SJS/TEN skin
(n ¼ 5) and skin of five patients presenting an adverse cutaneous
reaction upon anti-PD-1 therapy had significant upregulation of
PI3, SPRR2B, GZMB, CXCL9, CXCL10, and CXCL11; whereas
expression of DSC3, LOR, FLG, and KRT1 were similar to those
in healthy skin. Differences were seen in the expression levels of
CCL27, NURR1, GNLY, FASLG, and PRF1, which were all up-
regulated in the skin of the five anti-PD-1 patients, but not in
SJS/TEN skin (Fig. 2B).
Taken together, our clinical, histologic, immunohistologic, and
gene expression analyses provide evidence that the adverse
cutaneous reactions observed in patients treated with anti-PD-1
antibodies are reminiscent of SJS/TEN and point to a role for PD-1
in regulating cytotoxic T-cell responses in the skin.
Discussion
The cross-talk between cancer cells and immune cells of the
tumor microenvironment is crucial for the outcome of antitumor
immune responses and immunotherapy. In various cancers, these
interactions often result in a local immunosuppression, resulting
in the escape of tumor cells from immunosurveillance. The use of
checkpoint inhibitors, such as antibodies to PD-1, leads to sig-
nificant clinical benefits by inducing advanced and metastatic
tumor regression. Although anti-PD-1 antibody therapy is safe
and well tolerated in patients with melanoma (2, 18–20), ad-
verse cutaneous reactions have been reported (2, 4, 9, 10, 21).
Here, we report and describe adverse cutaneous reactions during
anti-PD-1 immunotherapy with pembrolizumab. In 22% of the
patients, which is more than reported in clinical trials (4, 7, 21),
we observed inflammatory skin lesions ranging from mild
MPRs, typically associated with scaling and/or lichenoid lesions
to very severe SJS-like skin lesions that slowly improved and
resulted in a chronic lichen planus.
Clinical and histologic features of the lesions strikingly resem-
ble the findings reported inmice with a disrupted PD-1 gene (22).
These mice develop a lupus-like inflammatory syndrome with
proliferative glomerulonephritis, arthritis with sometimes
granulomatous inflammation and skin lesions, reported as "der-
matitis-like lesions, necrotic lesions, and erythema" (22). The
histologies of the skin of these mice present features compatible
with lichen planus, including acanthosis, hypergranulosis, and
apoptotic keratinocytes, together with a lymphocytic infiltrate of
the grenz zone of the basalmembrane resulting in a vacuolization
and, sometimes, split formation (22).
The histologic analysis of these human adverse cutaneous
reaction cases demonstrated signs of a cytotoxic skin eruption
characterized by an accumulation of CD8þ T cells at the dermo-
epidermal junction andCD8þ T-cell exocytosis into the epidermis
with apoptotic keratinocytes. These features can also be observed
in severe immune-mediated skin diseases, such as acute GVHD
and SJS/TEN. Gene expression analysis of lesional skin from anti-
PD-1–treated patients revealed a gene expression profile resem-
bling SJS/TEN with an upregulation of major inflammatory
chemokines, such as CXCL9, CXCL10, and CXCL11, of cytotoxic
mediators such as PRF1 and GZMB and the pro-apoptotic mol-
ecule FASLG, as well as an upregulation of PD-L1, which was
confirmed by IHC in three cases. In contrast, the expression
pattern of selected genes in the skin lesions of anti-PD-1–treated
patients was different from that seen in acute GVHD and MPR.
Therefore, clinical, histologic, immunohistologic, and gene
Figure 1.
Clinical and histologic presentation of a patient with metastatic melanoma
developing a severe adverse cutaneous reaction (ACR) upon treatment
with pembrolizumab. A–D, SJS. E–H, lichen planus. A, clinical features
of SJS. B, histology of SJS (hematoxylin–eosin stain). C, PD-1 stain of SJS.
D, PD-L1 stain of SJS. E, clinical features of lichen planus. F, histology
of lichen planus. G, PD-1 stain of lichen planus. H, PD-L1 stain of lichen planus.
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expression analyses strongly suggest that, at least in somepatients,
anti-PD-1 antibody can induce SJS/TEN–like adverse cutaneous
reactions.
The intensity of the immune-mediated tissue damage varies
and is interindividual, a possible explanation could be the genetic
predisposition and variation based on SNPs in genes related to
immune functions. These genetic background alterations can
cause differences in the susceptibility to develop cutaneous drug
reactions.
The exact pathomechanism of the adverse cutaneous reac-
tions occurring upon pembrolizumab and nivolumab therapy
remains to be elucidated. Although vitiligo can be considered as
a successful (re)-activation of T cells with a repertoire specific to
melanocyte antigens, the induction of a cytotoxic response to
Figure 2.
Gene expression profiling.A, themRNA expression levels of 6,564 different genesweremeasured in lesional skin of MPR; n¼ 8), TEN/SJS (n¼ 5), and GVHD (n¼ 9)
patients and skin of healthy donors (n ¼ 8) using the Affymetrix Human Transcriptome Array 2.0. The relative expression levels were normalized to healthy
skin and indicated as fold change (2
DDCt).B, themRNAexpression levels of selected genesweremeasured in lesional skin of patients developing a skin drug eruption
under anti-PD-1 therapy (n ¼ 5). The relative expression levels were normalized to healthy skin (n ¼ 4) and indicated as fold change (2
DDCt). Statistical
analyses were performed using the Student t test.  , P  0.05;  , P  0.01;  , P  0.001;  , P  0.0001.
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keratinocytes was not expected and is indicative of the activation
of T cells with non-melanoma–derived self-antigen specificity
(ies). Interestingly, both vitiligo and/or cutaneous reactions
emerging during nivolumab treatment in patients with melano-
ma have recently been reported to be associated with overall
survival (23). As a consequence, cutaneous reactions during anti-
PD-1 treatment could potentially be used as biomarkers in the
therapy. Although larger prospective analyses are still needed to
validate this association, detection and diagnosis of cutaneous
reactions during anti-PD-1 therapy gain further importance in this
context. By inhibiting T-cell activation and sustaining Tregs (24),
the PD-1/PD-L pathway plays amajor role in peripheral tolerance,
including transplant (25) and feto-maternal tolerance (26). The
concept of a tolerogenic role for PD-1/PD-1L has emerged from
observations that PD-1–deficient mice develop autoimmune
pathologies (27), including lichenoid reactions (22). One could
hypothesize that, at the steady state, PD-1/PD-L interactions are
crucial for the homeostasis of T cells in the skin and for preventing
severe skin-directed inflammatory reactions from occurring. In
line with this, it has been recently reported that in amousemodel
that PD-L1 expressed on keratinocytes presenting self-antigens,
regulates autoreactive CD8þ T-cell activity and prevents the devel-
opment of cutaneous autoimmune disease (28). The reason for
which cutaneous adverse events in anti-PD-1–treated patients can
vary from vitiligo to SJS-like reactions remains unknown, and
larger series of subjects would be required to assess this. A detailed
characterization of the T cells causing damage to healthy tissues in
patients treated with anti-PD-1 antibodies, as well as comple-
mentary skin investigations in patients without adverse skin
reactions, would be of interest for a better understanding and,
ultimately, the prevention of such severe forms of adverse cuta-
neous reactions.
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 Severe Sweet’s Syndrome with Elevated 
Cutaneous Interleukin-1β after Azathioprine 
Exposure: Case Report and Review of the 
Literature 
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 Sweet’s syndrome (SS), or acute febrile 
neutrophilic dermatosis, belongs to the 
group of the so-called neutrophilic derma-
toses and was first described in 1964 by 
Robert Douglas Sweet  [1] . The cutaneous 
lesions of SS typically appear as tender, red 
or purple-red papules or nodules. They 
most frequently occur on the upper ex-
tremities, face and neck  [2] . Less common-
ly SS can present as a pustular dermatosis 
 [3] . Affected patients may appear dramat-
ically ill. Fever and leukocytosis usually
accompany the skin eruption. Several clin-
ical conditions have been linked to SS. A 
probable association between the occur-
rence of the following conditions and the 
development of SS is considered likely: 
cancer (hematologic malignancies and sol-
id tumors), infections (most commonly of 
the upper respiratory tract and the gastro-
intestinal tract), inflammatory bowel dis-
ease (IBD) (includes Crohn’s disease and 
ulcerative colitis), medications (granulo-
cyte colony-stimulating factor [G-CSF] as 
the most commonly reported medication), 
and pregnancy  [2] .
 Various medications have been report-
ed to induce SS, including G-CSF, anti-
biotics, retinoids, antiepileptics and anti-
hypertensives. More recently azathioprine 
 Key Words 
 Azathioprine · Inflammatory bowel
disease · Neutrophilic dermatosis · Sweet’s 
syndrome · Interleukin-1β 
 Abstract 
 Sweet’s syndrome (SS) is a dermatosis with 
systemic symptoms characterized by tender, 
red nodules or papules, occasionally covered 
with vesicles, pustules or bullae, usually af-
fecting the upper limbs, face and neck. SS is 
frequently observed in patients with leuke-
mia or connective tissue diseases, while it is 
rather seldom in patients with inflammatory 
bowel disease. The exact pathogenesis of SS 
is only partially understood. We report the 
case of a 50-year-old patient with indetermi-
nate colitis, presenting with a febrile diffuse 
papulopustular and necrotizing skin erup-
tion that healed with significant scarring and 
appeared 14 days after onset of treatment 
with azathioprine. Histological examination 
revealed the presence of features typical of 
SS, gene expression analysis very high levels 
of interleukin-1β (IL-1β) mRNA in lesional 
skin, and immunohistochemistry high levels 
of IL-1β at the protein level. SS associated 
with azathioprine is being increasingly re-
ported and is reviewed herein. 
 © 2015 S. Karger AG, Basel 
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(AZA), the nitroimidazole of 6-mercapto-
purine, which is widely used as a corticoste-
roid-sparing agent in a variety of autoim-
mune inflammatory diseases, has been in-
creasingly reported as a potential cause of 
SS  [4–14] . Here we report a severe case of 
SS associated with AZA therapy, review the 
literature concerning similar cases report-
ed to date and analyze the expression of the 
proinflammatory cytokine interleukin-1β 
(IL-1β) in our patient’s skin lesions.
 Case Description 
 A 50-year-old male smoker was emer-
gently referred to our department for an 
impressive febrile diffuse pustular and nec-
rotizing skin eruption. He had a back-
ground history of a IBD, namely indeter-
minate colitis affecting the sigmoid colon 
that had first been diagnosed 5 months pre-
viously. Oral sulfasalazine therapy had 
been ineffective. Approximately 5 weeks 
prior to presentation, he had experienced
a flare of his colitis managed with an oral 
medication of 50 mg prednisone daily. 14 
days prior to presentation, AZA had been 
introduced at a dose of 50 mg once daily.
 The patient’s current illness began 
about 4 days prior to his transfer to our 












































































 Dermatology 2015;230:293–298 
DOI: 10.1159/000371879
294
ulopapular rash predominantly on the 
trunk, accompanied by high fever and
fatigue. In the following days he devel-
oped a painful cutaneous eruption that was 
most marked over the upper back, shoul-
ders, neck and face. This was accompanied 
by loose, partially bloody diarrhea with 
more than twenty bowel movements per 
day. There were no relevant symptoms 
pertaining to other organ systems. Upon 
arrival he was febrile (39.6   °   C), tachycar-
dic (129 beats/min) and had a blood pres-
sure of 116/84 mm Hg. Examination of
the patient’s skin revealed a florid erup-
tion consisting of scattered well-delimited 
nummular erythematous papulopustular 
lesions 2–10 mm in diameter, many of 
which were depressed in the center ( fig. 1 ). 
Fresh lesions were infiltrated erythematous 
plaques with a central pustule; older lesions 
were infiltrated erythematous plaques with 
a brown-colored central crust. The cutane-
ous eruption was mostly confined to the 
upper torso, face and neck, but the mucosa 
was also affected, with aphthous lesions 
5–10 mm in diameter and a fibrinous base 
( fig. 2 ).
 Laboratory results showed a strongly el-
evated white cell count with pronounced 
neutrophilia and markedly raised C-reac-
tive protein ( table  1 ). Swabs were taken 
from the pustular skin lesions for culture, 
and two sets of blood cultures were collect-
ed. An incisional skin biopsy was taken 
from a pustular plaque on the right upper 
back for histopathology.
 Pending the results of the above inves-
tigations, a provisional diagnosis of neu-
trophilic dermatosis (most closely resem-
bling SS) was made, and the patient’s daily 
prednisone 50 mg dose was substituted by 
intravenous hydrocortisone 400 mg daily. 
The condition was considered to be likely 
associated with the patient’s underlying 
colitis, and since AZA-induced SS had 
been reported in a handful of previously 
published cases, therapy with AZA was in-
terrupted. The patient responded well to 
intravenous steroids with flattening of his 
skin lesions, disappearance of the pustules 
and appearance of crusts covering the le-
sions. Simultaneously his body tempera-
ture normalized. Histopathological exami-
nation of the skin biopsy taken at onset 
( fig. 3 ) revealed marked superficial edema 
with florid neutrophilic infiltration in the 
whole dermal thickness, consistent with SS 
syndrome. Cultures taken prior to antibi-
otic therapy from blood and skin swabs 
were all sterile. Complete healing of skin 
lesions with residual hypopigmented scars 
occurred within 3 weeks. Given the pa-
tient’s active colitis and the impossibility to 
further treat with AZA as a steroid-sparing 
agent, we decided to start infliximab on the 
ninth day of hospitalization both for induc-
tion and maintenance therapy. According 
to a telephone follow-up 1 year later, there 
were no recurrences of his symptoms, and 
his colitis was well controlled by therapy 
with infliximab and mesalazine.
 A very recent review of the literature up 
to the 30th of May 2014 identified 16 re-
ported cases of AZA-induced SS ( table 2 ) 
 [4–8, 10–17] . Analysis of these 16 reported 
cases shows an age distribution upon onset 
ranging from 9 to 89 years, an association 
of AZA-induced SS with IBD in 13 of 16 
cases (81%), and an onset within the first 
month of AZA therapy (with an average 
time to onset of 33 days, range 7–330) in 15 
of 16 patients (94%) ( table 2 ). In the seven 
case reports in which the thiopurine meth-
yltransferase (TPMT) levels were indicat-
ed, no deficiency in TPMT existed, making 
a defect in AZA methylation and metab-
olism unlikely, and the latter an unlikely 
cause of the observed neutrophilic derma-
tosis. Rechallenge with AZA was tested in 
6 of the reported cases and was positive in 
bc
a
 Fig. 1. Florid cutaneous eruption of the upper torso, face and neck consisting of erythem-
atous papulopustular lesions 2–10 mm in diameter, many of them with a central depres-
sion and/or erosion ( a ,  c ), evolving over time to central crusting ( b ). 
 Fig. 2. Large aphthous lesions with a fibri-
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all of them, thus indicating direct causality 
of AZA in these cases of SS.
 The pathogenesis of SS is incompletely 
understood. The association with underly-
ing diseases and drugs suggests a hypersen-
sitivity reaction, and it has been suggested 
that a dysregulation of cytokine release in-
cluding IL-1, granulocyte-macrophage col-
ony-stimulating factor (GM-CSF), G-CSF 
and interferon-γ may be involved  [18, 19] . 
Based on reports linking IL-1β to diseases 
associated with neutrophilic infiltration of 
the skin, such as the rare genetic autoin-
flammatory syndrome associating pyogen-
ic arthritis, pyoderma gangrenosum and 
acne, named PAPA syndrome  [20] , and the 
cryopyrin-associated periodic syndromes 
(CAPS)  [21] , we analyzed IL-1β expression 
levels in the skin lesions of the reported pa-
tient. As shown in  figure 4 , mRNA levels 
for IL-1β in our patient’s skin biopsy as-
sessed by quantitative RT-PCR with cDNA 
primers for the housekeeping gene RPL27 
(forward 5 ′ -ATC GCC AAG AGA TCA 
AAG ATA A-3 ′ , reverse 5 ′ -TCT GAA 
GAC ATC CTT ATT GAC G-3 ′ ) and IL-1β 
(forward 5 ′ -CAC GAT GCA CCT GTA 
CGA TCA-3 ′ , reverse 5 ′ -GTT GCT CCA 
TAT CCT GTC CCT-3 ′ ) were over 250-
fold higher than those observed in normal 
skin, and this was associated with enhanced 
expression of the mature active form of IL-
1β in inflammatory cells – mainly neutro-
phils – of the dermal infiltrate as identified 
by immunohistochemistry.
 Discussion 
 Acute febrile neutrophilic dermatosis 
or SS is a prototypic neutrophilic dermato-
sis first described in 1964 by Dr. Robert 
Douglas Sweet  [1] . The characteristic clini-
cal manifestations of this disorder include 
acute eruption of tender, red or purple-red 
papules, nodules or plaques, occasionally 
associated with pustules, bullae or ulcers, 
and constant systemic symptoms (pyrexia, 
fatigue). Together with cutaneous manifes-
tation SS can nearly involve any organ sys-
tem. Inflammation in some of these organs 
can cause serious long-term quality of life 
impairment. The sight-threatening ocular 
manifestations merit particular mention 
 [22] . Cutaneous biopsies reveal an inflam-
matory infiltrate consisting mainly of ma-
ture neutrophils in the upper dermis.
 The pathogenesis of SS is unknown. 
The association of the disorder with infec-
tions, IBD, drugs, autoimmune diseases 
and malignancies, as well as the higher in-
cidence in women, suggest a hypersensitiv-
ity reaction  [23] . One current attractive hy-
pothesis regarding the pathogenesis of SS is 
a local or systemic dysregulation of cyto-
kine secretion. Among the potentially re-
sponsible cytokines are IL-1, IL-3, IL-6, IL-
8, G-CSF, GM-CSF and interferon-γ  [18] . 
Elevated serum levels of IL-1, IL-2 and 
interferon-γ, but not IL-4, suggest that the 
expression of Th1 cytokines may be in-
volved in the pathogenesis of this syn-
drome  [18] .
 SS does fulfill the current criteria for 
classification as an autoinflammatory dis-
ease  [24] . Autoinflammatory diseases are a 
relatively new category of diseases distinct 
from allergic and autoimmune diseases 
and characterized by seemingly unpro-
voked recurrent inflammation in the ab-
sence of evidence of circulating autoan-
tibodies or an antigen-specific T cell re-
sponse  [25] . Genetic mutations affecting 
proteins of the inflammasome complex or 
proteins that regulate the function of the 
inflammasome have been found in several 
of the autoinflammatory syndromes. In-
Table 1. Summary of laboratory investigation findings
Test Result Normal range
Hemoglobin, g/dl 9.1 13.4 – 17.0
White cell count, ×103/μl 22.4 3.0 – 9.6
Neutrophils, ×103/μl 20.16 1.4 – 8.0
Platelets, ×103/μl 602 143 – 400
Sodium, mmol/l 134 136 – 145
Potassium, mmol/l 3.9 3.3 – 4.5
Urea, mmol/l 6.6 2.14 – 7.14
Creatinine, μmol/l 94 62 – 106
Albumin, g/l 27 40 – 49




















 Fig. 3. Skin biopsy taken on the upper back showing marked superficial edema with florid 
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 Fig. 4.  a Analysis of IL-1β mRNA levels by quantitative RT-PCR in the patient’s skin bi-
opsy and healthy control skin.  b Immunohistochemical stainings with an anti-IL-1β an-
tibody and with an appropriate isotype control antibody were performed on the patient’s 































1 [8] 9/F ulcerative colitis 10 days no rechallenge N yes
2 [4] 39/F Crohn’s disease 28 days yes N yes
3 [4] 33/M systemic lupus erythematosus 14 days no rechallenge N yes
4 [14] 46/M ulcerative colitis 14 days yes NR yes
5 [6] 49/M ulcerative colitis 11 months yes NR yes
6 [7] 32/M Crohn’s disease 7 days yes above ref. range yes
7 [7] 68/M myasthenia gravis 10 days no rechallenge above ref. range yes
8 [7] 42/M ulcerative colitis 14 days no rechallenge NR yes
9 [13] 89/F bullous pemphigoid 18 days no rechallenge N yes
10 [11] 45/M Crohn’s disease 14 days yes NR yes
11 [12] 55/M Crohn’s disease 7 days yes NR yes
12 [10] 53/M ulcerative colitis 7 days no rechallenge NR yes
13 [15] 50/M indeterminate colitis 14 days no rechallenge NR yes
14 [17] 75/M Crohn’s disease 14 days no rechallenge NR no
15 [5] 81/F Crohn’s disease 14 days no rechallenge NR yes
16 [16] 51/M Crohn’s disease 10 days no rechallenge N yes
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flammasomes are a group of protein com-
plexes that recognize a diverse set of patho-
gen- and/or danger-associated inflamma-
tion-inducing stimuli and that control the 
production of important proinflammatory 
cytokines such as IL-1β and IL-18  [26] . 
Mutations in inflammasome components 
may result in overactivity of the inflamma-
some or failure to limit IL-1-mediated in-
flammation, as is the case in CAPS such as 
Muckle-Wells syndrome that are due to ac-
tivating mutations of the inflammasome 
component NLRP3. In a large number of 
autoinflammatory diseases, systemic corti-
costeroids have only modest effect. Biolog-
ic agents such as anakinra (Kineret ® ), a re-
combinant IL-1R antagonist, can result in 
a dramatic and consistent improvement in 
those syndromes where a clear link to IL-1 
has been shown  [27] . Likewise therapy with 
canakinumab, a human monoclonal anti-
body targeted at IL-1β, has been shown to 
induce rapid, durable and complete clinical 
responses in 97% of CAPS patients studied 
 [28] . Our data showing very high levels of 
IL-1β mRNA and protein in the skin le-
sions of our patient are supportive of the 
above notion that SS is an autoinflamma-
tory disease, and suggest that IL-1β may 
contribute to the neutrophilic infiltration 
of the skin and fever that characterize SS. 
According to the recently updated classi-
fication of autoinflammatory disease, our 
case is a type 1, complex/acquired autoin-
flammatory disease  [25] .
 Prednisone or prednisolone at an ini-
tial dose of 0.5–1.5 mg/kg body weight/
day, with gradual tapering over 2–4 weeks, 
represents the standard first-line treat-
ment for SS. In recurrent disease, therapy 
with colchicine, potassium iodide, dap-
sone, doxycycline, non-steroidal anti-in-
flammatory agents and cyclosporine has 
been described, with mixed results  [29] . A 
few case reports mention successful use of 
infliximab (5 mg/kg) on a compassionate 
use basis in refractory SS. Evidence for any 
of these therapeutic regimens is however 
limited as based on case reports and small 
case series. Recently very encouraging re-
sponses to Kineret have been reported in 
patients with refractory SS, further sug-
gesting that IL-1α or IL-1β play a signifi-
cant role in the pathophysiology of this 
disease  [30, 31] .
 One of the more frequently reported 
diseases associated with classical SS is IBD. 
Benton et al.  [32] described its association 
with ulcerative colitis for the first time in 
1985. Since then, a large number of case re-
ports have confirmed this association  [32–
46] . The association of SS with Crohn’s dis-
ease is less common, with fewer than 40 
cases described in the literature. SS associ-
ated with IBD tends to be more common in 
women (87%) and is usually associated 
with active disease  [47] . The presence of
extraintestinal symptoms, such as joint 
symptoms and other skin manifestations, 
is frequent in patients with IBD-associated 
SS  [48] . As mentioned earlier, SS may be 
also associated with medications  [2] , the 
administration of G-CSF being respon-
sible for the majority of drug-induced cas-
es of SS. Many patients with IBD are treat-
ed with AZA as a corticosteroid-sparing 
agent. When SS occurs in such patients, 
IBD is the first suspected cause of the syn-
drome, given the well-reported association 
 [10, 15] . However, in the last few years sev-
eral papers reporting a possible association 
between AZA and SS have been published 
( table 2 )  [4–8, 10–17] . Interestingly, two of 
the cases reporting AZA-associated SS had 
an underlying disease other than IBD, and 
rechallenge of patients with AZA repro-
duced SS lesions in all 6 cases rechallenged, 
both facts providing support for a poten-
tial role of AZA as a trigger/co-factor in 
certain cases of SS  [4, 7] .
 The AZA hypersensitivity syndrome, 
which typically occurs within the first 4 
weeks of initiation of AZA therapy  [9] and 
is characterized by systemic symptoms 
identical to those of SS (fever, leukocytosis, 
malaise, arthralgia), was considered to be 
the cause in many of these cases ( table 2 ). 
A review of the English language literature 
by Bidinger et al.  [4] showed that about 
50% of patients with a hypersensitivity re-
action to AZA had cutaneous manifesta-
tions. The majority thereof had biopsy or 
clinical features consistent with a neutro-
philic dermatosis. Interestingly, withdraw-
al of AZA and rechallenge with the drug 
indicated that at least in some of the above-
mentioned cases  [4, 6, 7, 11, 12, 14] , a direct 
association between AZA and SS existed. 
In another case, on the other hand, the 
AZA dose was increased and the rash even-
tually resolved  [41] . As the systemic mani-
festations described for AZA hypersensi-
tivity syndrome have all also been reported 
to occur with varying frequencies in SS, it 
is presumed that both denominations refer 
to variants of the same disease  [49, 50] .
 Our patient with SS developing 14 days 
after initiation of AZA therapy for active 
IBD meets all of the diagnostic criteria for 
drug-induced SS as presented by Walker 
and Cohen in 1996  [51] . Especially the lo-
calization and the clinical outcome argu-
ments against the presence of an AZA hy-
persensitivity syndrome. The latter tends 
to favor the lower extremities and most cas-
es resolve within 2–3 days after withdrawal 
of the medication and may not necessitate 
an increase in corticosteroid dose. In view 
of the impressive clinical presentation re-
sulting in permanent skin scarring, rechal-
lenge with AZA as a proof of causality was 
not performed. Full resolution of clinical 
symptoms occurred upon therapy with 
systemic steroids and infliximab. Our data 
showing involvement of IL-1β in SS, taken 
together with reports of successful therapy 
of SS with the IL-1 receptor antagonist 
anakinra, suggest that IL-1 plays a role in 
the pathogenesis of SS, and the latter ther-
apy may be optimal in steroid-refractory 
cases of SS. However, anakinra was not 
shown to be effective in IBD. For that rea-
son a different strategy was chosen in the 
patient discussed here.
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amplification in the molecular diagnosis of XLI patients; and initial
screening of exons 7-10 of the STS for point mutations by DNA
sequencing for those patients who are already excluded for
complete or partial gene deletions.
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Letter to the Editor
Metastatic melanoma cell lines do not secrete
IL-1b but promote IL-1b production
from macrophages
To the Editor
Tumors secrete pro-inflammatory cytokines, chemokines, and
other soluble factors in the microenvironment. Interleukin-1b (IL-
1b) is a pleiotropic pro-inflammatory cytokine involved in cell
growth, differentiation, and regulation of immune responses [1].
IL-1b is often detected in human cancer tissues including breast
cancer, pancreatic cancer, and glioblastoma [2]. It has been
reported that the expression levels of the IL-1b gene or protein
are associated with the invasiveness and metastasis of cancers [3].
On the other hand, IL-1b production from tumor cells may be
considered as a threat by the host’s immune system. In this aspect,
it has been reported that IL-1b-producing melanoma cells induce
reduced tumor growth by recruiting immune cells [4]. Therefore,
melanoma cells must have a precise mechanism of IL-1b
regulation but it remains largely unknown.
IL-1b is first synthesized as a biologically inactive precursor
(pro-IL-1b). Pro-IL-1b is then cleaved by caspase-1 to biologically
active mature IL-1b, resulting in its release into the extracellular
space [1]. Therefore, we first analyzed IL-1b production from
melanoma cell lines. THP-1 macrophages and melanoma cells were
primed or not with phorbol-12-myristate-13-acetate (PMA,
500 nM) and exposed to the IL-1b inducer ionomycin (1.5 mM).
Under these conditions and in contrast to THP-1 monocytic cells,
13 metastatic melanoma cell lines were not able to secrete IL-1b
(Fig. 1a). Inflammasomes are a multi-protein complexes whose
assembly and activation are responsible for the processing of
caspases-1 and -5 [1]. The NOD-like receptor pyrin domain
containing-3 (NLRP3) inflammasome has been the most studied
inflammasome to date. This high molecular weight complex is
composed of NLRP3, apoptosis-associated speck-like protein
containing a CARD domain (ASC) adaptor protein, and the cysteine
protease caspase-1 [1]. Assembly of the NLRP3 inflammasome
activates caspase-1, which mediates maturation of proinflamma-
tory cytokines such as IL-1b and IL-18.
To address the expression levels of inflammasome components
in metastatic melanoma cells, we performed reverse transcription
polymerase chain reaction (RT-PCR) analyses. In contrast to THP-1
cells, one or several inflammasome components were not
expressed in A375, Me191, and Me290 metastatic melanoma cell
lines [5,6] (Fig. 1b). In addition, pro-IL-1b and pro-IL-18 transcripts
were not detected in Me191 and Me290 cells (Fig. 1b). To further
determine the expression pattern of inflammasome components in
melanoma cells, we used 6 primary and 21 metastatic melanoma cell
lines as reported previously (Supplemental Tables 1 and 2) [5,6]. One
hundred percent of cell lines derived from primary melanomas
expressed ASC. In contrast, only 19 percent of cell lines derived from
metastatic melanomas expressed ASC (Fig. 1c). Also, caspase-1,
NLRP3, IL-1b, and AIM2 were expressed in a lower proportion of
metastatic melanoma cell lines when compared to cell lines derived
from primary melanoma cell lines (Fig. 1c). In tumors, ASC
expression is inversely correlated with the methylation status of
the ASC promoter region [7]. Analysis of the methylation profile of
ASC by MeDIP [8] revealed that 2 out of 4 tested cell lines had a
methylated ASC-promoter (Fig. 1d). M000921 and M010817 [5,6]
were found to have DNA methylation in the promoter region of ASC
but not M990115 and M010119 [5,6]. ASC expression was then
assessed by qRT-PCR and showed to inversely correlate with ASC
methylation (data not shown). Consistently with this observation, a
treatment with the demethylating agent 5-azacythitidine (AZA,
2.5 mM) induced the restoration of ASC expression as observed by
RT-PCR (Fig. 1e) and western blotting (Fig. 1 f). These results suggest
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Fig. 1. Metastatic melanoma cells are not able to secrete IL-1b. (a) IL-1b secretion by THP-1 macrophages and A375 and Mamel82 metastatic human melanoma cell lines by analyzing
supernatants from their culture by ELISA (R&D Systems, Minneapolis, MN). N.D., not detected. (b) mRNA expression of ASC, NLRP3, caspase-1, pro-IL-1b, pro-IL-18, and GAPDH in THP-1
and metastatic melanoma cell lines. Total RNAfromTHP-1 cells and metastaticmelanoma cell lines (A375, Me191,Me290, and MaMel82)was isolated withanRNeasyMini Kit (QIAGEN,
Hilden Germany). RT-PCR was performed with a thermal cycler (Biometra, Gottingen, German). (c) Evaluation of the expression of inflammasome components and IL-1b in primary
(n = 6)and metastatic (n = 21)melanomacell lines by RT-PCR. (d) MeDIPanalysis of fourmelanoma cell cultures. Two melanomacell cultures,M010817 and M000921 weresignificantly
methylated in the promoter region of ASC having a log 2 ratio >1 of methylated DNA compared to input. The other two-melanoma cell cultures, M990115 and M010119, were not
significantly methylated in the promoter region of ASC. (e) A375 human metastatic melanoma cells were treated with 2.5 mM AZA for 24 h and ASC expression was assessed by RT-PCR
and (f) Western blotting. All data are presented as mean  SD and are representative of two experiments. P-values were calculated with Wilcoxon singled-rank test. *p < 0.05.
Fig. 2. Necrotic melanoma cells promote IL-1b secretion from macrophages. (a) Human primary monocytes were exposed to different proportions of necrotic cells (A2059/A375
human metastatic melanoma) per for 24 h and IL-1b secretion was measured in the supernatant with ELISA. Necrotic products of cells were separated between soluble and debris
fraction. (b) THP-1 macrophages were treated with inflammasome activators (MSU, 150 mg/ml and Nigericin, 5 mM), or necrotic (debris or supernatant?) A375 metastatic human
melanoma cell line for 6, 12, and 24 h and IL-1b secretion was measured in the culture supernatant with ELISA. (c) THP-1 cells pre-treated with ZVAD for 30 min were incubated
with necrotic A375 for 24 h and IL-1b secretion was measured in the supernatant with ELISA. (d) NLRP3, ASC and caspase-1 knock down THP-1 were incubated with necrotic
soluble of A375 for 24 h and IL-1b secretion was measured in the supernatants with ELISA and compared to the one of lamin knock down exposed to DMSO (vehicle) or ZVAD. All
IL-1b ELISA data are presented as mean  SD and are representative of two experiments. P-values were calculated with Wilcoxon singled-rank test. *p < 0.05.
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because of the lack of one or more inflammasome components, and
DNA methylation is one of the mechanisms that can silence the
expression of these components.
Macrophages are potent producers of IL-1b and reported to be
present in the melanoma skin lesion [9]. Necrotic melanoma cells
are often found in cutaneous melanomas of patients with
progressive disease [10] and may be a source of danger-associated
molecular patterns sensed by NLRs [1]. Therefore, we next
analyzed whether necrotic melanoma cells promote IL-1b
production from macrophages. The soluble fraction and debris
from necrotic A2058, and A375 melanoma cell lines promoted IL-
1b production from human primary monocytes in a dose-
dependent manner (Fig. 2a). We also show that IL-1b production
from THP-1 macrophages was detected after adding soluble
fraction or debris from necrotic melanoma cells (Fig. 2b). A pre-
treatment of THP-1 cells with the caspase inhibitor Z-VAD-fmk (Z-
VAD) (5 mM) prior to exposure to the soluble fraction or debris
from necrotic A375 melanoma cells significantly suppressed IL-1b
production (Fig. 2c), suggesting a caspase-dependent mechanism.
To further confirm that IL-1b production from THP-1 cells depends
on inflammasome activation, we generated ASC, caspase-1, and
NLRP3 knock-down THP-1 macrophages. All THP-1 cells trans-
duced with either ASC-shRNA, NLRP3-shRNA or caspase-1-shRNAs
showed a dramatic decrease of IL-1b production compared to
control lamin-shRNA THP-1 (Fig. 2d), demonstrating that IL-1b
release upon exposure to products of necrotic melanoma cells
depends on the NLRP3 inflammasome. Finally, we examined IL-1b
expression in naevus, superficially spreading melanomas (SSM),
nodular melanomas (NM), and skin metastases of melanoma by
immunohistochemistry. IL-1b positive cells were not detected in
naevus and SSM, whilst they were in NM and skin metastasis of
melanoma (Fig. 2e). Consistent with in vitro experiments, these IL-
1b positive cells were melanophages but not melanoma cells.
In summary, we demonstrate that the inability of metastatic
melanoma cells to secrete IL-1b is due to the lack of expression of
one or more inflammasome components. On the other hand, one or
more factors originating from necrotic melanoma cells can promote
IL-1b production by macrophages. Taken together, metastatic
melanoma cells seem to have lost the ability for IL-1b production
whereas macrophages of the microenvironment secrete high
amounts of IL-1b in response to putative danger signals released
by necrotic tumor cells. It has been reported that the expression
levels of the IL-1b protein are associated with the invasiveness and
metastasis of cancers. In this respect, IL-1b is an important factor for
the expansion of metastatic melanoma. However, the cellular source
of IL-1b in tumors is not clear. Here, we demonstrate that IL-1b is
produced by macrophages upon stimulation with danger signals
from necrotic melanoma cells. Although not being able to produce
IL-1b themselves, tumor cells may benefit from IL-1b release by
macrophages present in the micro-environment. A better under-
standing of the mechanisms and consequences of IL-1b production
by infiltrating macrophages may be of interest for the development
of IL-1b targeted therapy, such as anti-IL-1b antibody (Canakinu-
mab), of metastatic melanoma.
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